Upload
phamquynh
View
217
Download
0
Embed Size (px)
Citation preview
DOI 10.1378/chest.11-2307 2012;141;e669S-e690SChest
SpencerVandvik, Maarten G. Lansberg, Gordon H. Guyatt and Frederick A.Anand, Randolph Guzman, Michael H. Criqui, Elie A. Akl, Per Olav Pablo Alonso-Coello, Sergi Bellmunt, Catherine McGorrian, Sonia S. Clinical Practice Guidelines
Evidence-BasedCollege of Chest Physicians Prevention of Thrombosis, 9th ed: AmericanDisease : Antithrombotic Therapy and Antithrombotic Therapy in Peripheral Artery
http://chestjournal.chestpubs.org/content/141/2_suppl/e669S.full.html
services can be found online on the World Wide Web at: The online version of this article, along with updated information and
e669S.DC1.html http://chestjournal.chestpubs.org/content/suppl/2012/02/03/141.2_suppl.Supplemental material related to this article is available at:
ISSN:0012-3692)http://chestjournal.chestpubs.org/site/misc/reprints.xhtml(
written permission of the copyright holder.this article or PDF may be reproduced or distributed without the priorDundee Road, Northbrook, IL 60062. All rights reserved. No part of Copyright2012by the American College of Chest Physicians, 3300Physicians. It has been published monthly since 1935.
is the official journal of the American College of ChestChest
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
CHEST Supplement
www.chestpubs.org CHEST / 141 / 2 / FEBRUARY, 2012 SUPPLEMENT e669S
ANTITHROMBOTIC THERAPY AND PREVENTION OF THROMBOSIS, 9TH ED: ACCP GUIDELINES
Background: This guideline focuses on antithrombotic drug therapies for primary and secondary prevention of cardiovascular disease as well as for the relief of lower-extremity symptoms and critical ischemia in persons with peripheral arterial disease (PAD). Methods: The methods of this guideline follow those described in Methodology for the Develop-ment of Antithrombotic Therapy and Prevention of Thrombosis Guidelines: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines in this supplement. Results: The most important of our 20 recommendations are as follows. In patients aged � 50 years with asymptomatic PAD or asymptomatic carotid stenosis, we suggest aspirin (75-100 mg/d) over no therapy (Grade 2B) for the primary prevention of cardiovascular events. For secondary prevention of cardiovascular disease in patients with symptomatic PAD (including patients before and after peripheral arterial bypass surgery or percutaneous transluminal angio-plasty), we recommend long-term aspirin (75-100 mg/d) or clopidogrel (75 mg/d) (Grade 1A). We recommend against the use of warfarin plus aspirin in patients with symptomatic PAD (Grade 1B). For patients undergoing peripheral artery percutaneous transluminal angioplasty with stenting, we suggest single rather than dual antiplatelet therapy (Grade 2C). For patients with refractory claudication despite exercise therapy and smoking cessation, we suggest addition of cilostazol (100 mg bid) to aspirin (75-100 mg/d) or clopidogrel (75 mg/d) (Grade 2C). In patients with crit-ical limb ischemia and rest pain unable to undergo revascularization, we suggest the use of pros-tanoids (Grade 2C). In patients with acute limb ischemia due to acute thrombosis or embolism, we recommend surgery over peripheral arterial thrombolysis (Grade 1B). Conclusions: Recommendations continue to favor single antiplatelet therapy for primary and secondary prevention of cardiovascular events in most patients with asymptomatic PAD, symp-tomatic PAD, and asymptomatic carotid stenosis. Additional therapies for relief of limb symptoms should be considered only after exercise therapy, smoking cessation, and evaluation for periph-eral artery revascularization. CHEST 2012; 141(2)(Suppl):e669S–e690S
Abbreviations: ABI 5 ankle brachial index; CAD 5 coronary artery disease; CAPRIE 5 Clopidogrel vs Aspirin in Patients at risk for Ischemic Events; MI 5 myocardial infarction; MWD 5 maximum walking distance; PAD 5 peripheral arterial disease; PTA 5 percutaneous transluminal angioplasty; RCT 5 randomized controlled trial; RR 5 risk ratio; rt-PA 5 recombinant tissue-type plasminogen activator
Antithrombotic Therapy in Peripheral Artery Disease Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Pablo Alonso-Coello , MD , PhD ; Sergi Bellmunt , MD ; Catherine McGorrian , MBBCh , BAO ; Sonia S. Anand , MD , PhD ; Randolph Guzman , MD, RVT ; Michael H. Criqui , MD , MPH ; Elie A. Akl , MD , MPH , PhD ; Per Olav Vandvik , MD , PhD ; Maarten G. Lansberg , MD , PhD ; Gordon H. Guyatt , MD, FCCP ; and Frederick A. Spencer, MD
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
e670S Antithrombotic Therapy in Peripheral Artery Disease
value preventing an MI substantially higher than avoiding a GI bleed, if they are in the moderate or high cardiovascular risk group, will be more likely to choose aspirin.
3.1-3.4. For secondary prevention patients with symptomatic PAD, we recommend one of the two following antithrombotic regimens to be contin-ued long term over no antithrombotic treat-ment: aspirin 75 to 100 mg daily or clopidogrel 75 mg daily (all Grade 1A) . We suggest not to use dual antiplatelet therapy with aspirin plus clopid-ogrel (Grade 2B) . We recommend not to use an antiplatelet agent with moderate-intensity war-farin (Grade 1B) .
4.1-4.4. For patients with intermittent claudi-cation refractory to exercise therapy (and smoking cessation), we suggest the use of cilostazol in addition to previously recommended antithrom-botic therapies (aspirin 75-100 mg daily or clopid-ogrel 75 mg daily) (Grade 2C) ; we suggest against the use of pent oxifylline, heparinoids, or pros-tanoids (Grade 2C) .
5.1. For patients with symptomatic PAD and critical leg ischemia/rest pain who are not can-didates for vascular intervention, we suggest the use of prostanoids in addition to previously recommended antithrombotic therapies (aspirin 75-100 mg daily or clopidogrel 75 mg daily) (Grade 2C) .
Values and preferences: Patients who do not value uncertain relief of rest pain and ulcer healing greater than avoidance of a high likelihood of drug-related side effects will be disinclined to take prostanoids.
6.1-6.3. In patients with acute limb ischemia due to arterial emboli or thrombosis, we sug-gest immediate systemic anticoagulation with unfractionated heparin over no anticoagula-tion (Grade 2C) ; we suggest reperfusion therapy (surgery or intraarterial thrombolysis) over no reperfusion therapy (Grade 2C) ; we recom-mend surgery over intraarterial thrombolysis (Grade 1B) . In patients undergoing intraarterial thrombolysis, we suggest recombinant tissue-type plasminogen activator (rt-PA) or urokinase over streptokinase (Grade 2C) .
7.1. For patients undergoing peripheral artery percutaneous transluminal angioplasty (PTA) with or without stenting, we recommend long-term aspirin (75-100 mg/day) or clopidogrel (75 mg/day) (Grade 1A) . For patients undergoing peripheral artery PTA with stenting, we suggest
Revision accepted August 31, 2011. Affi liations: From the Iberoamerican Cochrane Centre (Dr Alonso-Coello), CIBERESP-IIB Sant Pau, Barcelona, Spain; Angiology (Dr Bellmunt), Vascular and Endovascular Surgery Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; The Heart House (Dr McGorrian), Mater Misericordiae University Hospital, Dublin, Ireland; Departments of Medicine and Clinical Epidemiology and Biostatistics (Drs Anand and Guyatt), McMaster University, Hamilton, ON, Canada; Section Vascular Surgery (Dr Guzman), University of Manitoba, St Boniface Hospital, Winnipeg, MB, Canada; Department of Family and Preventive Medicine (Dr Criqui), University of California San Diego School of Medicine, La Jolla, CA; Department of Medicine (Dr Akl), State University of New York at Buffalo, Buffalo, NY; Norwegian Knowledge Centre for the Health Services and Department of Medicine Gjøvik (Dr Vandvik), Innlandet Hospital Trust, Gjøvik, Norway; Stanford Stroke Center (Dr Lansberg), Stanford Univer-sity Medical Center, Palo Alto, CA; and Department of Medicine (Dr Spencer), McMaster University, Hamilton, ON, Canada. Funding/Support: The Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines received support from the National Heart, Lung, and Blood Institute [R13 HL104758] and Bayer Schering Pharma AG. Support in the form of educa-tional grants were also provided by Bristol-Myers Squibb; Pfi zer, Inc; Canyon Pharmaceuticals; and sanofi -aventis US. Disclaimer: American College of Chest Physician guidelines are intended for general information only, are not medical advice, and do not replace professional medical care and physician advice, which always should be sought for any medical condition. The complete disclaimer for this guideline can be accessed at http://chestjournal.chestpubs.org/content/141/2_suppl/1S. Correspondence to: Frederick A. Spencer, MD, Department of Medicine, McMaster University, St Joseph’s Health Care, 50 Charlton Ave E, Hamilton, ON, L8N 4A6, Canada; e-mail: [email protected] © 2012 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians ( http://www.chestpubs.org/site/misc/reprints.xhtml ). DOI: 10.1378/chest.11-2307
Summary of Recommendations
Note on Shaded Text: Throughout this guideline, shading is used within the summary of recommenda-tions sections to indicate recommendations that are newly added or have been changed since the pub-lication of Antithrombotic and Thrombolytic Therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Rec-ommendations that remain unchanged are not shaded.
2.1. For persons with asymptomatic peripheral arterial disease (PAD), we suggest aspirin 75 to 100 mg daily over no aspirin therapy (Grade 2B) .
Remarks: Aspirin slightly reduces total mortality regardless of cardiovascular risk profi le if taken over 10 years. In people at moderate to high risk of cardio-vascular events, the reduction in myocardial infarc-tion (MI) is closely balanced with an increase in major bleeds. Whatever their risk status, people who are averse to taking medication over a prolonged time period for very small benefi ts will be disinclined to use aspirin for primary prophylaxis. Individuals who
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
www.chestpubs.org CHEST / 141 / 2 / FEBRUARY, 2012 SUPPLEMENT e671S
events and mortality. The patient-important outcomes (ie, total mortality, nonfatal MI, nonfatal stroke, major nonfatal extracranial bleed) are the same outcomes considered for recommendations for CAD and stroke. However, we review the effects of antithrombotic therapy on outcomes specifi c to PAD (eg, rest pain of the limbs, quality of life, or amputation).
Studies evaluating antithrombotic therapy imme-diately following peripheral bypass graft surgery or percutaneous endovascular procedures generally have used graft patency or reocclusion as the primary end point. These outcomes are surrogates for patient-important outcomes of quality of life and limb ampu-tation, which are seldom reported.
We consider the desirable and undesirable con-sequences of antithrombotic therapy in the follow-ing populations or patient groups: (1) persons with asymptomatic PAD, (2) patients with symptomatic PAD (including those with claudication or critical [chronic] limb ischemia and rest pain or prior periph-eral arterial revascularization), (3) patients with acute limb ischemia and threatened limb loss, (4) patients following peripheral arterial revascularization, and (5) persons with asymptomatic and symptomatic carotid stenosis. Table 1 and Table S1 describe both the question defi nition (ie, population, intervention, comparator, and outcome) and the study types con-sidered for each question. (Tables that contain an “S” before the number denote supplementary tables not contained in the body of the article and avail-able instead in an online data supplement. See the “Acknowledgments” for more information.)
High-quality evidence supports an effect of aspi-rin on vascular mortality. In addition, a recent meta-analysis provided moderate-quality evidence that long-term use of aspirin reduces mortality from spe-cifi c cancer types. 1 In a population of patients with symptomatic vascular disease, vascular disease and cancer are the leading causes of death. Therefore, we have chosen total mortality over a 10-year period as the main outcome of interest. When data are avail-able, we included fatal intracranial or extracranial bleeding with vascular death or total mortality under the general category of antithrombotic therapy-related deaths. Nonfatal hemorrhagic strokes and ischemic strokes are included together as nonfatal strokes. Although the former is a complication and decrease in the latter is a benefi cial effect of antithrombotic therapy, their impact on patient morbidity is similar.
1.0 Methods
Estimation of Baseline Risks and Absolute Effects of Treatment
In order to estimate absolute benefi ts and harms associated with a given therapy, we performed the following steps. First,
single rather than dual antiplatelet therapy (Grade 2C) .
Values and preferences: Patients who place a high value on an uncertain reduction in the risk of limb loss and a relatively low value on avoiding a defi nite increased risk of bleeding are more likely to choose to use dual antiplatelet therapy.
8.1-8.4. We recommend one of the following antithrombotic regimens to be continued long-term following peripheral artery bypass graft surgery over no antithrombotic treatment: aspi-rin 75 to 100 mg daily or clopid ogrel 75 mg daily (all Grade 1A) . We recommend single antiplatelet therapy over antiplatelet therapy and warfarin (Grade 1B) . In patients undergoing below-knee bypass graft surgery with prosthetic grafts, we suggest clopidogrel 75 mg/d plus aspirin (75-100 mg/d) over aspirin alone for 1 year (Grade 2C) . For all other patients, we suggest single over dual antiplatelet therapy (Grade 2B) .
9.1. For persons with asymptomatic carotid ste-nosis, we suggest aspirin 75 to 100 mg daily over no aspirin therapy (Grade 2B) .
Remarks: Aspirin slightly reduces total mortality regardless of cardiovascular risk profi le if taken over 10 years. In people at moderate to high risk of car-diovascular events, the reduction in MI is closely balanced with an increase in major bleeds. What-ever their risk status, people who are averse to taking medication over a prolonged time period for very small benefi ts will be disinclined to use aspirin for primary prophylaxis.
9.2-9.3. In patients with symptomatic carotid ste-nosis (including recent carotid endarterectomy), we recommend long-term antiplatelet therapy with clopidogrel (75 mg once daily) or aspirin-extended-release dipyridamole (25 mg/200 mg bid) or aspirin (75-100 mg once daily) over no antiplatelet therapy (Grade 1A) . We suggest either clopidogrel (75 mg once daily) or aspirin-extended-release dipyridamole (25 mg/200 mg bid) over aspirin (75-100 mg) (Grade 2B) .
This article focuses on the use of antithrombotic drugs in patients with peripheral arterial disease
(PAD). PAD is associated with a high prevalence of atherosclerosis in other vascular beds. The leading causes of morbidity and mortality in patients with PAD are myocardial infarction (MI) and stroke; therefore, as in patients with coronary artery disease (CAD), the primary benefi t of antithrombotic therapy in this patient population is prevention of vascular
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
e672S Antithrombotic Therapy in Peripheral Artery Disease
Tabl
e 1—
[Int
rodu
ctio
n] S
tru
ctu
red
Cli
nica
l Q
ues
tion
s
Sect
ion
Info
rmal
Que
stio
n
PIC
O Q
uest
ion
Popu
latio
nIn
terv
entio
nC
ompa
rato
rO
utco
me
2.0
Asy
mpt
omat
ic P
AD
2.
1C
hoic
e of
ant
ithro
mbo
tic
ther
apy
Patie
nts
with
as
ympt
omat
ic P
AD
(e
g, A
BPI
, 0
.9
Asp
irin
Plac
ebo
Tota
l mor
talit
yN
onfa
tal M
IN
onfa
tal s
trok
eM
ajor
non
fata
l ext
racr
ania
l ble
edin
g3.
0 Sy
mpt
omat
ic P
AD
: pre
vent
ion
of c
ardi
ovas
cula
r ev
ents
3.
1C
hoic
e of
ant
ithro
mbo
tic
ther
apy
Patie
nts
with
sy
mpt
omat
ic P
AD
Asp
irin
Plac
ebo
Tota
l mor
talit
yN
onfa
tal M
IN
onfa
tal s
trok
eM
ajor
non
fata
l ext
racr
ania
l ble
edin
g
3.
2C
lopi
dogr
elA
spir
in
3.3
Asp
irin
1 cl
opid
ogre
lA
spir
in
3.4
Asp
irin
1 o
ral a
ntic
oagu
lant
sA
spir
in4.
0 Sy
mpt
omat
ic P
AD
: man
agem
ent o
f cla
udic
atio
n
4.1
Cho
ice
of a
ntith
rom
botic
th
erap
yPa
tient
s w
ith
clau
dica
tion
Hep
arin
sPl
aceb
oQ
ualit
y of
life
Max
imum
wal
king
dis
tanc
eM
ajor
non
fata
l ext
racr
ania
l ble
edin
gM
orta
lity
Adv
erse
eve
nts
4.
2C
ilost
azol
Plac
ebo
or p
ento
xify
lline
4.
3Pe
ntox
ifylli
nePl
aceb
o
4.4
Pros
tagl
andi
nsPl
aceb
o
5.0
Sym
ptom
atic
PA
D: m
anag
emen
t of c
ritic
al li
mb
isch
emia
5.
1C
hoic
e of
ant
ithro
mbo
tic
ther
apy
Patie
nts
with
cri
tical
lim
b is
chem
ia
unab
le to
und
ergo
re
vasc
ular
izat
ion
Pros
tagl
andi
nsPl
aceb
oR
est-
pain
rel
ief
Ulc
er h
ealin
gA
mpu
tatio
nsM
orta
lity
Adv
erse
eve
nts
6.0
Acu
te li
mb
isch
emia
6.
1C
hoic
e of
ant
ithro
mbo
tic
ther
apy
Patie
nts
with
acu
te
limb
isch
emia
Unf
ract
iona
ted
hepa
rin
No
antic
oagu
latio
nD
eath
Am
puta
tion
Non
fata
l str
oke
Maj
or n
onfa
tal e
xtra
cran
ial b
leed
ing
6.
2In
traa
rter
ial t
hrom
boly
tic th
erap
ySu
rger
y
6.3
Uro
kina
se o
r rt
-PA
Stre
ptok
inas
e7.
0 E
ndov
ascu
lar
surg
ery
7.
1C
hoic
e of
ant
ithro
mbo
tic
ther
apy
post
-PTA
� st
ent
Patie
nts
unde
rgoi
ng
PTA
Asp
irin
plu
s di
pyri
dam
ole
Plac
ebo
Vess
el r
este
nosi
s/oc
clus
ion
Asp
irin
/dip
yrid
amol
ePh
enpr
ocou
mon
Ticl
opid
ine
Phen
proc
oum
onU
nfra
ctio
nate
d he
pari
n Su
bcut
aneo
us n
adro
pari
n (L
MW
H)
(Con
tinue
d)
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
www.chestpubs.org CHEST / 141 / 2 / FEBRUARY, 2012 SUPPLEMENT e673S
Tabl
e 1—
Con
tinu
ed
Sect
ion
Info
rmal
Que
stio
n
PIC
O Q
uest
ion
Popu
latio
nIn
terv
entio
nC
ompa
rato
rO
utco
me
8.0
Ope
n lo
wer
-lim
b va
scul
ar s
urge
ry
8.1
Cho
ice
of a
ntith
rom
botic
th
erap
yPa
tient
s un
derg
oing
an
y gr
aft
Asp
irin
or
aspi
rin/
dipy
rida
mol
ePl
aceb
oVa
scul
ar m
orta
lity
Non
fata
l MI
Non
fata
l str
oke
Maj
or n
onfa
tal e
xtra
cran
ial b
leed
ing
Am
puta
tion
8.
2A
spir
in o
r as
piri
n/di
pyri
dam
ole
Oth
er a
gent
s
8.3
Clo
pido
grel
plu
s as
piri
nA
spir
in
8.4
Ora
l ant
icoa
gula
nts �
aspi
rin
Asp
irin
8.
5Pa
tient
s un
derg
oing
be
low
-kne
e pr
osth
etic
gr
aft
Asp
irin
plu
s cl
opid
ogre
lA
spir
in
9.0
Car
otid
ste
nosi
s
9.1
Cho
ice
of a
ntith
rom
botic
th
erap
yPa
tient
s w
ith
asym
ptom
atic
ca
rotid
ste
nosi
s
Asp
irin
Plac
ebo
Tota
l mor
talit
yN
onfa
tal M
IN
onfa
tal s
trok
eM
ajor
non
fata
l ext
racr
ania
l ble
edin
gA
ntip
late
let a
gent
s po
st
enda
rter
ecto
my
Plac
ebo
9.
2Pa
tient
s w
ith s
ympt
omat
ic
caro
tid s
teno
sis
9.
3Pa
tient
s w
ith c
arot
id
sten
osis
und
ergo
ing
enda
rter
ecto
my
AB
PI 5
ankl
e-br
achi
al p
ress
ure
inde
x; L
MW
H 5
low
-mol
ecul
ar-w
eigh
t he
pari
n; M
I 5 m
yoca
rdia
l in
farc
tion;
PA
D 5
per
iphe
ral
arte
rial
dis
ease
; PI
CO
5 p
opul
atio
n, i
nter
vent
ion,
com
para
tor,
outc
ome;
PT
A 5
per
cuta
neou
s tr
ansl
umin
al a
ngio
plas
ty; r
t-PA
5 re
com
bina
nt ti
ssue
-typ
e pl
asm
inog
en a
ctiv
ator
.
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
e674S Antithrombotic Therapy in Peripheral Artery Disease
the lower limb to that of the arm. This relatively simple clinical test was originally used to confi rm the diagnosis of PAD and assess its severity. Low ABI ( , 0.90) has been shown to be an independent predictor of MI, stroke, and vascular mortality inde-pendent of other cardiovascular risk factors. 5-9 The ABI, therefore, has been promoted as a simple, inex-pensive, noninvasive screening tool for the assess-ment of future cardiovascular risk. In a meta-analysis of � 48,000 healthy men and women, ABI , 0.90 at baseline was associated with an approximate dou-bling of the 10-year mortality, cardiovascular mor-tality, and major coronary event rate after adjusting for the Framingham risk score. 10
Therefore, when evaluating a patient for primary prevention with aspirin, we suggest using a risk strat-ifi cation tool such as the Framingham risk score, which provides estimates of low ( , 10%), moderate (10%-20%), and high risk ( . 20%) of cardiovascular events over 10 years. If, in addition, the patient has an ABI , 0.90, we suggest doubling this score, thus possibly increasing the patient’s risk from a low to moderate or a moderate to high category. 10
2.1 Aspirin
We consider the evidence for aspirin therapy for the primary prevention of CAD (see section 1.1 in Vandvik et al 4 in this supplement) applicable to patients with asymptomatic PAD. On the basis of an individual participant data meta-analysis, 11 aspi-rin would be expected to prevent 19 and 31 nonfatal MIs and lead to 16 and 22 major extracranial bleeding events per 1,000 moderate- and high-risk patients treated, respectively (Table S2). In addition, long-term aspirin use has been associated with a signifi cant decrease in cancer mortality, 12 likely contributing to the decrease in total mortality associated with long-term aspirin therapy observed in another meta-analysis. 13 On the basis of these data and regardless of vascular risk, aspirin use in 60-year-old men would also result in six fewer deaths (12 fewer to 0 fewer) per 1,000 patients treated for 10 years. The overall quality of evidence is moderate given the impreci-sion in the estimates for total mortality.
The relative effect of aspirin on prevention of vas-cular events, bleeding, and total mortality are likely similar in patients with cardiovascular risk factors, asymptomatic PAD, and asymptomatic carotid ste-nosis. Our recommendations for primary prevention in asymptomatic patients with PAD are therefore identical to those described in Vandvik et al. 4
Recommendation
2.1. For persons with asymptomatic PAD, we suggest aspirin 75 to 100 mg daily over no aspi-rin therapy (Grade 2B) .
we generated relative effect estimates (relative risks) from the highest-quality published meta-analysis of randomized con-trolled trials (RCTs). If no such meta-analyses were available or were out of date, we conducted our own meta-analyses of relevant RCTs or used relative risk estimates from single RCTs in the absence of other relevant RCTs.
Ideally, in order to approximate the benefi t of a given therapy in the real world, estimates of baseline risk (control group risks) would be derived from population-based observational studies. Unfortunately, for most of our clinical questions, we were unable to identify observational studies of suffi cient quality that reported all relevant outcomes. In such cases, we derived control group risk estimates from a representative control arm of a relevant meta-analysis or RCT and adjusted them to our specifi ed time frame. Detailed explanations of our choices are presented in each section.
Values and Preferences
The relative weight given to outcomes (eg, an extracranial bleed compared with an MI or a stroke) greatly affects the trade-offs between desirable and undesirable consequences of antithrombotic therapy. Unfortunately, limited data guide us with respect to the relative impact of these events on a patient’s quality of life. 2 As described in Guyatt et al, 3 in this supplement we have used ratings from participating guideline panelists’ estimates of patient valuation of the outcomes of interest. The ratings sug-gest that nonfatal major extracranial bleeding (which is usually readily treated and with few long-lasting consequences) carries only slightly less weight than a nonfatal MI (which also often has limited long-term consequences) but substantially less weight than a stroke (which often is associated with long-term disability). Our decisions are based on a disutility or negative weight of stroke of three times the disutility of a major extracranial bleed.
Trade-offs between desirable and undesirable consequences of alternative management strategies sometimes represent close-call situations. In making recommendations in such situations, we have taken a primum non nocere (fi rst do no harm) approach, placing the burden of proof with those who would claim a benefi t of treatment. In other words, when a treatment is associated with uncertain benefi t and an appreciable probability of impor-tant harm, we recommend against such treatment.
We identifi ed the relevant evidence for our clinical ques-tions with the assistance of a team of methodologists and med-ical librarians as outlined in Guyatt et al. 3 Systematic literature searches for systematic reviews and original studies were per-formed until the date of January 15, 2010. After that date, we scanned the literature regularly, although this was not performed as systematic literature searches.
2.0 Primary Prevention of Cardiovascular Events in Patients With Asymptomatic PAD
As in the article by Vandvik et al 4 of this supplement, primary prevention refers to the use of an interven-tion to prevent events prior to any clinically manifested disease. Hence, even though nearly every 70-year-old man or woman has signifi cant vascular changes, they are candidates for primary (as opposed to secondary) prevention unless they have clinically manifested vascu-lar disease (ie, claudication; history of peripheral vascu-lar procedures; known history of CAD, MI, or stroke).
Most asymptomatic patients with PAD will be iden-tifi ed through ankle-brachial index (ABI) screening. The ABI is the ratio of the highest systolic BP in
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
www.chestpubs.org CHEST / 141 / 2 / FEBRUARY, 2012 SUPPLEMENT e675S
domized trial that directly compared clopidogrel and aspirin in secondary prevention of cardiovascular events, and we consider this trial to be the most cred-ible source of evidence. 15 More than 19,000 patients with atherosclerotic vascular disease manifested as a recent stroke, recent MI, or symptomatic PAD received clopidogrel or aspirin. After a mean follow-up of 1.9 years, clopidogrel was associated with a pos-sible reduction in nonfatal MI and nonfatal extracra-nial bleeding and little or no effect on total mortality. Table S4 summarizes the quality of evidence and main fi ndings of the CAPRIE trial. The results indi-cate no effect of clopidogrel on total mortality com-pared with aspirin. These results are consistent with a meta-analysis of 10 studies examining the effects of thienopyridine derivatives (eg, clopidogrel, ticlopi-dine) vs aspirin in patients at high vascular risk. 16
3.3 Dual Antiplatelet Therapy With Clopidogrel and Aspirin vs Single Antiplatelet Therapy
A Cochrane systematic review evaluated short- and long-term dual antiplatelet therapy in patients with established CAD. 17 Only one large-scale RCT, the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoid-ance (CHARISMA) trial, has evaluated the long-term effi cacy of clopidogrel and aspirin vs aspirin alone. 18 This trial followed 15,603 patients with established vascular disease or multiple risk factors for a mean period of 28 months. Table S5 summarizes the qual-ity of evidence and fi ndings from this trial. Results of the study failed to demonstrate or exclude an effect of dual antiplatelet therapy relative to aspirin on total mortality or nonfatal MI. Dual antiplatelet therapy was associated with a possible reduction in nonfatal stroke and a possible increase in nonfatal extracranial bleeding. We considered the quality of evidence to be moderate because of imprecise effect estimates for all outcomes. Although this study included patients with other vascular diseases, we considered its fi nd-ings directly applicable to patients with symptomatic PAD. We did not deem subgroup analyses suggesting different effects of dual antiplatelet therapy in symp-tomatic vs asymptomatic patients to be credible. 14
3.4 Warfarin Plus Aspirin vs Aspirin Alone
Although studies comparing warfarin to placebo or aspirin have been conducted in patients with PAD, these have been small in size and focused on PAD-specifi c outcomes (eg, lower-extremity pain, bypass graft patency) rather than on rates of subsequent stroke, MI, or vascular death. Subsequent sections summarize these studies.
Of the available trials of patients with asymptom-atic CAD comparing warfarin plus aspirin to aspirin
Remarks: Aspirin slightly reduces total mortality regardless of cardiovascular risk profi le if taken over 10 years. In people at moderate to high risk of car-diovascular events, the reduction in MI is closely balanced with an increase in major bleeding events. Whatever the risk status, people averse to taking medication over a prolonged time period for very small benefi ts will be disinclined to use aspirin for primary prophylaxis. Individuals who value prevent-ing an MI substantially higher than avoiding a GI bleed, if they are in the moderate or high cardiovas-cular risk strata, will be more likely to choose aspirin.
3.0 Secondary Prevention of Cardiovascular Events in Patients With Symptomatic PAD
3.1-3.3 Antiplatelet Therapies for Secondary Prevention of Cardiovascular Events in Patients With Symptomatic PAD
Because antiplatelet therapy would be expected to result in similar relative reductions in vascular events such as MI or stroke in patients with PAD or CAD, we considered RCTs enrolling patients with PAD, CAD, or both to support our recommen-dations for both conditions. Although many of the included studies conducted post hoc analyses limited to patients enrolled for symptomatic PAD, we did not fi nd these subgroup analyses credible based on criteria proposed by Sun et al. 14 Therefore, our rec-ommendations for antiplatelet therapy as secondary prevention of cardiovascular events in symptomatic patients with PAD are identical to those described in sections 2.1.1, 2.1.2, 2.1.3, and 2.1.5 of Vandvik et al. 4 For the reader’s interest, we briefl y review the perti-nent evidence in the following sections.
3.1 Aspirin
Table S3 summarizes the quality of evidence and main fi ndings from a meta-analysis of individual participant data from 16 randomized trials with 17,000 patients with established vascular disease (six trials of patients with previous MI and 10 of patients with previous transient ischemic attack or stroke). 11 In this population at high risk for a serious vascular event (8.2% yearly risk), aspirin signifi cantly reduced total mortality, nonfatal MI, and nonfatal stroke but increased nonfatal extracranial bleeding events. The number of vascular events and total deaths prevented was far greater than the number of bleeding events that resulted from aspirin.
3.2 Clopidogrel vs Aspirin
The Clopidogrel vs Aspirin in Patients at Risk for Ischemic Events (CAPRIE) trial is the only ran-
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
e676S Antithrombotic Therapy in Peripheral Artery Disease
directly and often used walking distance as a surrogate. We make inferences regarding quality of life based on these data, inferences that are less certain because of indirectness. Because these therapies have not been shown to have an impact on cardiovascular events, they are considered only as possible additions to previously recommended antiplatelet treatments.
Patients with intermittent claudication have lower-extremity discomfort with walking, thereby limiting activity. In general, claudication itself is not associ-ated with limb loss and is responsive to smoking ces-sation and exercise therapy. Cessation of tobacco use can signifi cantly reduce lower-extremity symp-toms and progression of PAD. 22,23 One systematic review suggested that structured exercise programs can improve maximal walking distance (MWD). 24 Therefore, additional drug therapy should be con-sidered only in patients who have troubling limi-tations even after smoking cessation and exercise therapy.
Selection of Baseline Risk
For the three comparisons of cilostazol, pentoxifyl-line, and prostanoids vs placebo, because controlled trials showed large improvements in walking test distance in patients in placebo groups, for the surro-gate outcome of MWD, we used a control response rate of 80%; that is, we assumed that 80% of untreated patients would show improvements in quality of life. We calculated the standardized mean differences, and when needed, we imputed SDs from other trials. We then converted standardized mean differences into risk differences 25,26 and present the results as the proportion of patients who experience an important benefi t in quality of life (inferred from MWD). For evaluation of bleeding risk associated with cilostazol compared with no cilostazol or placebo, we used the control group risk estimate from a systematic review of 10 RCTs evaluating cilostazol in addition to dual antiplatelet therapy in coronary percutaneous trans-luminal angioplasty (PTA) and stenting. 27
4.1 Cilostazol
Cilostazol is a phosphodiesterase III inhibitor of platelet activation and relaxes vascular smooth muscle. Ten RCTs that compared cilostazol 100 mg bid to placebo have been located in two systematic reviews. 28,29 Pooling data from seven studies com-paring cilostazol vs placebo suggested that regard-ing health-related quality of life (as inferred from MWD), patients receiving cilostazol are more likely to experience an important benefi t than those receiving placebo (79 more per 1,000 [55 more to 100 more]) ( Table 3 , Table S7). Changes in quality of life were evaluated directly in four of the studies
alone, all were in the setting of a recent acute coro-nary syndrome, and a number had only short-term follow-up. It is unknown whether the response to warfarin therapy, particularly with respect to bleed-ing, might differ in patients with symptomatic CAD vs symptomatic PAD. Therefore, we used only RCTs specifi cally enrolling patients with symptomatic PAD for our evaluation of warfarin therapy.
For the comparison of warfarin plus aspirin vs aspi-rin alone for nonfatal vascular outcomes, we used the event rates from participants taking aspirin in a meta-analysis of 16 RCTs evaluating aspirin use vs no aspi-rin use in patients with vascular disease adjusted to a 5-year time interval as our baseline risk estimate. 10 Because this meta-analysis does not provide data on total mortality or nonfatal major extracranial bleeds, we derived baseline risk estimates from the aspirin arm in the CHARISMA trial (total mortality) and CAPRIE trial (major nonfatal extracranial bleeding events). 15,18
We identifi ed three RCTs evaluating warfarin (international normalized ratio, 2.0-3.0) plus aspirin vs aspirin alone in 3,048 patients with established PAD. 19-21 Table 2 and Table S6 provide details about the qual ity of evidence and fi ndings from our meta-analysis of the three included studies. Results failed to demonstrate or exclude an effect of warfarin plus aspirin vs aspirin alone on mortality, nonfatal MI, or nonfatal stroke. However, there was a signifi cant increase in major bleeding events with warfarin plus aspirin compared with aspirin alone. The overall qual-ity of evidence is low.
Recommendation
3.1-3.4. For secondary prevention in patients with symptomatic PAD, we recommend one of the two following antithrombotic regimens to be continued long term over no antithrombotic treatment: aspirin 75 to 100 mg daily or clopid-ogrel 75 mg daily (all Grade 1A) . We suggest not to use dual antiplatelet therapy with aspirin plus clopidogrel (Grade 2B) . We recommend not to use an antiplatelet agent with moderate-intensity warfarin (Grade 1B) .
4.0 Antithrombotic Therapy for the Management of Patients With Claudication
In the previous section, we recommended aspi-rin or clopidogrel for the prevention of nonfatal MI, nonfatal stroke, or vascular death for all patients with symptomatic PAD. In this section, we evaluate other therapies with antiplatelet and antithrombotic properties (eg, cilostazol, pentoxifylline, prostanoids) for their effect on quality of life. Unfortunately, most studies have not evaluated quality of life as an outcome
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
www.chestpubs.org CHEST / 141 / 2 / FEBRUARY, 2012 SUPPLEMENT e677S
Tabl
e 2—
[Sec
tion
3.1
-3.4
] Su
mm
ary
of F
indi
ngs:
Mod
erat
e-In
tens
ity
War
fari
n (I
NR
2.0
-3.0
) P
lus
Asp
irin
vs
Asp
irin
Alo
ne f
or S
econ
dary
Pre
vent
ion
of
Car
diov
ascu
lar
Eve
nts
in P
atie
nts
Wit
h Sy
mpt
omat
ic P
AD
20,2
1,22
Out
com
esPa
rtic
ipan
ts (S
tudi
es),
Fol
low
-up
Qua
lity
of th
e E
vide
nce
(GR
AD
E)
Rel
ativ
e E
ffec
t (95
% C
I)
Ant
icip
ated
Abs
olut
e E
ffec
ts O
ver
5 y
Ris
k W
ith A
spir
inR
isk
Diff
eren
ce W
ith
War
fari
n +
Asp
irin
(95%
CI)
Tota
l mor
talit
y3,
048
(3 R
CT
), 35
-60
mo
Low
due
to im
prec
isio
n a an
d in
cons
iste
ncy b
RR
1.1
1 (0
.79-
1.55
)12
0 pe
r 1,
000 c
13 m
ore
per
1,00
0 (f
rom
25
few
er to
66
mor
e)M
I no
nfat
al e
vent
s3,
048
(3 R
CT
), 35
-60
mo
Mod
erat
e du
e to
im
prec
isio
n a R
R 0
.95
(0.6
4-0.
1.41
)80
per
1,0
00 d
4 fe
wer
per
1,0
00 (f
rom
28
few
er to
32
mor
e)St
roke
, inc
ludi
ng n
onfa
tal
isch
emic
and
hem
orrh
agic
st
roke
s e
3,04
8 (3
RC
T),
35-6
0 m
oM
oder
ate
due
to
impr
ecis
ion a
RR
0.9
2 (0
.64-
1.33
)11
0 pe
r 1,
000 d
8 fe
wer
per
1,0
00 (f
rom
39
few
er to
36
mor
e)
Maj
or e
xtra
cran
ial b
leed
no
nfat
al e
vent
s2,
994
(2 R
CT
), 35
-60
mo
Hig
hR
R 2
.39
(1.5
0-3.
82)
40 p
er 1
,000
f 55
mor
e pe
r 1,
000
(fro
m 2
0 m
ore
to
112
mor
e)B
urde
n of
trea
tmen
tN
/A g
Hig
hW
arfa
rin
. as
piri
nW
arfa
rin:
dai
ly m
edic
atio
n, d
ieta
ry a
nd
activ
ity r
estr
ictio
ns, f
requ
ent b
lood
te
stin
g/m
onito
ring
, inc
reas
ed
hosp
ital/c
linic
vis
its d
Asp
irin
: dai
ly m
edic
atio
n on
ly
CA
PRIE
5 C
lopi
dogr
el v
s A
spir
in i
n Pa
tient
s at
Ris
k fo
r Is
chem
ic E
vent
s; C
HA
RIS
MA
5 C
lopi
dogr
el f
or H
igh
Ath
erot
hrom
botic
Ris
k an
d Is
chem
ic S
tabi
lizat
ion,
Man
agem
ent,
and
Avo
idan
ce;
GR
AD
E 5
Gra
des
of R
ecom
men
datio
ns, A
sses
smen
t, D
evel
opm
ent,
and
Eva
luat
ion;
IN
R 5
inte
rnat
iona
l nor
mal
ized
rat
io; N
/A 5
not
app
licab
le; R
CT
5 ra
ndom
ized
con
trol
led
tria
l; R
R 5
risk
rat
io. S
ee
Tabl
e 1
lege
nd fo
r ex
pans
ion
of o
ther
abb
revi
atio
ns.
a The
95%
CI
for
abso
lute
eff
ect i
nclu
des
bene
fi t a
nd h
arm
. b E
xces
s ca
ncer
dea
ths
in o
ne s
tudy
with
war
fari
n an
d as
piri
n. c C
ontr
ol g
roup
ris
k es
timat
es fo
r to
tal m
orta
lity
com
e fr
om th
e as
piri
n ar
m o
f the
CH
AR
ISM
A tr
ial.
d Con
trol
gro
up r
isk
estim
ates
for
nonf
atal
MI
and
nonf
atal
str
oke
(isch
emic
, hem
orrh
agic
, and
unk
now
n ca
use)
com
e fr
om o
bser
ved
even
ts in
a m
eta-
anal
ysis
of 1
6 R
CTs
in s
econ
dary
pre
vent
ion.
11
e Of t
otal
non
fata
l str
okes
, tw
o of
48
(4%
) with
asp
irin
and
17
of 5
0 (3
4%) w
ith w
arfa
rin
plus
asp
irin
wer
e he
mor
rhag
ic.
f Con
trol
gro
up r
isk
estim
ates
for
maj
or b
leed
s co
me
from
the
obse
rved
eve
nts
in th
e as
piri
n-al
one
arm
of t
he C
APR
IE tr
ial. 15
g A
s fa
r as
we
are
awar
e, n
o st
udie
s ha
ve e
valu
ated
diff
eren
ces
in b
urde
n of
trea
tmen
t bet
wee
n pa
tient
s w
ith P
AD
taki
ng w
arfa
rin
vs a
spir
in. T
here
are
stu
dies
eva
luat
ing
qual
ity o
f life
in p
atie
nts
duri
ng
war
fari
n tr
eatm
ent (
with
dis
para
te fi
ndin
gs),
but t
hese
are
lim
ited
by s
mal
l sam
ple
size
, lac
k of
com
para
tor,
and
othe
r de
sign
issu
es.
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
e678S Antithrombotic Therapy in Peripheral Artery Disease
Tabl
e 3—
[Sec
tion
4.1
-4.4
] Su
mm
ary
of F
indi
ngs:
Cil
osta
zol
vs P
lace
bo
in P
atie
nts
Wit
h Sy
mpt
omat
ic P
AD
and
Cla
udi
cati
on28
Out
com
esPa
rtic
ipan
ts (S
tudi
es),
Fol
low
-up
Qua
lity
of th
e E
vide
nce
(GR
AD
E)
Rel
ativ
e E
ffec
t (95
% C
I)
Ant
icip
ated
Abs
olut
e E
ffec
ts
Ris
k W
ithou
t Cilo
staz
olR
isk
Diff
eren
ce W
ith C
ilost
azol
(95%
CI)
Tota
l mor
talit
y1,
439
(1 R
CT
30 ),
34 m
oL
ow d
ue to
bia
s a and
impr
ecis
ion b
RR
0.9
4 (0
.64-
1.39
)68
per
1,0
00 c
4 fe
wer
per
1,0
00 (f
rom
27
few
er to
26
mor
e)M
I no
nfat
al e
vent
s…
……
……
Stro
ke, i
nclu
ding
non
fata
l isc
hem
ic
and
hem
orrh
agic
str
okes
……
……
…
Maj
or e
xtra
cran
ial b
leed
2,27
3 (6
RC
T),
1-6
mo
Low
due
to in
dire
ctne
ss d a
nd
inco
nsis
tenc
y e R
R 0
.89
(0.4
6-1.
73)
44 p
er 1
,000
c 5
few
er p
er 1
,000
(fro
m 2
4 fe
wer
to
32 m
ore)
Qua
lity
of li
fe a
s in
ferr
ed fr
om
max
imum
wal
king
dis
tanc
e (im
port
ant o
utco
me)
1,89
0 (7
RC
T),
3-6
mo
Low
due
to b
ias,
f inc
onsi
sten
cy g
and
indi
rect
ness
h 1.
09 (1
.06-
1.12
)80
0 pe
r 1,
000
79 m
ore
per
1,00
0 (5
5 m
ore
to 1
00 m
ore)
i
See
Tabl
e 1
and
2 le
gend
s fo
r ex
pans
ion
of a
bbre
viat
ions
. a U
ncle
ar c
once
alm
ent o
f allo
catio
n. b C
I in
clud
es im
port
ant b
enefi
t an
d ha
rm; o
nly
101
even
ts.
c Con
trol
gro
up r
isk
estim
ates
com
e fr
om o
bser
ved
even
ts r
epor
ted
in p
lace
bo a
rms
of in
clud
ed s
tudi
es.
d Dat
a fr
om s
tudi
es c
ompa
ring
cilo
staz
ol v
s pl
aceb
o in
add
ition
to a
spir
in a
nd c
lopi
dogr
el fo
llow
ing
perc
utan
eous
cor
onar
y in
terv
entio
n. e C
Is in
clud
e pr
otec
tive
effe
ct a
nd h
arm
. f U
ncle
ar c
once
alm
ent o
f allo
catio
n in
four
of s
even
stu
dies
. g M
oder
ate
hete
roge
neity
( I 2 5
69%
). h U
se o
f sur
roga
te e
nd p
oint
(wal
king
dis
tanc
e fo
r qu
ality
of l
ife).
i Cal
cula
ted
from
poo
led
stan
dard
ized
mea
n di
ffer
ence
s, c
onve
rted
into
ris
k di
ffer
ence
(ass
umed
con
trol
res
pons
e ra
te o
f 80%
).
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
www.chestpubs.org CHEST / 141 / 2 / FEBRUARY, 2012 SUPPLEMENT e679S
an important risk of publication bias; thus, the overall quality of the evidence was deemed to be low.
4.3 Heparins (Including Low-Molecular Weight Heparins)
A Cochrane systematic review of the use of hep-arin products in patients with intermittent claudica-tion 37 identifi ed fi ve eligible studies (Table S8). 38-42 In the pooled data, there were no deaths, no bleed-ing events, and nine cardiovascular events with no signifi cant differences between heparins and placebo. Effects of heparin on walking distance were only eval-uable from one RCT in which heparin 12,500 units subcutaneously daily or placebo were administered for two 3-month periods followed by 6 months of observation in a crossover design. Aspirin was admin-istered throughout the 18-month period. 38 Results failed to establish or exclude benefi t or harm from heparin (112 more with improvement in quality of life per 1,000 [58 fewer to 149 more]) (Table S8).
4.4 Prostanoids
Prostaglandins (prostaglandin E1, prostaglandin I2, and their derivatives) are potent inhibitors of plate-let activation, adhesion, and aggregation and have vasodilatory and antithrombotic effects. A meta-analysis of fi ve studies (1,636 patients) suggested that with regard to quality of life as inferred from MWD, patients receiving prostaglandins are more likely to experience an important benefi t than those receiving placebo (79 more per 1,000 [58 more to 98 more]) but have a higher risk of adverse events (RR, 2.61; 95% CI, 1.40-4.85). 43 There was substan-tial heterogeneity between study results ( I 2 5 64%). Results failed to demonstrate or exclude an effect of prostaglandins vs placebo on nonfatal stroke, nonfatal MI, revascularization, or death. The overall quality of the evidence is low due to risk of bias and imprecision and for quality of life, indirectness (Table S9).
Recommendation
4.1-4.4. For patients with intermittent claudica-tion refractory to exercise therapy and smoking cessation, we suggest the use of cilostazol in addition to previously recommended anti-thrombotic therapies (aspirin 75-100 mg daily or clopidogrel 75 mg daily) (Grade 2C) ; we sug-gest against the use of pentoxifylline, hepari-noids, or prostanoids (Grade 2C) .
5.0 Critical Limb Ischemia
Patients with critical limb ischemia have inade-quate resting blood fl ow to the lower limbs, resulting
comparing cilostazol 100 mg bid to placebo. 31-34 All four trials reported results consistent with our infer-ences from MWD: a signifi cant improvement in the physical health subscale of the SF-36 (Short Form Health Survey ), suggesting an improvement in over-all physical function. However, the overall health-related quality of life was not improved, with no changes in the mental health components (eg, social functioning, role-emotional subscale). In the largest of the trials, the results failed to demonstrate or exclude an effect of cilostazol on total mortality. 30
Regarding quality of life (as inferred from MWD), patients receiving cilostazol 100 mg bid were more likely to experience an important benefi t than those receiving pentoxifylline. 35 There were no signifi cant differences in total mortality or adverse events (any adverse event or serious adverse events).
A separate review of a pharmaceutical safety database included eight RCTs of patients with symptomatic PAD. 36 The authors did not list the individual trials included in this database. There were 1,374 participants randomized to cilostazol (475 patient-years exposure) and 973 randomized to placebo (357 patient-years exposure). Although a formal meta-analysis does not appear to have been undertaken, the review reported no difference in rates of MI (1.0% vs 0.8%), stroke (0.5% vs 0.5%), or death (0.6% vs 0.5%) between patients with symptom-atic PAD taking cilostazol or those taking placebo. 36 Major or minor bleeding rates were not reported.
As we considered whether to add cilostazol to existing antithrombotic therapy, we relied on bleed-ing data from studies comparing cilostazol to no cil-ostazol in patients undergoing coronary stenting (and already taking aspirin and clopidogrel) to estimate bleeding risk associated with this therapy. A system-atic review of cilostazol in patients undergoing per-cutaneous coronary intervention included 10 RCTs (2,809 patients) comparing triple therapy with aspi-rin, clopidogrel, and cilostazol to aspirin plus clopid-ogrel. 27 Results failed to demonstrate or exclude an effect of cilostazol on major bleeding (risk ratio [RR], 0.89; 95% CI, 0.46-1.73).
4.2 Pentoxifylline
Pentoxifylline was compared with placebo in six small RCTs in patients with intermittent claudication. A pooled analysis of these trials failed to demon-strate a difference between pentoxifylline and pla-cebo in quality of life as inferred from MWD (31 more per 1,000 [47 less to 94 more]). 29 Pentox-ifylline was associated with more adverse events (96 more per 1,000 [21 more to 181 more]). The studies included had limitations in design and exe-cution and showed marked variability, and there was
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
e680S Antithrombotic Therapy in Peripheral Artery Disease
80% of peripheral emboli originate in the heart (eg, left atrial appendage, left ventricular apex, native and prosthetic cardiac valves). In the remaining cases, emboli originate from the aorta or peripheral vessels themselves or are of venous origin (paradoxical with migration through patent foramen ovale and atrial septal defect). Thrombotic occlusion is most com-monly associated with advanced atherosclerosis, with slow progression of disease. 47 The limb typically has developed a collateral blood supply, and the fi nal occlusion of the stenotic vessel often is not immedi-ately limb threatening. 45,47
6.1 Anticoagulation for Acute Limb Ischemia
Regardless of the cause and level of acute limb ischemia, patients usually receive short-term anti-coagulation treatment with therapeutic doses of heparin to reduce the extent of ischemic injury by preventing clot propagation and further embolism. Although the logic of this approach is widely accepted, there are no formal studies demonstrating improved outcomes with anticoagulation. The expected adverse effect of preoperative anticoagulant therapy is an increased risk of bleeding, including wound hema-tomas. To our knowledge, there are no randomized trials directly comparing unfractionated heparin with other anticoagulants in this setting.
6.2 Thrombolysis vs Surgery for Acute Limb Ischemia
Treatment of acute limb ischemia is directed at restoration of fl ow to the occluded artery, which is now commonly accomplished by either surgery or catheter-directed intraarterial thrombolysis. Although no formal data support either reperfusion therapy over anticoagulation alone or supportive care, the high risk of limb loss (and subsequent associated morbidity and mortality) without blood fl ow restora-tion has led to widespread use of both modalities.
Table 5 and Table S11 summarize the results from a meta-analysis that provides the best evidence regarding the comparative benefi ts and harms of intraarterial thrombolysis vs surgery. 48 This meta-analysis presented data from fi ve randomized trials of 1,180 patients. 49-53 We provide absolute effect estimates based on control (surgical arm) event rates from these trials. In summary, thrombolysis com-pared with surgery appeared to have little or no effect on limb salvage but was associated with an increase risk in stroke (10 per 1,000 treated) and major bleeding (16 per 1,000 treated) at 30 days. Results failed to demonstrate or exclude an effect of thrombolysis vs surgery on amputation or death. We consider the overall quality of evidence to be moderate because of inconsistency and imprecision.
in rest pain, ulceration, and eventually gangrene and limb loss. Such patients are candidates for prompt revascularization. Pertinent outcomes include relief of pain, quality of life, and limb salvage.
5.1 Prostanoids
Investigators have also administered prostaglan-dins to patients with critical limb ischemia in hopes of relieving rest pain and healing ischemic ulcers. A Cochrane systematic review identifi ed 13 studies comparing prostanoids to placebo in patients with critical limb ischemia without chance of rescue or reconstructive intervention. 44 These studies mea-sured outcomes in different ways. The authors of the review dealt with this variability by dichoto-mizing the continuous results. Pain relief was defi ned as any improvement on a validated pain scale. Ulcer healing was defi ned as any decrease in lesion surface area and presence of granulation tissue. The overall quality of the evidence is low because of limitations in design, imprecision, and inconsistency.
Prostanoids improved rest pain and ulcer healing (77 and 136 patients per 1,000 treated, respectively) but did not signifi cantly prevent amputations or decrease mortality ( Table 4 , Table S10). Prostanoids were poorly tolerated, with � 75% of subjects experi-encing at least one adverse event compared with 31% of controls (the most commonly reported adverse effects were headache, nausea, vomiting, diarrhea, and facial fl ushing). A sensitivity analysis restricted to the eight highest-quality studies found similar results with respect to the fi ve outcome variables.
Recommendation
5.1. For patients with symptomatic PAD and critical leg ischemia/rest pain who are not can-didates for vascular intervention, we suggest the use of prostanoids in addition to previously recommended antithrombotic therapies (aspi-rin 75-100 mg daily or clopidogrel 75 mg daily) (Grade 2C) .
Values and preferences: Patients who do not value uncertain relief of rest pain and ulcer healing greater than avoidance of a high likelihood of drug-related side effects will be disinclined to undergo prostanoid therapy.
6.0 Acute Limb Ischemia
Acute limb ischemia results from a sudden inter-ruption of blood fl ow to an extremity. 45 The most common causes of nontraumatic acute arterial occlu-sion are embolism and thrombosis. 45-47 Approximately
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
www.chestpubs.org CHEST / 141 / 2 / FEBRUARY, 2012 SUPPLEMENT e681S
Tabl
e 4—
[Sec
tion
5.1
] Su
mm
ary
of F
indi
ngs:
Pro
stan
oids
vs
Pla
ceb
o in
Pat
ient
s W
ith
Cri
tica
l L
imb
Isc
hem
ia I
neli
gib
le f
or R
evas
cula
riza
tion
44
Out
com
esPa
rtic
ipan
ts (S
tudi
es),
Fol
low
-up
Qua
lity
of th
e E
vide
nce
(GR
AD
E)
Rel
ativ
e E
ffec
t (95
% C
I)
Ant
icip
ated
Abs
olut
e E
ffec
ts
Ris
k W
ithou
t Pro
stan
oids
Ris
k D
iffer
ence
With
Pro
stan
oids
(95%
CI)
Tota
l mor
talit
y1,
391
(5 R
CT
), 32
wk
Low
due
to r
isk
of b
ias,
a in
cons
iste
ncy,
b and
impr
ecis
ion c
RR
1.0
7 (0
.65-
1.75
)12
1 pe
r 1,
000 d
8 m
ore
per
1,00
0 (f
rom
42
few
er to
90
mor
e)M
I no
nfat
al e
vent
s...
......
......
Stro
ke, i
nclu
ding
non
fata
l isc
hem
ic
and
hem
orrh
agic
str
okes
......
......
...
Maj
or e
xtra
cran
ial b
leed
......
......
...R
est p
ain
relie
f (an
y im
prov
emen
t on
val
idat
ed s
cale
)1,
116
(9 R
CT
), 21
.4 w
kM
oder
ate
due
to r
isk
of b
ias a
RR
1.3
2 (1
.1-1
.57)
243
per
1,00
0 d 77
mor
e pe
r 1,
000
(fro
m 2
4 m
ore
to
138
mor
e)U
lcer
hea
ling
(any
dec
reas
e in
siz
e or
gra
nula
tion
tissu
e)1,
132
(8 R
CT
), 17
.5 w
kL
ow d
ue to
ris
k of
bia
s a and
in
cons
iste
ncy e
RR
1.5
4 (1
.22-
1.96
)25
3 pe
r 1,
000 d
136
mor
e pe
r 1,
000
(fro
m 5
5 m
ore
to
242
mor
e)A
mpu
tatio
ns (m
ajor
or
min
or
ampu
tatio
ns)
1,79
0 (9
RC
T),
23.1
wk
Low
due
to r
isk
of b
ias a a
nd
impr
ecis
ion f
RR
0.8
9 (0
.76-
1.04
)31
3 pe
r 1,
000 d
34 fe
wer
per
1,0
00 (f
rom
75
few
er to
12
mor
e)A
dver
se e
vent
s71
6 (8
RC
T),
14.4
mo
Mod
erat
e du
e to
ris
k of
bia
s a R
R 2
.35
(1.9
9-2.
78)
77 p
er 1
,000
g 10
3 m
ore
per
1,00
0 (f
rom
76
mor
e to
13
7 m
ore)
394
per
1,00
0 g 53
1 m
ore
per
1,00
0 (f
rom
390
mor
e to
70
1 m
ore)
See
Tabl
e 1
and
2 le
gend
s fo
r ex
pans
ion
of a
bbre
viat
ions
. a U
ncle
ar a
lloca
tion
of c
once
alm
ent a
nd b
lindi
ng c
once
rns.
b I 2 5
40%
. c C
Is in
clud
e bo
th im
port
ant b
enefi
t an
d ha
rm. S
mal
l num
ber
of e
vent
s (1
45).
d Con
trol
gro
up r
isk
estim
ates
com
e fr
om m
edia
n co
ntro
l gro
up r
ates
or
repr
esen
tativ
e co
ntro
l gro
up r
isk
of th
e in
clud
ed s
tudi
es.
e I 2 5
44%
. f C
Is in
clud
e im
port
ant b
enefi
t an
d ha
rm.
g Rep
rese
ntat
ive
cont
rol g
roup
ris
k.
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
e682S Antithrombotic Therapy in Peripheral Artery Disease
Tabl
e 5—
[Sec
tion
6.1
-6.3
] Su
mm
ary
of F
indi
ngs:
Thr
omb
olys
is v
s Su
rger
y fo
r th
e T
reat
men
t of
Acu
te L
imb
Isc
hem
ia48
Out
com
esPa
rtic
ipan
ts (S
tudi
es),
Fol
low
-up
Qua
lity
of th
e E
vide
nce
(GR
AD
E)
Rel
ativ
e E
ffec
t (95
% C
I)
Ant
icip
ated
Abs
olut
e E
ffec
ts
Ris
k W
ith S
urge
ryR
isk
Diff
eren
ce W
ith T
hrom
boly
sis
(95%
CI)
Tota
l mor
talit
y at
1 y
a 76
8 (3
RC
Ts), b 1
2 m
oL
ow d
ue to
impr
ecis
ion c
and
inco
nsis
tenc
y d R
R 0
.74
(0.3
5-1.
58)
169
per
1,00
0 e 43
few
er p
er 1
,000
(fro
m 1
09 fe
wer
to
98 m
ore)
MI
nonf
atal
eve
nts
......
......
...St
roke
s at
30
d in
clud
es n
onfa
tal i
sche
mic
an
d he
mor
rhag
ic s
trok
es f
1,18
0 (5
RC
Ts), b,
g 1-1
2 m
oM
oder
ate
due
to
impr
ecis
ion h
0.01
(0.0
0-0.
02) i
0 pe
r 1,
000 e
10 m
ore
per
1,00
0 (f
rom
0 fe
wer
to
20 m
ore)
Maj
or e
xtra
cran
ial b
leed
at 3
0 d
1,07
0 (4
RC
Ts), b 1
-12
mo
Mod
erat
e du
e to
im
prec
isio
n j R
R 2
.34
(1.3
2-4.
14]
12 p
er 1
,000
e 16
mor
e pe
r 1,
000
(fro
m 3
mor
e to
37
mor
e)L
imb
salv
age
at 1
y65
4 (2
RC
Ts), b 1
2 m
oL
ow d
ue to
impr
ecis
ion c
and
inco
nsis
tenc
y k R
R 1
.00
(0.8
6-1.
17)
754
per
1,00
0 e 0
few
er p
er 1
,000
(fro
m 1
06 fe
wer
to
128
mor
e)A
mpu
tatio
n at
1 y
768
(3 R
CTs
), a 12
mo
Mod
erat
e du
e to
im
prec
isio
n c R
R 1
.10
(0.8
8-1.
38)
190
per
1,00
0 e 19
mor
e pe
r 1,
000
(fro
m 2
2 fe
wer
to
72 m
ore)
See
Tabl
e 1
and
2 le
gend
s fo
r ex
pans
ion
of a
bbre
viat
ions
. a O
urie
l et a
l 48 r
epor
ted
that
one
of 5
4 de
aths
in th
e th
rom
boly
sis
grou
p w
as fr
om in
trac
rani
al h
emor
rhag
e, w
here
as n
one
of 4
6 in
the
surg
ery
grou
p w
ere
from
intr
acra
nial
hem
orrh
age.
b For
one
stu
dy u
sing
thre
e di
ffer
ent d
oses
of t
he th
rom
boly
tic a
gent
, onl
y th
e op
timal
dos
e is
use
d fo
r co
mpa
riso
n w
ith s
urge
ry. C
ontr
ol g
roup
ris
k es
timat
es c
ome
from
con
trol
eve
nt r
ates
in th
e m
edia
n st
udy
(aft
er a
rran
ging
ris
ks in
incr
easi
ng o
rder
). c T
he 9
5% C
I fo
r ab
solu
te e
ffec
t inc
lude
s im
port
ant b
enefi
t an
d ha
rm.
d I 2 5
80%
. e C
ontr
ol r
isk
estim
ates
from
med
ian
or r
epre
sent
ativ
e co
ntro
l gro
up r
isk
of in
clud
ed s
tudi
es.
f Of r
epor
ted
nonf
atal
str
okes
, all
happ
ened
in th
e th
rom
boly
sis
grou
p, a
nd a
ll w
ere
intr
acra
nial
hem
orrh
ages
(eig
ht o
f eig
ht [1
00%
]).
g Wea
ver
et a
l 53 in
clud
ed p
atie
nts
with
bot
h ac
ute
and
chro
nic
limb
isch
emia
. h T
he 9
5% C
I fo
r ab
solu
te e
ffec
t inc
lude
s im
port
ant b
enefi
t an
d ha
rm; l
ow n
umbe
r of
eve
nts
(eig
ht).
i Poo
led
risk
diff
eren
ce p
rese
nted
inst
ead
of r
elat
ive
risk
. j T
he 9
5% C
Is a
re w
ide,
low
num
ber
of e
vent
s (6
0).
k I 2 5
49%
.
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
www.chestpubs.org CHEST / 141 / 2 / FEBRUARY, 2012 SUPPLEMENT e683S
dures. Current practice is very heterogeneous and often is based on indirect evidence from studies in patients undergoing coronary stenting.
7.1 Antithrombotic Therapy Following PTA With and Without Stent Procedures
A Cochrane review 59 pooled data from two early studies, including 356 patients undergoing lower-extremity PTA without stent placement, and found a possible reduction in reocclusion at 6 months in patients taking aspirin plus dipyridamole compared with placebo (OR, 0.69; 95% CI, 0.44-1.10). 60,61 Two other studies failed to demonstrate or exclude an effect of aspirin and dipyridamole vs phenprocoumon (vitamin K antagonist) in reocclusion at 6 months following PTA (OR, 0.78; 95% CI, 0.43-1.41). 62,63 One study failed to demonstrate or exclude an effect on 12-month reocclusion in patients taking ticlopidine compared with phenprocoumon (OR, 0.71; 95% CI, 0.37-1.36). 64 An additional study randomized 179 patients following PTA (pelvic or lower extremity) complicated by extensive dissection to IV unfraction-ated heparin vs subcutaneous nadroparin (a low-molecular-weight heparin) administered for 1 week postprocedure (followed by 6 months of aspirin in each arm). 65 Nadroparin was associated with a reduction in vessel restenosis/occlusion at 6 months (OR, 0.35; 95% CI, 0.19-0.65) but failed to demonstrate or exclude an effect on amputation (OR, 1.0; 95% CI, 0.20-5.10).
We have identifi ed no RCTs comparing anti-thrombotic agents post-PTA with stent placement. Indeed, it remains unclear whether PTA with stent placement is superior to PTA alone with respect to patient-important outcomes. In a recent meta-analysis of 10 RCTs, PTA plus routine stenting for superfi cial femoropopliteal arterial disease was asso-ciated with a possible reduction in restenosis (RR, 0.85; 95% CI, 0.69-1.06) compared with PTA without routine stenting but failed to demonstrate or exclude an effect on need for target vessel revascularization (RR, 0.98; 95% CI, 0.78-1.23). 66
Nevertheless, stenting is performed frequently. Despite low-quality evidence regarding thienopyri-dines in patients undergoing PTA with stent place-ment for PAD, many interventionists provide a loading dose of clopidogrel in addition to aspirin pre-procedure and then continue dual antiplatelet ther-apy for 1 to 3 months post-PTA (particularly if a stent is placed in a small peripheral vessel). The rationale for this practice is based on the results from coro-nary artery stenting trials (see section 3 of Vandvik et al 4 in this supplement).
We are skeptical about extrapolating these data to all patients with PAD given differences in the
6.3 Comparison of Intraarterial Thrombolytic Agents for Acute Limb Ischemia
In the past, thrombolysis for acute limb ischemia was administered by IV; now this strategy has been replaced by catheter-directed thrombolysis. Evi-dence comparing the effi cacy of different intraarte-rial thrombolytic agents for acute limb ischemia is limited. However, in a Cochrane systematic review, Robertson et al 54 identifi ed four randomized trials comparing recombinant tissue-type plasminogen activator (rt-PA), urokinase, or streptokinase for the management of acute lower-limb ischemia. 55-58 Included was one small RCT comparing intraarte-rial streptokinase to intraarterial rt-PA in 40 patients with acute limb ischemia. 55 With streptokinase, there was an increased rate of amputation at 30 days (seven of 20 vs one of 20; RR, 7.0; 95% CI, 0.95-51.80). Results failed to demonstrate or exclude an effect of streptokinase vs intraarterial rt-PA on asymptomatic limb salvage, major hemorrhage, or death.
Initially, streptokinase was the most widely used agent, but since this study 55 and because of other safety concerns (eg, allergic reactions), it has largely been replaced by urokinase and rt-PA. 54 Three RCTs compared intraarterial urokinase to rt-PA for acute peripheral arterial occlusion. 56-58 The overall quality for this comparison is low because of imprecision in outcome estimates as well as limitations in design and execution. Results failed to demonstrate or to exclude an effect of intraarterial rt-PA vs intraarterial uroki-nase on amputation, limb salvage, major hemorrhage, or death (Table S12).
Recommendation
6.1-6.3. In patients with acute limb ischemia due to arterial emboli or thrombosis, we sug-gest immediate systemic anticoagulation with unfractionated heparin over no anticoagula-tion (Grade 2C) ; we suggest reperfusion therapy (surgery or intraarterial thrombolysis) over no reperfusion therapy (Grade 2C) ; and we recom-mend surgery over intraarterial thrombolysis (Grade 1B) . In patients undergoing intraarterial thrombolysis, we suggest rt-PA or urokinase over streptokinase (Grade 2C) .
7.0 Endovascular Revascularization in Patients With Symptomatic PAD
Patients with refractory claudication, rest pain, and ischemia often require revascularization for symp-tomatic relief and limb salvage. Increasingly, patients are undergoing PTA with or without stent placement. Few studies guide clinicians regarding type and dura-tion of antithrombotic therapy following such proce-
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
e684S Antithrombotic Therapy in Peripheral Artery Disease
that evaluated the impact of aspirin and dipyridamole vs placebo in patients postinfrainguinal (venous or prosthetic) bypass graft surgery (for refractory clau-dication and limb salvage). The relative effects of aspirin plus dipyridamole vs aspirin alone have not been evaluated.
The overall quality of the evidence is low because of indirectness (loss of graft patency being a surro-gate for amputation) and bias ( Table 6 , Table S13). Aspirin plus dipyridamole may result in 22 fewer graft occlusions per 1,000 patients (32 fewer to 12 fewer) treated for 12 months. Only one study pro-vided data on amputation rates wherein aspirin plus dipyridamole compared with placebo for 12 months was associated with a possible reduction in amputa-tions (34 fewer amputations per 1,000 patients treated [51 fewer to one more]). Pooled data from three studies reporting other vascular outcomes suggested that treatment with aspirin plus dipyridamole was associated with a possible reduction in nonfatal MI but failed to demonstrate or exclude an effect on nonfatal stroke. Aspirin plus dipyridamole was associ-ated with a possible increase in bleeding (eight more major bleeding events per 1,000 treated [one fewer to 30 more]).
8.2 Aspirin With or Without Dipyridamole vs Other Agents
The same Cochrane review presented evidence from studies comparing aspirin with or without dipyri-damole to other agents. 68 These other agents included low-molecular-weight heparin, indobufen, pentox-ifylline, and prostaglandins. All these studies failed to demonstrate or exclude an effect of these agents compared with aspirin with or without dipyridam-ole in long-term graft patency or major extracranial bleeding. Individual studies were underpowered for assessment of treatment differences in MI, stroke, or mortality.
8.3 Clopidogrel Plus Aspirin vs Aspirin Alone
The Clopidogrel and Acetylsalicyclate Acid in Bypass Surgery for Peripheral Arterial Disease (CASPAR) study randomized 851 patients under-going unilateral below-knee bypass graft surgery for PAD to clopidogrel (75 mg/d) plus aspirin (75-100 mg/d) vs placebo plus aspirin. 75 In the overall cohort, aspirin and clopidogrel failed to demon-strate or exclude an effect on limb amputation, non-fatal extracranial bleeding, or total mortality compared with aspirin alone (Table S14).
Randomization of patients in this trial was strati-fi ed according to graft type (venous or prosthetic), and the investigators undertook prespecifi ed analy-sis of these subgroups. In the subgroup of patients
risk of stent thrombosis (lower in stenting of larger-caliber peripheral arteries compared with smaller coronary arteries), difference in stent types, and dif-fering outcomes related to stent thrombosis (limb ischemia vs MI). Furthermore, dual antiplatelet ther-apy is associated with an increased risk of major bleeding compared with single antiplatelet ther-apy (see sections 2 and 3 of Vandvik et al 4 in this supplement).
Recommendation
7.1. For patients undergoing peripheral artery PTA with or without stenting, we recommend long-term aspirin (75-100 mg/d) or clopidogrel (75 mg/d) (Grade 1A) . For patients undergoing peripheral artery PTA with stenting, we suggest single rather than dual antiplatelet therapy (Grade 2C) .
Values and preferences: Patients who place a high value on an uncertain reduction in the risk of limb loss and a relatively low value on avoiding a potential increased risk of bleeding are likely to choose to use dual antiplatelet therapy.
8.0 Antithrombotic Therapy Following Peripheral Artery Bypass Graft Surgery
In this section, we review evidence from studies evaluating antithrombotic therapy following periph-eral bypass surgery. For the most part, these data do not suggest that recommendations for antithrom-botic therapy following peripheral artery bypass sur-gery should differ from that in other patients with symptomatic PAD. One exception is the use of dual antiplatelet therapy in patients following prosthetic graft bypass surgery.
Selection of Baseline Risk Estimate
For the comparison of warfarin vs aspirin or clopid-ogrel plus aspirin vs aspirin following PAD surgery, we used as our baseline risk estimate the event rates from patients receiving aspirin in the Dutch Bypass Oral Anticoagulants or Aspirin (BOA) study normalized to 1 year. 67 For the comparison of aspi-rin plus dipyridamole vs placebo, we calculated base-line risk estimates in the placebo group by applying the relative risk for placebo vs aspirin plus dipyri-damole to the aforementioned aspirin baseline risk estimate. 68
8.1 Aspirin and Dipyridamole vs Placebo
We used the data from the Cochrane review of six RCTs with a total of 966 patients 69-74 by Brown et al 68
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
www.chestpubs.org CHEST / 141 / 2 / FEBRUARY, 2012 SUPPLEMENT e685S
Tabl
e 6—
[Sec
tion
8.1
-8.3
] Su
mm
ary
of F
indi
ngs:
Asp
irin
Plu
s D
ipyr
idam
ole
vs P
lace
bo
for
Pre
vent
ion
of T
hrom
bos
is A
fter
Per
iphe
ral
Byp
ass
Surg
ery
Out
com
esPa
rtic
ipan
ts (S
tudi
es),
Fol
low
-up
Qua
lity
of th
e E
vide
nce
(GR
AD
E)
Rel
ativ
e E
ffec
t (9
5% C
I)
Ant
icip
ated
Abs
olut
e E
ffec
ts O
ver
1 y
Ris
k W
ithou
t Asp
irin
Ris
k D
iffer
ence
With
Asp
irin
(95%
CI)
Tota
l mor
talit
y75
0 (3
RC
Ts),
12 m
oM
oder
ate
due
to im
prec
isio
n a R
R 0
.86
(0.6
-1.2
2)10
5 pe
r 1,
000 b
14 fe
wer
per
1,0
00 (f
rom
42
few
er to
23
mor
e)M
I no
nfat
al e
vent
s66
7 (3
RC
Ts),
12 m
oM
oder
ate
due
to im
prec
isio
n c R
R 0
.65
(0.4
-1.0
6)28
per
1,0
00 b
9 fe
wer
per
1,0
00 (f
rom
16
few
er to
1
mor
e)St
roke
, d inc
ludi
ng n
onfa
tal i
sche
mic
an
d he
mor
rhag
ic s
trok
es66
7 (3
RC
Ts),
12 m
oM
oder
ate
due
to im
prec
isio
n a R
R 0
.79
(0.4
2-1.
49)
27 p
er 1
,000
b 5
few
er p
er 1
,000
(fro
m 1
5 fe
wer
to
13 m
ore)
Maj
or e
xtra
cran
ial b
leed
e 59
8 (2
RC
Ts),
12 m
oM
oder
ate
due
to im
prec
isio
n f R
R 1
.86
(0.8
5-4.
04)
10 p
er 1
,000
b 8
mor
e pe
r 1,
000
(fro
m 1
few
er to
30
mor
e)A
mpu
tatio
n14
8 (1
RC
Ts),
12 m
oL
ow d
ue to
ris
k of
bia
s g and
im
prec
isio
n c R
R 0
.52
(0.2
7-1.
01)
71 p
er 1
,000
b 34
few
er p
er 1
,000
(fro
m 5
1 fe
wer
to
1 m
ore)
Am
puta
tion
infe
rred
from
loss
of
gra
ft p
aten
cy96
6 (6
RC
Ts),
12 m
oL
ow d
ue to
ris
k of
bia
s g and
in
dire
ctne
ss h
RR
0.6
8 (0
.55-
0.83
)71
per
1,0
00 b
22 fe
wer
per
1,0
00 (f
rom
32
few
er to
12
few
er)
See
Tabl
e 1
and
2 le
gend
s fo
r ex
pans
ion
of a
bbre
viat
ions
. a T
he 9
5% C
Is in
clud
e im
port
ant b
enefi
t an
d ha
rm.
b Con
trol
gro
up r
isk
estim
ate
deri
ved
from
app
licat
ion
of r
elat
ive
risk
of p
lace
bo v
s as
piri
n/di
pyri
dam
ole
to a
spir
in e
vent
rat
e in
a la
rge
RC
T (B
OA
[Dut
ch B
ypas
s O
ral a
ntic
oagu
lant
s or
Asp
irin
stu
dy])
co
mpa
ring
war
fari
n to
asp
irin
follo
win
g pe
riph
eral
art
ery
bypa
ss s
urge
ry. 61
c T
he 9
5% C
Is in
clud
e im
port
ant b
enefi
t an
d no
ben
efi t.
d Non
e of
the
stro
kes
was
due
to in
trac
rani
al h
emor
rhag
e. e O
f the
se b
leed
s, fi
ve o
f 19
(26%
) wer
e G
I. f T
he 9
5% C
Is in
clud
e no
ben
efi t
and
impo
rtan
t har
m.
g Pro
blem
s w
ith a
lloca
tion
conc
ealm
ent,
blin
ding
. h G
raft
pat
ency
is s
urro
gate
for
ampu
tatio
n.
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
e686S Antithrombotic Therapy in Peripheral Artery Disease
in patients undergoing below-knee prosthetic graft placement, our recommendations for long-term anti-thrombotic therapy following peripheral bypass surgery are the same as those for other patients with symp-tomatic PAD (see section 2).
Recommendation
8.1-8.4. We recommend one of the following antithrombotic regimens to be continued long term in most patients following peripheral artery bypass graft surgery over no antithrom-botic treatment: aspirin 75 to 100 mg daily or clopidogrel 75 mg daily (all Grade 1A) . We rec-ommend single antiplatelet therapy over anti-platelet therapy and warfarin (Grade 1B) . In patients undergoing below-knee bypass graft surgery with prosthetic grafts, we suggest clo-pidogrel 75 mg/d plus aspirin (75-100 mg/d) over aspirin alone for 1 year (Grade 2C) . For all other patients, we suggest single over dual anti-platelet therapy (Grade 2B) .
9.0 Carotid Artery Stenosis
Carotid stenosis may coexist in asymptomatic patients as well as in symptomatic patients with CAD or PAD. Recent prevalence estimates range from 0.2% in men aged , 50 years to 7.5% in men aged � 80 years. 76
9.1 Primary Prevention of Cardiovascular Events
As with patients with asymptomatic PAD, we con-sider the evidence for aspirin therapy for the primary prevention of vascular events and total mortality described in Vandvik et al 4 applicable to patients with asymptomatic carotid stenosis (Table S2). Patients with asymptomatic carotid stenosis may be stratifi ed into low, moderate, or high risk for vascular events as described in section 2 of the cited article. Our recom-mendations for primary prevention in patients with asymptomatic carotid stenosis, therefore, are iden-tical to those for patients with asymptomatic PAD or at risk for CAD. Section 1.2 of Vandvik et al 4 in this supplement provides a more-detailed discussion of the evidence.
9.2 Antithrombotic Therapy for Secondary Prevention in Patients With Symptomatic Carotid Stenosis
The article by Lansberg et al 77 in this supplement provides a full description of the evidence and rec-ommendations for antithrombotic therapy for sec-ondary prevention in patients with symptomatic carotid stenosis. Recommendations are repeated here for readers’ ease of use.
undergoing venous graft bypass (n 5 598), there were no signifi cant differences in the rates of amputation, major bleeding, or death between the two treatment arms. However, in the subgroup of patients under-going prosthetic graft bypass (n 5 253), there was a signifi cant decrease in amputations in patients treated with clopidogrel plus aspirin (24 per 1,000 treated; 95% CI, 35 fewer to three fewer; P 5 .008 using the Wald test for interaction) (Table S15). The sub-study analysis failed to demonstrate or exclude an effect of clopidogrel and aspirin on total mor-tality or major extracranial bleeding. The quality of this evidence is considered low given very serious imprecision.
8.4 Oral Anticoagulants vs Antiplatelet Agents
The BOA study randomized 2,650 patients who had undergone infrainguinal bypass grafting to either high-intensity oral anticoagulation (with phen-procoumon or acenocoumarol [target international normalized ratio, 3-4.5]) or aspirin. 67 Table S16 pro-vides a review of the evidence and quality of this study. This study failed to demonstrate or exclude an effect of oral anticoagulation vs aspirin on all-cause mortality, nonfatal stroke, or limb loss. Although associated with a possible reduction in nonfatal MI, there was a signifi cant increase in extra-cranial major bleeding events in the oral anticoagula-tion group.
Warfarin Plus Aspirin vs Warfarin Alone: Two studies compared warfarin plus aspirin to aspirin alone in patients after lower-limb surgical bypass. 19,20 Both studies were included in the previous eval-uation of the comparison of warfarin plus aspirin vs aspirin alone in patients with symptomatic PAD (see section 3).
In summary, the quality of the evidence for antiplatelet and antithrombotic therapy following PAD surgery for patient-important outcomes, such as amputation, limb loss, and mortality is low to moderate. Aspirin plus dipyridamole was associated with a possible reduction in amputation compared with placebo, but no comparison with aspirin alone has been performed. We did not identify any stud-ies comparing aspirin alone to no aspirin. Aspirin plus clopidogrel was associated with a decrease in amputations over aspirin alone in a subgroup of patients undergoing prosthetic graft placement in one study. 75 Warfarin with or without aspirin is asso-ciated with a signifi cant increase in extracranial bleed-ing compared with aspirin alone. The impact of these therapies on other critical vascular outcomes (nonfa-tal MI or stroke) cannot be adequately assessed based on these studies. With the exception of a weak rec-ommendation for clopid ogrel plus aspirin for 1 year
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
www.chestpubs.org CHEST / 141 / 2 / FEBRUARY, 2012 SUPPLEMENT e687S
Recommendations
9.1. For persons with asymptomatic carotid ste-nosis, we suggest aspirin 75 to 100 mg daily over no aspirin therapy (Grade 2B) .
Remarks: Aspirin slightly reduces total mortality regardless of cardiovascular risk profi le if taken over 10 years. In people at moderate to high risk of cardio-vascular events, the reduction in MI is closely balanced with an increase in major bleeds. Whatever their risk status, people who are averse to taking medication over a prolonged time period for very small benefi ts will be disinclined to use aspirin for primary prophylaxis.
9.2-9.3. In patients with symptomatic carotid stenosis (including recent carotid endarterec-tomy), we recommend long-term antiplatelet therapy (clopidogrel [75 mg once daily] or aspirin-extended-release dipyridamole [25 mg/200 mg bid] or aspirin [75-100 mg once daily]) over no antiplatelet therapy (Grade 1A) . We suggest either clopidogrel (75 mg once daily) or aspirin-extended-release dipyridamole (25 mg/200 mg nid) over aspirin (75-100 mg/day) (Grade 2B) .
Acknowledgments Author contributions: As Topic Editor, Dr Alonso-Coello over-saw the development of this article, including the data analysis and subsequent development of the recommendations contained herein. Dr Alonso-Coello: contributed as Topic Editor. Dr Bellmunt: contributed as a frontline clinician . Dr McGorrian: contributed as a panelist. Dr Anand: contributed as a panelist. Dr Guzman: contributed as a panelist. Dr Criqui: contributed as a panelist. Dr Akl: contributed as a panelist. Dr Vandvik: contributed as a panelist. Dr Lansberg: contributed as a panelist. Dr Guyatt: contributed as a panelist. Dr Spencer: contributed as Deputy Editor. Financial/nonfi nancial disclosures: The authors of this guide-line provided detailed confl ict of interest information related to each individual recommendation made in this article. A grid of these disclosures is available online at http://chestjournal.chestpubs.org/content/141/2_suppl/e669S/suppl/DC1. In summary, the authors have reported to CHEST the following confl icts of interest: Dr Bullmunt received funds from Roche for a study unrelated to this guideline and received funds from Ferrer Laboratory for writing a public document related to cilostazol. Dr McGorrian has received conference travel support from Pfi zer Ireland Ltd. Dr Guyatt is co-chair of the GRADE Working Group. Drs Alonso-Coello, Akl, and Vandvik are members of and promi-nent contributors to the GRADE Working Group. Drs Anand, Guzman, Criqui, Lansberg, and Spencer have reported that no potential confl icts of interest exist with any companies/organiza-tions whose products or services may be discussed in this article . Role of sponsors : The sponsors played no role in the develop-ment of these guidelines. Sponsoring organizations cannot recom-mend panelists or topics, nor are they allowed prepublication access to the manuscripts and recommendations. Guideline panel members, including the chair, and members of the Health & Sci-ence Policy Committee are blinded to the funding sources. Fur-ther details on the Confl ict of Interest Policy are available online at http://chestnet.org. Other contributions: We acknowledge Saurabh Kalra for his important contribution to this article, especially in the section on
9.3 Antithrombotic Therapy for Secondary Prevention in Patients Following Carotid Endarterectomy
We believe that the evidence for patients with symptomatic carotid stenosis also applies to patients following carotid endarterectomy (even if previ-ously asymptomatic). Therefore, recommendations for therapy following carotid endartectomy are the same as for patients with symptomatic carotid stenosis.
There are no studies evaluating timing of initiation of antithrombotic therapy before or after endarter-ectomy. For recommendations regarding continua-tion and discontinuation of antithrombotic therapy and timing of reinitiation relative to surgery, see Douketis et al 78 in this supplement.
For completeness, we summarize the limited direct evidence for antiplatelet therapy in patients follow-ing carotid endarterectomy. A Cochrane systematic review identifi ed six RCTs comparing antiplatelet therapy to no antiplatelet therapy in patients with symptomatic or asymptomatic carotid stenosis under-going carotid endarterectomy (with � 3 months of follow-up). 79 Four of the trials tested aspirin (dose range, 50-1,300 mg), 80-83 one trial tested aspirin (990 mg) plus dipyridamole (225 mg), 84 and one trial tested indobufen (400 mg). 85 Five of the six trials used placebo controls. Timing of initiation of anti-platelet therapy ranged from 12 h prior to carotid endarterectomy to up to 3 months after carotid endarterectomy; treatment and follow-up duration ranged from 6 to 54 months. Antiplatelet drugs were associated with a signifi cant reduction in strokes (OR, 0.58; 95% CI, 0.34-0.98); the estimated abso-lute effect was 34 fewer per 1,000 patients treated (2 fewer to 54 fewer). Results failed to demonstrate or exclude an effect of antiplatelet therapy on vas-cular mortality, nonfatal MI, or nonfatal extracranial hemorrhages. Overall quality of the evidence is low because of risk of bias, imprecision, and inconsistency.
Previously presented data in patients with vas-cular disease suggested no benefi t and probable increased harm associated with increasing aspirin doses (section 2 of Vandvik et al 4 ). In addition, the Aspirin and Carotid Endarterectomy trial randomly assigned 2,849 patients scheduled for endarterec-tomy to one of four doses of aspirin (81, 325, 650, and 1,300 mg). 86 Aspirin was started before surgery and continued for 3 months. The combined rate of stroke, MI, and death was lower in the low-dose groups (81 and 325 mg) than in the high-dose groups at 30 days (5.4% vs 7.0%, P 5 .07) and at 3 months (6.2% vs 8.4%, P 5 .03). No RCTs measured patient-important outcomes comparing clopidogrel vs aspirin or clopidogrel plus aspirin vs single antiplatelet ther-apy in patients undergoing carotid endarterectomy.
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
e688S Antithrombotic Therapy in Peripheral Artery Disease
12 . Rothwell PM , Fowkes FG , Belch JF , Ogawa H , Warlow CP , Meade TW . Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from ran-domised trials . Lancet . 2011 ; 377 ( 9759 ): 31 - 41 .
13 . Raju NC , Sobieraj-Teague M , Hirsh J , O’Donnell M , Eikelboom J . Effect of aspirin mortality in primary prevention of cardiovascular disease . Am J Med . 2011 ;124(7):621-6329.
14 . Sun X , Briel M , Walter SD , Guyatt GH . Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses . BMJ . 2010 ; 340 : c117 .
15 . CAPRIE Steering Committee . A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events . Lancet . 1996 ; 348 : 1329 - 1339 .
16 . Sudlow CL , Mason G , Maurice JB , Wedderburn CJ , Hankey GJ . Thienopyridine derivatives versus aspirin for pre-venting stroke and other serious vascular events in high vas-cular risk patients . Cochrane Database Syst Rev . 2009 ;( 4 ): CD001246 .
17 . Keller TT , Squizzato A , Middeldorp S . Clopidogrel plus aspi-rin versus aspirin alone for preventing cardiovascular disease . Cochrane Database Syst Rev . 2007 ;( 3 ): CD005158 .
18 . Bhatt DL , Fox KA , Hacke W , et al ; CHARISMA Inves-tigators . Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events . N Engl J Med . 2006 ; 354 ( 16 ): 1706 - 1717 .
19 . Johnson WC , Williford WO ; Department of Veterans Affairs Cooperative Study #362 . Benefi ts, morbidity, and mortality asso-ciated with long-term administration of oral anticoagulant ther apy to patients with peripheral arterial bypass proce-dures: a prospective randomized study . J Vasc Surg . 2002 ; 35 ( 3 ): 413 - 421 .
20 . Sarac TP , Huber TS , Back MR , et al . Warfarin improves the outcome of infrainguinal vein bypass grafting at high risk for failure . J Vasc Surg . 1998 ; 28 ( 3 ): 446 - 457 .
21 . Anand S , Yusuf S , Xie C , et al ; Warfarin Antiplatelet Vascular Evaluation Trial Investigators . Oral anticoagulant and anti-platelet therapy and peripheral arterial disease . N Engl J Med . 2007 ; 357 ( 3 ): 217 - 227 .
22 . Girolami B , Bernardi E , Prins MH , et al . Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis . Arch Intern Med . 1999 ; 159 ( 4 ): 337 - 345 .
23 . Jonason T , Bergström R . Cessation of smoking in patients with intermittent claudication. Effects on the risk of periph-eral vascular complications, myocardial infarction and mor-tality . Acta Med Scand . 1987 ; 221 ( 3 ): 253 - 260 .
24 . Gardner AW , Poehlman ET . Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis . JAMA . 1995 ; 274 ( 12 ): 975 - 980 .
25 . Furukawa TA . From effect size into number needed to treat . Lancet . 1999 ; 353 ( 9165 ): 1680 .
26 . Thorlund K , Walter S , Johnston B , Furukawa TA , Guyatt G . Pooling health-related quality of life outcomes in meta-analysis—a tutorial and review of methods for enhancing interpretability. Research Synthesis Methods. 2011 .
27 . Tamhane U , Meier P , Chetcuti S , et al . Effi cacy of cilostazol in reducing restenosis in patients undergoing contemporary stent based PCI: a meta-analysis of randomised controlled trials . EuroIntervention . 2009 ; 5 ( 3 ): 384 - 393 .
28 . Robless P , Mikhailidis DP , Stansby GP . Cilostazol for periph-eral arterial disease . Cochrane Database Syst Rev . 2008 ;( 1 ): CD003748 .
29 . Squires H , Simpson E , Meng Y , Harnan S , Stevens J , Wong R. Cilostazol, Naftidrofuryl Oxalate, Pentoxifylline, and Inositol Nicotinate for Intermittent Claudication in People With Peripheral Arterial Disease . London, England: National Institute for Health and Clinical Excellence; 2011 :1-252.
acute limb ischemia. We acknowledge Kristian Thorlund, PhD, for assistance on presentation of continuous outcomes. We thank John Eikelboom, MD, for his contribution of estimates of total mortality for patients on or off aspirin (primary prevention) and Sam Schulman, MD, for assistance with interpretation of bleeding defi nitions. We thank John Wong, MD, for assistance in identify-ing cost-effectiveness implications. Endorsements: This guideline is endorsed by the American Association for Clinical Chemistry, the American College of Clin-ical Pharmacy, the American Society of Health-System Pharma-cists, the American Society of Hematology, and the International Society of Thrombosis and Hematosis. Additional information: The supplement Tables can be found in the Online Data Supplement at http://chestjournal.chestpubs.org/content/141/2_suppl/e669S/suppl/DC1.
References 1 . Rothwell PM , Wilson M , Elwin CE , et al . Long-term effect
of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of fi ve randomised trials . Lancet . 2010 ; 376 ( 9754 ): 1741 - 1750 .
2 . MacLean S , Mulla S , Akl EA , et al . Patient values and pref-erences in decision making for antithrombotic therapy: a systematic review: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines . Chest . 2012 ; 141 ( 2 ) (suppl): e1S-e23S.
3 . Guyatt GH , Norris SL , Schulman S , et al . Methodology for the development of antithrombotic therapy and prevention of thrombosis guidelines: antithrombotic therapy and pre-vention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines . Chest . 2012 ; 141 ( 2 ) (suppl): 50S-67S.
4 . Vandvik PO , Lincoff AM , Gore JM , et al. Primary and sec-ondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest . 2011 ;141(2)(suppl):e637S-e668S.
5 . Leng GC , Fowkes FG , Lee AJ , Dunbar J , Housley E , Ruckley CV . Use of ankle brachial pressure index to pre-dict cardiovascular events and death: a cohort study . BMJ . 1996 ; 313 ( 7070 ): 1440 - 1444 .
6 . Newman AB , Shemanski L , Manolio TA , et al ; The Cardiovascular Health Study Group . Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study . Arterioscler Thromb Vasc Biol . 1999 ; 19 ( 3 ): 538 - 545 .
7 . Resnick HE , Lindsay RS , McDermott MM , et al . Relation-ship of high and low ankle brachial index to all-cause and cardiovascular disease mortality: the Strong Heart Study . Circulation . 2004 ; 109 ( 6 ): 733 - 739 .
8 . Ogren M , Hedblad B , Isacsson SO , Janzon L , Jungquist G , Lindell SE . Non-invasively detected carotid stenosis and ischaemic heart disease in men with leg arteriosclerosis . Lancet . 1993 ; 342 ( 8880 ): 1138 - 1141 .
9 . van der Meer IM , Bots ML , Hofman A , del Sol AI , van der Kuip DA , Witteman JC . Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarc-tion: the Rotterdam Study . Circulation . 2004 ; 109 ( 9 ): 1089 - 1094 .
10 . Fowkes FG , Murray GD , Butcher I , et al ; Ankle Brachial Index Collaboration . Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis . JAMA . 2008 ; 300 ( 2 ): 197 - 208 .
11 . Baigent C , Blackwell L , Collins R , et al ; Antithrombotic Trialists’ (ATT) Collaboration . Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials . Lancet . 2009 ; 373 ( 9678 ): 1849 - 1860 .
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
www.chestpubs.org CHEST / 141 / 2 / FEBRUARY, 2012 SUPPLEMENT e689S
49 . Ouriel K , Veith FJ , Sasahara AA ; Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators . A comparison of recombinant urokinase with vascular surgery as initial treat-ment for acute arterial occlusion of the legs . N Engl J Med . 1998 ; 338 ( 16 ): 1105 - 1111 .
50 . Nilsson L , Albrechtsson U , Jonung T , et al . Surgical treatment versus thrombolysis in acute arterial occlusion: a randomised controlled study . Eur J Vasc Surg . 1992 ; 6 ( 2 ): 189 - 193 .
51 . Ouriel K , Shortell CK , DeWeese JA , et al . A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia . J Vasc Surg . 1994 ; 19 ( 6 ): 1021 - 1030 .
52 . Ouriel K , Veith FJ , Sasahara AA ; TOPAS Investigators . Thrombolysis or peripheral arterial surgery: phase I results . J Vasc Surg . 1996 ; 23 ( 1 ): 64 - 75.
53 . Weaver FA , Comerota AJ , Youngblood M , Froehlich J , Hosking JD , Papanicolaou G . Surgical revascularization versus thrombolysis for nonembolic lower extremity native artery occlusions: results of a prospective randomized trial. The STILE Investigators. Surgery versus Thrombolysis for Ischemia of the Lower Extremity . J Vasc Surg . 1996 ; 24 ( 4 ): 513 - 523.
54 . Robertson I , Kessel DO , Berridge DC . Fibrinolytic agents for peripheral arterial occlusion . Cochrane Database Syst Rev . 2010 ;( 3 ): CD001099 .
55 . Berridge DC , Gregson RH , Hopkinson BR , Makin GS . Randomized trial of intra-arterial recombinant tissue plas-minogen activator, intravenous recombinant tissue plasmin-ogen activator and intra-arterial streptokinase in peripheral arterial thrombolysis . Br J Surg . 1991 ; 78 ( 8 ): 988 - 995 .
56 . Mahler F , Schneider E , Hess H ; Steering Committee, Study on Local Thrombolysis . Recombinant tissue plasminogen activator versus urokinase for local thrombolysis of femoro-popliteal occlusions: a prospective, randomized multicenter trial . J Endovasc Ther . 2001 ; 8 ( 6 ): 638 - 647 .
57 . Meyerovitz MF , Goldhaber SZ , Reagan K , et al . Recombi-nant tissue-type plasminogen activator versus urokinase in peripheral arterial and graft occlusions: a randomized trial . Radiology . 1990 ; 175 ( 1 ): 75 - 78 .
58 . Schweizer J , Altmann E , Stösslein F , Florek HJ , Kaulen R . Comparison of tissue plasminogen activator and urokinase in the local infi ltration thrombolysis of peripheral arterial occlusions . Eur J Radiol . 1996 ; 22 ( 2 ): 129 - 132 .
59 . Dörffl er-Melly J , Koopman MM , Prins MH , Büller HR . Antiplatelet and anticoagulant drugs for prevention of rest-enosis/reocclusion following peripheral endovascular treat-ment . Cochrane Database Syst Rev . 2005 ;( 1 ): CD002071 .
60 . Heiss HW , Just H , Middleton D , Deichsel G . Reocclusion prophylaxis with dipyridamole combined with acetylsalicylic acid following PTA . Angiology . 1990 ; 41 ( 4 ): 263 - 269 .
61 . Study Group on Pharmacological Treatment After TPA. Platelet inhibition with ASA/dipyridamole after percutaneous balloon angioplasty in patients with symptomatic lower limb arterial disease. A prospective double-blind trial . Eur J Vasc Surg . 1994 ; 8 ( 1 ): 83 - 88 .
62 . Do DD , Mahler F . Low-dose aspirin combined with dipyrida-mole versus anticoagulants after femoropopliteal percutaneous transluminal angioplasty . Radiology . 1994 ; 193 ( 2 ): 567 - 571 .
63 . Pilger E , Lammer J , Bertuch H , et al . Nd:YAG laser with sapphire tip combined with balloon angioplasty in periph-eral arterial occlusions. Long-term results . Circulation . 1991 ; 83 ( 1 ): 141 - 147 .
64 . Schneider E . Rezidivprophylaxe nach perkutaner translu-minaler Angioplastie (PTA): antikoagulation versus ticlopi-din. In: Huber H, ed. Fortschritte in der Angiologie . Bern, Switzerland: Sage; 1987 : 355 - 356 .
65 . Schweizer J , Müller A , Forkmann L , Hellner G , Kirch W . Potential use of a low-molecular-weight heparin to prevent
30 . Hiatt WR , Money SR , Brass EP . Long-term safety of cilosta-zol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg . 2008 ;47(2):330-336.
31 . Beebe HG , Dawson DL , Cutler BS , et al . A new pharma-cological treatment for intermittent claudication: results of a randomized, multicenter trial . Arch Intern Med . 1999 ; 159 ( 17 ): 2041 - 2050 .
32 . Money SR , Herd JA , Isaacsohn JL , et al . Effect of cilosta-zol on walking distances in patients with intermittent clau-dication caused by peripheral vascular disease . J Vasc Surg . 1998 ; 27 ( 2 ): 267 - 274, discussion 274-275.
33 . Strandness DE Jr , Dalman RL , Panian S , et al . Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study . Vasc Endovascular Surg . 2002 ; 36 ( 2 ): 83 - 91 .
34 . O’Donnell ME , Badger SA , Sharif MA , Young IS , Lee B , Soong CV . The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. J Vasc Surg . 2009 ;49(5):1226-1234.
35 . Dawson DL , Cutler BS , Hiatt WR , et al . A comparison of cilostazol and pentoxifylline for treating intermittent claudi-cation . Am J Med . 2000 ; 109 ( 7 ): 523 - 530 .
36 . Pratt CM . Analysis of the cilostazol safety database . Am J Cardiol . 2001 ; 87 ( 12A ): 28D - 33D .
37 . Cosmi B , Conti E , Coccheri S . Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for inter-mittent claudication . Cochrane Database Syst Rev . 2001 ;( 3 ): CD001999 .
38 . Antonicelli R , Sardina M , Scotti A , Bonizzoni E , Paciaroni E ; Italian CAP Study Group . Randomized trial of the effects of low-dose calcium-heparin in patients with peripheral arterial disease and claudication . Am J Med . 1999 ; 107 ( 3 ): 234 - 239 .
39 . Tesi M , Bronchi GF , Carini A , Morfi ni M , Cinotti S, Filiberti E . Effi cacy and safety of a new low molecular weight heparin in the medium term treatment of atherosclerotic arteriopathy of the lower limbs. J Drug Dev . 1989 ; 2 (2): 73 - 82 .
40 . Calabrò A , Piarulli F , Milan D , Rossi A , Coscetti G , Crepaldi G . Clinical assessment of low molecular weight heparin effects in peripheral vascular disease . Angiology . 1993 ; 44 ( 3 ): 188 - 195 .
41 . Mannarino E , Pasqualini L , Innocente S , et al . Effi cacy of low-molecular-weight heparin in the management of inter-mittent claudication . Angiology . 1991 ; 42 ( 1 ): 1 - 7 .
42 . Palmieri G , Ambrosi G , Agrati AM , Ferraro G , Marcozzi S . A new low molecular weight heparin in the treatment of peripheral arterial disease . Int Angiol . 1988 ; 7 ( 3 suppl ): 41 - 47 .
43 . Momsen AH , Jensen MB , Norager CB , Madsen MR , Vestersgaard-Andersen T , Lindholt JS . Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised con-trolled studies . Eur J Vasc Endovasc Surg . 2009 ; 38 ( 4 ): 463 - 474 .
44 . Ruffolo AJ , Romano M , Ciapponi A . Prostanoids for crit-ical limb ischaemia . Cochrane Database Syst Rev . 2010 ;( 1 ): CD006544 .
45 . Walker TG . Acute limb ischemia . Tech Vasc Interv Radiol . 2009 ; 12 ( 2 ): 117 - 129 .
46 . Norgren L , Hiatt WR , Dormandy JA , Nehler MR , Harris KA , Fowkes FG . Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg . 2007 ;45(suppl S):S5-S67.
47 . O’Connell JB , Quiñones-Baldrich WJ . Proper evaluation and management of acute embolic versus thrombotic limb ischemia . Semin Vasc Surg . 2009 ; 22 ( 1 ): 10 - 16 .
48 . Berridge DC , Kessel D , Robertson I . Surgery versus thromboly-sis for acute limb ischaemia: initial management . Cochrane Database Syst Rev . 2002 ;( 3 ): CD002784 .
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
e690S Antithrombotic Therapy in Peripheral Artery Disease
restenosis in patients with extensive wall damage following peripheral angioplasty . Angiology . 2001 ; 52 ( 10 ): 659 - 669 .
66 . Kasapis C , Henke PK , Chetcuti SJ , et al . Routine stent implantation vs. percutaneous transluminal angioplasty in femoropopliteal artery disease: a meta-analysis of randomized controlled trials . Eur Heart J . 2009 ; 30 ( 1 ): 44 - 55 .
67 . Dutch Bypass Oral Anticoagulants or Aspirin (BOA) Study Group. Effi cacy of oral anticoagulants compared with aspirin after infrainguinal bypass surgery (The Dutch Bypass Oral Anticoagulants or Aspirin Study): a randomised trial . Lancet . 2000 ; 355 ( 9201 ): 346 - 351 .
68 . Brown J , Lethaby A , Maxwell H , Wawrzyniak AJ , Prins MH . Antiplatelet agents for preventing thrombosis after periph-eral arterial bypass surgery . Cochrane Database Syst Rev . 2008 ;( 4 ): CD000535 .
69 . Clyne CA , Archer TJ , Atuhaire LK , Chant AD , Webster JH . Random control trial of a short course of aspirin and dipyri-damole (Persantin) for femorodistal grafts . Br J Surg . 1987 ; 74 ( 4 ): 246 - 248 .
70 . Goldman M , McCollum C . A prospective randomized study to examine the effect of aspirin plus dipyridamole on the patency of prosthetic femoro-popliteal grafts. Vasc Surg . 1984 ; 18 (4): 217 - 221 .
71 . Donaldson DR , Salter MCP , Kester RC , et al . The infl u-ence of platelet inhibition on the patency of femoro-popliteal Dacron bypass grafts . Vasc Surg . 1985 ; 19 (4): 224 - 230 .
72 . Green RM , Roedersheimer LR , DeWeese JA . Effects of aspirin and dipyridamole on expanded polytetrafl uoroethyl-ene graft patency . Surgery . 1982 ; 92 ( 6 ): 1016 - 1026 .
73 . Kohler TR , Kaufman JL , Kacoyanis G , et al . Effect of aspirin and dipyridamole on the patency of lower extremity bypass grafts . Surgery . 1984 ; 96 ( 3 ): 462 - 466 .
74 . McCollum C , Alexander C , Kenchington G , Franks PJ , Greenhalgh R . Antiplatelet drugs in femoropopliteal vein bypasses: a multicenter trial . J Vasc Surg . 1991 ; 13 ( 1 ): 150 - 162.
75 . Belch JJ , Dormandy J , Biasi GM , et al . Results of the random-ized, placebo-controlled clopidogrel and acetylsalicylic acid in bypass surgery for peripheral arterial disease (CASPAR) trial. J Vasc Surg . 2010 ;52(4):825-833.
76 . de Weerd M , Greving JP , Hedblad B , et al . Prevalence of asymptomatic carotid artery stenosis in the general popula-
tion: an individual participant data meta-analysis . Stroke . 2010 ; 41 ( 6 ): 1294 - 1297 .
77 . Lansberg MG , O’Donnell MJ , Khatri P , et al . Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines . Chest . 2012 ; 141 ( 2 ) (suppl): e601S-e636S.
78 . Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2)(suppl):e326S-e350S.
79 . Engelter S , Lyrer P . Antiplatelet therapy for preventing stroke and other vascular events after carotid endarterec-tomy . Cochrane Database Syst Rev . 2003 ;( 3 ): CD001458 .
80 . Fields WS , Lemak NA , Frankowski RF , Hardy RJ . Con-trolled trial of aspirin in cerebral ischemia. Part II: surgical group . Stroke . 1978 ; 9 ( 4 ): 309 - 319 .
81 . Boysen G , Sørensen PS , Juhler M , et al . Danish very-low-dose aspirin after carotid endarterectomy trial . Stroke . 1988 ; 19 ( 10 ): 1211 - 1215 .
82 . Kretschmer G , Pratschner T , Prager M , et al . Antiplatelet treatment prolongs survival after carotid bifurcation endar-terectomy. Analysis of the clinical series followed by a con-trolled trial . Ann Surg . 1990 ; 211 ( 3 ): 317 - 322 .
83 . Lindblad B , Persson NH , Takolander R , Bergqvist D . Does low-dose acetylsalicylic acid prevent stroke after carotid sur-gery? A double-blind, placebo-controlled randomized trial . Stroke . 1993 ; 24 ( 8 ): 1125 - 1128 .
84 . Harker LA , Bernstein EF , Dilley RB , et al . Failure of aspirin plus dipyridamole to prevent restenosis after carotid endar-terectomy . Ann Intern Med . 1992 ; 116 ( 9 ): 731 - 736 .
85 . Pratesi C , Pulli R , Milanesi G , Lavezzari M , Pamparana F , Bertini D . Indobufen versus placebo in the prevention of restenosis after carotid endarterectomy: a double-blind pilot study . J Int Med Res . 1991 ; 19 ( 3 ): 202 - 209 .
86 . Taylor DW , Barnett HJ , Haynes RB , et al . Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators . Lancet . 1999 ; 353 ( 9171 ): 2179 - 2184 .
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
Online Data SupplementCHEST
1 © 2012 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians ( www . chestjournal . org / site / misc / reprints . xhtml ). DOI: 10.1378/chest.11-2307
Antithrombotic Therapy in Peripheral Artery Disease
Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines
Pablo Alonso-Coello , MD, PhD ; Sergi Bellmunt , MD ; Catherine McGorrian , MBBCh, BAO ; Sonia S. Anand , MD, PhD ; Randolph Guzman , MD, RVT ; Michael H. Criqui , MD, MPH ; Elie A. Akl , MD , MPH, PhD ; Per Olav Vandvik , MD, PhD ; Maarten G. Lansberg , MD, PhD ; Gordon H. Guyatt , MD, FCCP ; and Frederick A. Spencer , MD
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
2© 2012 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/site/misc/reprints.xhtml). DOI: 10.1378/chest.11-2307
Tabl
e S1
—[I
ntro
duct
ion]
Qu
esti
on D
efi n
itio
n an
d E
ligi
bil
ity
Cri
teri
a fo
r A
ntit
hrom
bot
ic T
reat
men
ts i
n PA
D
Sect
ion
Info
rmal
Que
stio
n
PIC
O Q
uest
ion
Popu
latio
nIn
terv
entio
nsC
ompa
rato
rO
utco
mes
2.0
Asy
mpt
omat
ic P
AD
2
.1C
hoic
e of
ant
ithro
mbo
tic
th
erap
yPa
tient
s w
ith a
sym
ptom
atic
PAD
(eg,
AB
PI ,
0.9
)A
spir
inPl
aceb
oTo
tal m
orta
lity
Non
fata
l MI
Non
fata
l str
oke
Maj
or n
onfa
tal
ex
trac
rani
al b
leed
3.0
Sym
ptom
atic
PA
D: p
reve
ntio
n of
car
diov
ascu
lar
even
ts
3
.1C
hoic
e of
ant
ithro
mbo
tic
th
erap
yPa
tient
s w
ith s
ympt
omat
ic P
AD
Asp
irin
Plac
ebo
Tota
l mor
talit
y
3
.2C
lopi
dogr
elA
spir
inN
onfa
tal M
I
3
.3A
spir
in 1
clop
idog
rel
Asp
irin
Non
fata
l str
oke
3
.4A
spir
in 1
OA
Cs
Asp
irin
Maj
or n
onfa
tal
ex
trac
rani
al b
leed
4.0
Sym
ptom
atic
PA
D: m
anag
emen
t of c
laud
icat
ion
4
.1C
hoic
e of
ant
ithro
mbo
tic
th
erap
yPa
tient
s w
ith c
laud
icat
ion
Hep
arin
sPl
aceb
oQ
ualit
y of
life
4
.2C
ilost
azol
Plac
ebo
or p
ento
xify
lline
Max
imum
wal
king
dist
ance
4
.3Pe
ntox
ifylli
nePl
aceb
oM
ajor
non
fata
l
extr
acra
nial
ble
edin
g
4
.4Pr
osta
glan
dins
Plac
ebo
Mor
talit
y
Adv
erse
eve
nts
5.0
Sym
ptom
atic
PA
D: m
anag
emen
t of c
ritic
al li
mb
isch
emia
5
.1C
hoic
e of
ant
ithro
mbo
tic
th
erap
yPa
tient
s w
ith c
ritic
al li
mb
is
chem
ia u
nabl
e to
und
ergo
re
vasc
ular
izat
ion
Pros
tagl
andi
nsPl
aceb
oR
est p
ain
relie
f
Ulc
er h
ealin
g
Am
puta
tions
Mor
talit
y
Adv
erse
eve
nts
(Con
tinu
ed)
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
3© 2012 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/site/misc/reprints.xhtml). DOI: 10.1378/chest.11-2307
Tabl
e S1
—C
onti
nued
Sect
ion
Info
rmal
Que
stio
n
PIC
O Q
uest
ion
Popu
latio
nIn
terv
entio
nsC
ompa
rato
rO
utco
mes
6.0
Acu
te li
mb
isch
emia
6
.1C
hoic
e of
ant
ithro
mbo
tic
th
erap
yPa
tient
s w
ith a
cute
limb
isch
emia
Unf
ract
iona
ted
hepa
rin
No
antic
oagu
latio
nD
eath
6
.2In
traa
rter
ial t
hrom
boly
tic
th
erap
ySu
rger
yA
mpu
tatio
n
6
.3U
roki
nase
or
rt-P
ASt
rept
okin
ase
Non
fata
l str
oke
Maj
or n
onfa
tal
ex
trac
rani
al b
leed
7.0
End
ovas
cula
r su
rger
y
7
.1C
hoic
e of
ant
ithro
mbo
tic
th
erap
y po
st P
TA �
sten
tPa
tient
s un
derg
oing
any
gra
ftA
spir
in p
lus
dipy
rida
mol
ePl
aceb
oVe
ssel
res
teno
sis/
oc
clus
ion
Asp
irin
/dip
yrid
amol
ePh
enpr
ocou
mon
Ticl
opid
ine
Phen
proc
oum
on
Unf
ract
iona
ted
hepa
rin
Subc
utan
eous
nadr
opar
in (L
MW
H)
8.0
Ope
n lo
wer
-lim
b va
scul
ar s
urge
ry
8
.1C
hoic
e of
ant
ithro
mbo
tic
th
erap
yPa
tient
s un
derg
oing
PTA
Asp
irin
or
aspi
rin/
dipy
rida
mol
ePl
aceb
oVa
scul
ar m
orta
lity
8
.2Pa
tient
s un
derg
oing
bel
ow-k
nee
pr
osth
etic
gra
ftA
spir
in o
r as
piri
n/di
pyri
dam
ole
Oth
er a
gent
sN
onfa
tal M
I
8
.3C
lopi
dogr
el p
lus
aspi
rin
Asp
irin
Non
fata
l str
oke
8
.4O
AC
s � as
piri
nA
spir
inM
ajor
non
fata
l
extr
acra
nial
ble
ed
8
.5A
spir
in p
lus
clop
idog
rel
Asp
irin
Am
puta
tion
9.0
Car
otid
ste
nosi
s
9
.1C
hoic
e of
ant
ithro
mbo
tic
th
erap
yPa
tient
s w
ith a
sym
ptom
atic
caro
tid s
teno
sis
Asp
irin
Plac
ebo
Tota
l mor
talit
y
9
.2Pa
tient
s w
ith s
ympt
omat
ic
ca
rotid
ste
nosi
sA
ntip
late
let a
gent
s po
st
en
dart
erec
tom
yPl
aceb
oN
onfa
tal M
I
9
.3Pa
tient
s w
ith c
arot
id s
teno
sis
un
derg
oing
end
arte
rect
omy
Non
fata
l str
oke
Maj
or n
onfa
tal
ex
trac
rani
al b
leed
A
BPI
5 a
nkle
-bra
chia
l pre
ssur
e in
dex;
LM
WH
5 lo
w-m
olec
ular
-wei
ght h
epar
in; M
I 5 m
yoca
rdia
l inf
arct
ion;
OA
C 5
ora
l ant
icoa
gula
nt; P
AD
5 p
erip
hera
l art
eria
l dis
ease
; PIC
O 5
pop
ulat
ion,
inte
rven
tion,
co
mpa
rato
r, ou
tcom
e; P
TA 5
per
cuta
neou
s tr
ansl
umin
al a
ngio
plas
ty; r
t-PA
5 re
com
bina
nt ti
ssue
-typ
e pl
asm
inog
en a
ctiv
ator
.
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
4© 2012 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/site/misc/reprints.xhtml). DOI: 10.1378/chest.11-2307
Tabl
e S2
—[S
ecti
on 1
.1]
Evi
denc
e P
rofi l
e: A
spir
in (
75-1
00 m
g) C
ompa
red
Wit
h N
o A
spir
in i
n th
e P
rim
ary
Pre
vent
ion
of C
ardi
ovas
cula
r D
isea
se
Qua
lity
Ass
essm
ent
Sum
mar
y of
Fin
ding
s
Part
icip
ants
(S
tudi
es),
Fol
low
-up
Ris
k of
Bia
sIn
cons
iste
ncy
Indi
rect
ness
Impr
ecis
ion
Publ
icat
ion
Bia
sR
elat
ive
Eff
ect
(95%
CI)
Ant
icip
ated
Abs
olut
e E
ffec
ts
Tim
e F
ram
e: 1
0 y
Qua
lity
of
Evi
denc
e W
ithou
t Asp
irin
With
Asp
irin
(9
5% C
I)
Ove
rall
mor
talit
y (c
ritic
al o
utco
me)
, inc
ludi
ng c
ance
r m
orta
lity,
vas
cula
r m
orta
lity,
and
fata
l ble
eds a
100,
076
(9 R
CTs
),
3.8-
10 y
No
seri
ous
ri
sk o
f bia
s b N
o se
riou
s
inco
nsis
tenc
yN
o se
riou
s
indi
rect
ness
Seri
ous
impr
ecis
ion
C
I in
clud
es
no b
enefi
t
Und
etec
ted
RR
0.9
4 (0
.88-
1.00
)60
-y-o
ld m
an c
Mod
erat
e du
e
to im
prec
isio
n 10
0 de
aths
per
1,0
00 d
6 fe
wer
dea
ths
pe
r 10
00 (f
rom
12
few
er
to 0
few
er)
Non
fata
l MI
(cri
tical
out
com
e)
95,0
00 (6
RC
Ts),
3.
8-10
yN
o se
riou
s
risk
of b
ias b
No
seri
ous
in
cons
iste
ncy
No
seri
ous
in
dire
ctne
ssN
o se
riou
s
impr
ecis
ion
Und
etec
ted
RR
0.7
7 (0
.69-
0.86
)L
ow-r
isk
popu
latio
n e H
igh
27 M
I pe
r 1,
000 d
6 fe
wer
MI
pe
r 1,
000
(fro
m 8
few
er
to 4
few
er)
Mod
erat
e-ri
sk p
opul
atio
n e
83 M
I pe
r 1,
000 d
19 fe
wer
MI
pe
r 1,
000
(fro
m 2
6 fe
wer
to
12
few
er)
Hig
h-ri
sk p
opul
atio
n e
136
MI
per
1,00
0 d 31
few
er M
I
per
1,00
0 (f
rom
42
few
er
to 1
9 fe
wer
)
Non
fata
l str
oke
(cri
tical
out
com
e), i
nclu
des
isch
emic
, hem
orrh
agic
, and
unk
now
n ca
use f
95,0
00 (6
RC
Ts),
3.
8-10
yN
o se
riou
s
risk
of b
ias b
No
seri
ous
in
cons
iste
ncy
No
seri
ous
in
dire
ctne
ssN
o se
riou
s
impr
ecis
ion
Und
etec
ted
RR
0.9
5 (0
.85-
1.06
)L
ow-r
isk
popu
latio
n e H
igh
23 s
trok
es p
er 1
,000
d 1
few
er s
trok
e
per
1,00
0 (f
rom
3 fe
wer
to
1 m
ore)
Mod
erat
e-ri
sk p
opul
atio
n e
65 s
trok
es p
er 1
,000
d 3
few
er s
trok
es
pe
r 1,
000
(fro
m 1
0 fe
wer
to
4m
ore)
Hig
h-ri
sk p
opul
atio
n e
108
stro
kes
per
1,00
0 d 5
few
er s
trok
es
pe
r 1,
000
(fro
m 1
6 fe
wer
to
6 m
ore)
(C
onti
nued
)
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
5© 2012 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/site/misc/reprints.xhtml). DOI: 10.1378/chest.11-2307
Qua
lity
Ass
essm
ent
Sum
mar
y of
Fin
ding
s
Part
icip
ants
(S
tudi
es),
Fol
low
-up
Ris
k of
Bia
sIn
cons
iste
ncy
Indi
rect
ness
Impr
ecis
ion
Publ
icat
ion
Bia
sR
elat
ive
Eff
ect
(95%
CI)
Ant
icip
ated
Abs
olut
e E
ffec
ts
Tim
e F
ram
e: 1
0 y
Qua
lity
of
Evi
denc
e W
ithou
t Asp
irin
With
Asp
irin
(9
5% C
I)
Maj
or e
xtra
cran
ial b
leed
(im
port
ant o
utco
me)
: mai
nly
GI
and
usua
lly d
efi n
ed a
s bl
eed
requ
irin
g tr
ansf
usio
n or
res
ultin
g in
dea
th e
95,0
00 (6
RC
Ts),
3.
8-10
yN
o se
riou
s
risk
of b
ias b
No
seri
ous
in
cons
iste
ncy
No
seri
ous
in
dire
ctne
ssN
o se
riou
s
impr
ecis
ion
Und
etec
ted
RR
1.5
4 (1
.30-
1.82
)L
ow-r
isk
popu
latio
n g H
igh
8 bl
eeds
per
1,0
00 d
4 m
ore
blee
ds
pe
r 1,
000
(fro
m 2
mor
e to
7 m
ore)
Mod
erat
e-ri
sk p
opul
atio
n g
24 b
leed
s pe
r 1,
000 d
16 m
ore
blee
ds
pe
r 1,
000
(fro
m 7
mor
e to
20
mor
e)
Hig
h-ri
sk p
opul
atio
n g
40 b
leed
s pe
r 1,
000 d
22 m
ore
blee
ds
pe
r 1,
000
(fro
m 1
2 m
ore
to 3
3 m
ore)
Bib
liogr
aphy
: Ant
ithro
mbo
tic T
rial
ists
’ (AT
T)
Col
labo
ratio
n; G
aige
nt C
, Bla
ckw
ell L
, Col
lins
R, e
t al
. Asp
irin
in t
he p
rim
ary
and
seco
ndar
y pr
even
tion
of v
ascu
lar
dise
ase:
col
labo
rativ
e m
eta-
anal
ysis
of
indi
vidu
al p
artic
ipan
t dat
a fr
om ra
ndom
ized
tria
ls. L
ance
t . 20
09;3
73(9
678)
:184
9-18
60. R
aju
N, S
obie
raj-T
eagu
e M
, Hir
sh J,
O’D
onne
ll M
, Eik
elbo
om J.
Eff
ect o
f asp
irin
on
mor
talit
y in
pri
mar
y pr
even
tion
of c
ardi
ovas
cula
r di
seas
e. A
m J
Med
, 201
1;12
4(7)
:621
-629
. a RC
T 5
rand
omiz
ed c
ontr
olle
d tr
ial;
RR
5 ri
sk r
atio
. See
Tab
le S
1 fo
r ex
pans
ion
of o
ther
abb
revi
atio
n.
a Thi
s sy
stem
atic
rev
iew
rep
orts
tota
l mor
talit
y an
d in
clud
es th
e m
ost r
ecen
t tri
als
but d
oes
not r
epor
t spe
cifi c
cau
ses
of m
orta
lity.
Oth
er m
eta-
anal
yses
that
use
indi
vidu
al p
atie
nt d
ata
repo
rt r
elat
ive
risk
es
timat
es fo
r va
scul
ar m
orta
lity
(RR
, 0.9
7; 9
5% C
I, 0
.87-
1.09
) can
cer
mor
talit
y (R
R, 0
.66;
95%
CI,
0.5
0-0.
87),
and
fata
l int
racr
ania
l ble
eds
(RR
, 1.7
3; 9
5% C
I, 0
.96-
3.13
). T
he r
isk
of a
fata
l ble
ed (i
nclu
ding
ex
trac
rani
al a
nd in
trac
rani
al) w
as lo
w (0
.3%
with
asp
irin
and
0.2
% w
ith c
ontr
ol).
b Bor
derl
ine
deci
sion
whe
re w
e di
d no
t rat
e do
wn
for r
isk
of b
ias.
Thr
ee o
f the
tria
ls d
id n
ot b
lind
patie
nts,
car
egiv
ers,
or o
utco
me
adju
dica
tor.
Sens
itivi
ty a
naly
ses i
n m
eta-
anal
ysis
by
Raj
u et
al d
id n
ot sh
ow
evid
ence
of r
isk
of b
ias.
c C
ontr
ol g
roup
ris
k es
timat
e fo
r 10
-y m
orta
lity
appl
y to
a 6
0-y-
old
man
and
com
e fr
om p
opul
atio
n-ba
sed
data
from
Sta
tistic
s N
orw
ay. M
orta
lity
incr
ease
s w
ith a
ge (e
g, 5
0-y-
old
man
, 50
deat
hs p
er 1
,000
in
10 y
) and
is lo
wer
in w
omen
than
in m
en (e
g, 3
% in
wom
en a
ged
50 y
vs
5% in
men
age
d 50
y).
d Con
trol
gro
up r
isk
estim
ates
in lo
w-,
mod
erat
e-, a
nd h
igh-
risk
car
diov
ascu
lar
grou
ps a
re b
ased
on
the
Fra
min
gham
sco
re. A
s ex
plai
ned
in th
e ar
ticle
, we
have
use
d da
ta fr
om a
n in
divi
dual
par
ticip
ant d
ata
(IPD
) met
a-an
alys
is to
pro
vide
est
imat
ed r
isks
for
patie
nt-im
port
ant o
utco
mes
not
cov
ered
by
the
Fra
min
gham
ris
k sc
ore.
We
have
als
o ad
just
ed fo
r 20
% o
vere
stim
atio
n as
soci
ated
with
Fra
min
gham
ris
k sc
ore.
e R
isk
grou
ps c
orre
spon
d to
low
ris
k (5
%),
med
ium
ris
k (1
5%),
or h
igh
risk
(25%
) acc
ordi
ng to
the
Fra
min
gham
sco
re (o
r ot
her
risk
tool
) to
estim
ate
10-y
ris
k.
f Of t
he s
trok
es in
the
tria
ls, 8
9 of
682
(13%
) with
out a
spir
in w
ere
hem
orrh
agic
and
116
of 6
55 (1
8%) w
ith a
spir
in w
ere
hem
orrh
agic
. g I
n th
e IP
D m
eta-
anal
ysis
, ris
k fo
r fu
ture
maj
or b
leed
ing
corr
elat
ed w
ith r
isk
for
futu
re c
ardi
ovas
cula
r ev
ents
. The
refo
re, w
e m
ake
the
assu
mpt
ion
that
a p
atie
nt a
t low
, med
ium
, or
high
ris
k of
futu
re c
ar-
diov
ascu
lar
even
ts (d
eter
min
ed b
y F
ram
ingh
am s
core
) will
be
at lo
w, m
ediu
m, o
r hi
gh r
isk
of fu
ture
maj
or b
leed
ing
even
ts, r
espe
ctiv
ely.
Tabl
e S2
—C
onti
nued
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
6© 2012 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/site/misc/reprints.xhtml). DOI: 10.1378/chest.11-2307
Tabl
e S3
—[S
ecti
on 3
.1-3
.4]
Evi
denc
e P
rofi l
e: A
spir
in v
s N
o A
spir
in i
n P
atie
nts
Wit
h Sy
mpt
omat
ic P
AD
Qua
lity
Ass
essm
ent
Sum
mar
y of
Fin
ding
s
Part
icip
ants
(S
tudi
es),
Fol
low
-up
Ris
k of
B
ias
Inco
nsis
tenc
yIn
dire
ctne
ssIm
prec
isio
nPu
blic
atio
n B
ias
Rel
ativ
e E
ffec
t (9
5% C
I)
Ant
icip
ated
Abs
olut
e E
ffec
ts
Tim
e F
ram
e: 5
y
Qua
lity
of
Evi
denc
e R
isk
With
out
Asp
irin
Ris
k D
iffer
ence
W
ith A
spir
in
(95%
CI)
Tota
l mor
talit
y (c
ritic
al o
utco
me)
: sud
den
deat
h, p
ulm
onar
y em
bolis
m, h
emor
rhag
e, u
nkno
wn
caus
e (p
ropo
rtio
n no
t rep
orte
d)
17,0
00 (1
6 R
CTs
),
27 m
oN
o se
riou
s
risk
of b
ias
No
seri
ous
lim
itatio
nsN
o se
riou
s
indi
rect
ness
Impr
ecis
e a
CI
incl
udes
be
nefi t
and
no
eff
ect
Und
etec
ted
RR
0.9
0 (0
.82-
0.99
)13
3 pe
r 1,
000 b
13 fe
wer
per
1,0
00
(f
rom
24
few
er
to 1
few
er)
Mod
erat
e du
e to
impr
ecis
ion a
Non
fata
l MI
(cri
tical
out
com
e)
17,0
00 (1
6 R
CTs
),
27 m
oN
o se
riou
s
risk
of b
ias
No
seri
ous
lim
itatio
nsN
o se
riou
s
indi
rect
ness
No
seri
ous
im
prec
isio
nU
ndet
ecte
dR
R 0
.69
(0.6
0-0.
80)
117
per
1,00
0 c 36
few
er p
er 1
,000
(fro
m 4
6 fe
wer
to
23
few
er)
Hig
h
Non
fata
l str
oke
(cri
tical
out
com
e), i
nclu
ding
isch
emic
, hem
orrh
agic
, and
unk
now
n ca
use c
17,0
00 (1
6 R
CTs
),
27 m
oN
o se
riou
s
risk
of b
ias
No
seri
ous
lim
itatio
nsN
o se
riou
s
indi
rect
ness
No
seri
ous
im
prec
isio
nU
ndet
ecte
dR
R 0
.81
(0.7
1-0.
92)
135
per
1,00
0 c 25
few
er p
er 1
,000
(fro
m 3
9 fe
wer
to
11
few
er)
Hig
h
Maj
or e
xtra
cran
ial b
leed
(im
port
ant o
utco
me)
17,0
00 (1
6 R
CTs
),
27 m
oN
o se
riou
s
risk
of b
ias
No
seri
ous
lim
itatio
nsIn
dire
ctne
ss. B
leed
ing
on
ly r
epor
ted
in
stro
ke/T
IA tr
ials
d
No
seri
ous
im
prec
isio
nU
ndet
ecte
dR
R 2
.69
(1.2
5-5.
76)
15 p
er 1
,000
e 25
mor
e pe
r 1,
000
(f
rom
4 m
ore
to 7
1 m
ore)
Mod
erat
e du
e to
indi
rect
ness
Bib
liogr
aphy
: Ant
ithro
mbo
tic T
rial
ists
’ (AT
T)
Col
labo
ratio
n; B
aige
nt C
, Bla
ckw
ell L
, Col
lins
R, e
t al
. Asp
irin
in t
he p
rim
ary
and
seco
ndar
y pr
even
tion
of v
ascu
lar
dise
ase:
col
labo
rativ
e m
eta-
anal
ysis
of
indi
vidu
al p
artic
ipan
t da
ta f
rom
ran
dom
ized
tri
als.
Lan
cet .
2009
;373
(967
8):1
849-
1860
. CA
PRIE
5 C
lopi
dogr
el v
s A
spir
in i
n Pa
tient
s at
Ris
k fo
r Is
chem
ic E
vent
s; C
HA
RIS
MA
5 C
lopi
dogr
el f
or H
igh
Ath
erot
hrom
botic
Ris
k an
d Is
chem
ic S
tabi
lizat
ion,
Man
agem
ent,
and
Avo
idan
ce; T
IA 5
tran
sien
t isc
hem
ic a
ttac
k. S
ee T
able
S1
and
S2 le
gend
s fo
r ex
pans
ion
of o
ther
abb
revi
atio
ns.
a Rat
ed d
own
for
impr
ecis
ion
beca
use
95%
CI
sugg
ests
pos
sibl
e be
nefi t
and
no
effe
ct o
n to
tal m
orta
lity
b Con
trol
gro
up r
isk
estim
ates
(with
out a
spir
in) c
ome
from
obs
erve
d ye
arly
eve
nt r
ates
in 1
6 R
CTs
rep
orte
d in
the
met
a-an
alys
is, a
djus
ted
to a
5-y
tim
e fr
ame.
The
con
trol
gro
up r
isk
estim
ate
for
tota
l mor
-ta
lity
with
out a
spir
in is
der
ived
from
the
even
t rat
e in
the
aspi
rin
arm
of t
he C
HA
RIS
MA
tria
l, us
ing
the
RR
of 0
.90
to g
et to
the
cont
rol g
roup
ris
k es
timat
e w
ithou
t asp
irin
. c O
f the
str
okes
in th
e m
eta-
anal
ysis
, 0.8
% w
ith a
spir
in w
ere
intr
acra
nial
hem
orrh
ages
, and
0.4
% o
f str
okes
with
out a
spir
in w
ere
intr
acra
nial
hem
orrh
ages
. d R
ated
dow
n fo
r in
dire
ctne
ss b
ecau
se b
leed
ing
was
onl
y re
port
ed in
sub
set o
f tri
als
with
str
oke/
TIA
pop
ulat
ions
. e T
o es
timat
e co
ntro
l gro
up r
isks
for
maj
or b
leed
ing
even
ts, w
e ha
ve u
sed
maj
or b
leed
ing
estim
ates
fro
m t
he a
spir
in a
rm in
the
CA
PRIE
tri
al a
s th
e st
artin
g po
int
(to
ensu
re c
onsi
sten
cy a
cros
s ev
iden
ce
profi
les)
. We
have
then
use
d th
e R
R o
f 2.6
9 to
get
to th
e co
ntro
l gro
up r
isk
estim
ate
with
out a
spir
in.
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
7© 2012 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/site/misc/reprints.xhtml). DOI: 10.1378/chest.11-2307
Tabl
e S4
—[S
ecti
on 3
.1-3
.4]
Evi
denc
e P
rofi l
e: C
lopi
dogr
el v
s A
spir
in f
or t
he S
econ
dary
Pre
vent
ion
of C
ardi
ovas
cula
r E
vent
s in
Pat
ient
s W
ith
Sym
ptom
atic
PA
D
Qua
lity
Ass
essm
ent
Sum
mar
y of
Fin
ding
s
Part
icip
ants
(S
tudi
es),
Fol
low
-up
Ris
k of
B
ias
Inco
nsis
tenc
yIn
dire
ctne
ssIm
prec
isio
nPu
blic
atio
n B
ias
Rel
ativ
e E
ffec
t (9
5% C
I)
Ant
icip
ated
Abs
olut
e E
ffec
ts
Tim
e F
ram
e: 5
y
Qua
lity
of
Evi
denc
e R
isk
With
A
spir
in
Ris
k D
iffer
ence
W
ith C
lopi
dogr
el
(95%
CI)
Tota
l mor
talit
y (c
ritic
al o
utco
me)
: fat
al M
I, fa
tal i
sche
mic
str
oke,
fata
l hem
orrh
agic
str
oke
and
othe
r va
scul
ar d
eath
a
19,1
85 (1
RC
T),
1.
9 y
No
seri
ous
ri
sk o
f bia
sN
o se
riou
s
inco
nsis
tenc
y Su
bgro
up a
naly
sis
sugg
este
d no
ben
efi t
in p
atie
nts
with
ac
ute
MI b
No
seri
ous
in
dire
ctne
ssSe
riou
s im
prec
isio
n
CI
incl
udes
ben
efi t
and
harm
with
cl
opid
ogre
l
Und
etec
ted
RR
0.9
8 (0
.87-
1.10
)12
0 pe
r 1,
000 c
2 fe
wer
per
1,0
00
(f
rom
16
few
er
to 1
2 m
ore)
Mod
erat
e du
e to
impr
ecis
ion
Non
fata
l MI
(cri
tical
out
com
e)
19,1
85 (1
RC
T),
1.
9 y
No
seri
ous
ri
sk o
f bia
sN
o se
riou
s
inco
nsis
tenc
yN
o se
riou
s
indi
rect
ness
Seri
ous
impr
ecis
ion
C
I in
clud
es b
enefi
t an
d no
ben
efi t
with
cl
opid
ogre
l
Und
etec
ted
RR
0.8
5 (0
.72-
1.0)
80 p
er 1
,000
c 12
few
er p
er 1
,000
(fro
m 2
2 fe
wer
to
0 m
ore)
Mod
erat
e du
e to
impr
ecis
ion
Non
fata
l str
oke
(cri
tical
out
com
e): i
sche
mic
and
hem
orrh
agic
str
oke d
19,1
85 (1
RC
T)
1.
9 y
No
seri
ous
ri
sk o
f bia
sN
o se
riou
s
inco
nsis
tenc
yN
o se
riou
s
indi
rect
ness
Seri
ous
impr
ecis
ion
C
I in
clud
es b
enefi
t an
d ha
rm w
ith
clop
idog
rel
Und
etec
ted
RR
0.9
4 (0
.83-
1.06
)11
0 pe
r 1,
000 c
6 fe
wer
per
1,0
00
(f
rom
18
few
er
to 6
mor
e)
Mod
erat
e du
e to
impr
ecis
ion
Maj
or e
xtra
cran
ial b
leed
(im
port
ant o
utco
me)
: any
ble
edin
g di
sord
er, s
ever
e e
19,1
85 (1
RC
T)
1.
9 y
No
seri
ous
ri
sk o
f bia
sN
o se
riou
s
inco
nsis
tenc
yN
o se
riou
s
indi
rect
ness
Seri
ous
impr
ecis
ion
C
I in
clud
es b
enefi
t an
d ha
rm w
ith
clop
idog
rel
Und
etec
ted
RR
0.8
8 (0
.7-1
.12)
40 p
er 1
,000
f 4
few
er p
er 1
,000
(fro
m 1
2 fe
wer
to
4 m
ore)
Mod
erat
e du
e to
impr
ecis
ion
Bib
liogr
aphy
: CA
PRIE
Ste
erin
g C
omm
ittee
. A r
ando
mis
ed, b
linde
d, tr
ial o
f clo
pido
grel
vs
aspi
rin
in p
atie
nts
at r
isk
for
isch
emic
eve
nts
(CA
PRIE
). L
ance
t . 19
96;3
48(9
038)
:132
9-13
39.
a Of t
he d
eath
s in
CA
PRIE
, 27
of 5
71 (4
.7%
) with
asp
irin
wer
e fa
tal b
leed
s an
d 23
of 5
60 (4
.1%
) with
clo
pido
grel
wer
e fa
tal b
leed
s. S
ee T
able
S1,
S2,
and
S3
lege
nds
for
expa
nsio
n of
abb
revi
atio
ns.
b Sub
grou
p an
alys
is o
f com
posi
te e
nd p
oint
rep
orte
d re
lativ
e ri
sk r
educ
tion
of 7
.3%
for
patie
nts
with
str
oke
and
23.8
% fo
r pa
tient
s w
ith P
AD
and
rel
ativ
e ri
sk in
crea
se o
f 3.7
% fo
r pa
tient
s w
ith M
I (t
est f
or
inte
ract
ion
P 5
.043
). B
ased
on
crite
ria
for
cred
ibili
ty, w
e di
d no
t bel
ieve
the
resu
lts fr
om th
e su
bgro
up a
naly
sis
and,
ther
efor
e, d
id n
ot r
ate
dow
n fo
r in
cons
iste
ncy.
c C
ontr
ol g
roup
ris
k es
timat
es fo
r to
tal m
orta
lity
com
es fr
om th
e as
piri
n ar
m o
f the
CH
AR
ISM
A tr
ial.
Est
imat
es fo
r M
I an
d st
roke
com
e fr
om o
bser
ved
even
ts in
a m
eta-
anal
ysis
of 1
6 R
CTs
in s
econ
dary
pr
even
tion
(Bai
gent
, see
Tab
le S
3 le
gend
) adj
uste
d to
5-y
tim
e fr
ame.
d O
f the
str
okes
in C
APR
IE, 2
4 of
486
(4.9
%) w
ith a
spir
in w
ere
hem
orrh
agic
, and
14
of 5
28 (2
.6%
) with
clo
pido
grel
wer
e he
mor
rhag
ic.
e Of t
he m
ajor
ext
racr
ania
l ble
eds
in C
APR
IE, 6
8 of
149
(45.
6%) w
ith a
spir
in w
ere
GI
and
47 o
f 132
(35.
6%) w
ith c
lopi
dogr
el w
ere
GI
( P 5
.05)
. f C
ontr
ol g
roup
ris
k es
timat
es c
ome
from
obs
erve
d m
ajor
ble
edin
g ev
ents
in th
e C
APR
IE tr
ial a
djus
ted
to 5
-y ti
me
fram
e an
d no
t fro
m th
e 16
stu
dies
incl
uded
in th
e m
eta-
anal
ysis
bec
ause
thes
e st
udie
s di
d no
t rep
ort m
ajor
ble
eds
cons
iste
ntly
.
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
8© 2012 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/site/misc/reprints.xhtml). DOI: 10.1378/chest.11-2307
Tabl
e S5
—[S
ecti
on 3
.1-3
.4]
Evi
denc
e P
rofi l
e: A
spir
in P
lus
Clo
pido
grel
vs
Asp
irin
for
Sec
onda
ry P
reve
ntio
n of
Car
diov
ascu
lar
Eve
nts
in P
atie
nts
Wit
h Sy
mpt
omat
ic P
AD
Qua
lity
Ass
essm
ent
Sum
mar
y of
Fin
ding
s
Part
icip
ants
(S
tudi
es),
Fol
low
-up
Ris
k of
Bia
sIn
cons
iste
ncy
Indi
rect
ness
Impr
ecis
ion
Publ
icat
ion
Bia
sR
elat
ive
Eff
ect
(95%
CI)
Ant
icip
ated
Abs
olut
e E
ffec
ts
Tim
e F
ram
e: 5
y
Qua
lity
of
Evi
denc
e R
isk
With
A
spir
in
Ris
k D
iffer
ence
With
A
spir
in 1
Clo
pido
grel
(9
5% C
I)
Tota
l mor
talit
y (c
ritic
al o
utco
me)
: inc
lude
s de
aths
from
car
diov
ascu
lar
caus
e an
d he
mor
rhag
e a
15,6
03 (1
RC
T),
28 m
oN
o se
riou
s
risk
of b
ias
No
seri
ous
In
cons
iste
ncy b
No
seri
ous
in
dire
ctne
ssSe
riou
s
impr
ecis
ion c
Und
etec
ted
RR
0.9
9 (0
.86-
1.14
)12
0 pe
r 1,
000 d
1 fe
wer
per
1,0
00
(f
rom
16
few
er
to 1
6 m
ore)
Mod
erat
e du
e to
impr
ecis
ion
Non
fata
l MI
(cri
tical
out
com
e)
15,6
03 (1
RC
T),
28 m
oN
o se
riou
s
risk
of b
ias
No
seri
ous
in
cons
iste
ncy
No
seri
ous
in
dire
ctne
ssSe
riou
s
impr
ecis
ion c
Und
etec
ted
RR
0.9
4 (0
.75-
1.18
)80
per
1,0
00 d
4 fe
wer
per
1,0
00
(f
rom
20
few
er
to 1
4 m
ore)
Mod
erat
e du
e to
impr
ecis
ion
Non
fata
l str
oke
(cri
tical
out
com
e): i
nclu
des
isch
emic
, hem
orrh
agic
, and
unk
now
n ca
use e
15,6
03 (1
RC
T),
28 m
oN
o se
riou
s
risk
of b
ias
No
seri
ous
in
cons
iste
ncy
No
seri
ous
in
dire
ctne
ssSe
riou
s
impr
ecis
ion c
Und
etec
ted
RR
0.8
1 (0
.64-
1.02
)11
0 pe
r 1,
000 d
20 fe
wer
per
1,0
00
(f
rom
39
few
er
to 2
mor
e)
Mod
erat
e du
e to
impr
ecis
ion
Maj
or e
xtra
cran
ial b
leed
(cri
tical
out
com
e): s
ever
e bl
eedi
ng a
s de
fi ned
by
the
GU
STO
cri
teri
a bu
t exc
lude
d fa
tal a
nd in
trac
rani
al b
leed
s f
15,6
03 (1
RC
T),
28 m
oN
o se
riou
s
risk
of b
ias
No
sero
us
in
cons
iste
ncy
No
seri
ous
in
dire
ctne
ssSe
riou
s
impr
ecis
ion g
Und
etec
ted
RR
1.2
5 (0
.97-
1.61
)40
per
1,0
00 h
10 m
ore
per
1,00
0
(fro
m 1
few
er
to 2
4 m
ore
Mod
erat
e du
e to
impr
ecis
ion
Bib
liogr
aphy
: Bha
tt D
, Fox
KA
, Hac
ke W
, et a
l. C
lopi
dogr
el a
nd a
spir
in v
s as
piri
n al
one
for
the
prev
entio
n of
ath
erot
hrom
botic
eve
nts.
N E
ngl J
Med
. 200
6;35
4(16
):170
6-17
17. G
UST
O 5
Glo
bal U
se o
f St
rate
gies
to O
pen
Occ
lude
d ar
teri
es. S
ee T
able
S1,
S2,
and
S3
lege
nds
for
expa
nsio
n of
oth
er a
bbre
viat
ions
. a O
f the
dea
ths
in C
HA
RIS
MA
, 17
of 5
71 (3
%) w
ith a
spir
in w
ere
fata
l ble
edin
g ev
ents
and
26
of 5
74 (4
.5%
) with
clo
pido
grel
and
asp
irin
wer
e fa
tal b
leed
ing
even
ts.
b Sub
grou
p an
alys
is fo
und
no s
igni
fi can
t eff
ect o
f clo
pido
grel
on
vasc
ular
mor
talit
y in
pat
ient
s w
ith e
stab
lishe
d ca
rdio
vasc
ular
dis
ease
, in
cont
rast
to in
crea
sed
mor
talit
y in
asy
mpt
omat
ic p
atie
nts.
We
judg
ed
clai
m o
f sub
grou
p ef
fect
to b
e no
t cre
dibl
e (h
igh
num
ber
of s
ubgr
oup
hypo
thes
es te
sted
, unc
lear
whe
ther
an
appr
opri
ate
test
for
inte
ract
ion
used
). c C
I in
clud
es im
port
ant b
enefi
t an
d ha
rm (f
or m
orta
lity)
and
no
bene
fi t (f
or s
trok
e).
d Con
trol
gro
up r
isk
estim
ates
for
tota
l mor
talit
y co
mes
from
the
aspi
rin
arm
of t
he C
HA
RIS
MA
tria
l. E
stim
ates
for
MI
and
stro
ke c
ome
from
obs
erve
d ev
ents
in a
met
a-an
alys
is o
f 16
RC
Ts in
sec
onda
ry
prev
entio
n (B
aige
nt, s
ee T
able
S3
lege
nd) a
djus
ted
to 5
-y ti
me
fram
e.
e Of t
he s
trok
es in
CH
AR
ISM
A, 2
7 of
189
(14%
) with
asp
irin
wer
e in
trac
rani
al h
emor
rhag
es, a
nd 2
6 of
150
(17%
) with
clo
pido
grel
wer
e in
trac
rani
al h
emor
rhag
es.
f We
excl
uded
fata
l ble
edin
g an
d in
trac
rani
al h
emor
rhag
e to
avo
id th
e do
uble
cou
ntin
g of
eve
nts i
n th
e C
HA
RIS
MA
tria
l. Pr
opor
tion
of se
vere
GI
blee
ds in
CH
AR
ISM
A w
as 0
.65%
(not
repo
rted
sepa
rate
ly
for
each
trea
tmen
t arm
). g C
I in
clud
es n
o be
nefi t
and
impo
rtan
t har
m.
h Con
trol
gro
up r
isk
estim
ates
com
e fr
om o
bser
ved
maj
or b
leed
ing
even
ts in
the
CA
PRIE
tria
l, ad
just
ed to
5-y
r tim
e fr
ame,
and
not
from
the
16 s
tudi
es in
clud
ed in
the
met
a-an
alys
is o
r fr
om C
HA
RIS
MA
as
thes
e st
udie
s di
d no
t rep
ort m
ajor
ble
eds
cons
iste
ntly
.
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
9© 2012 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/site/misc/reprints.xhtml). DOI: 10.1378/chest.11-2307
Tabl
e S6
—[S
ecti
on 3
.1-3
.4]
Evi
denc
e P
rofi l
e: M
oder
ate-
Inte
nsit
y W
arfa
rin
(IN
R 2
.0-3
.0)
Plu
s A
spir
in v
s A
spir
in A
lone
for
Sec
onda
ry P
reve
ntio
n of
Car
diov
ascu
lar
Eve
nts
in P
atie
nts
Wit
h Sy
mpt
omat
ic P
AD
Qua
lity
Ass
essm
ent
Sum
mar
y of
Fin
ding
s
Part
icip
ants
(S
tudi
es),
Fol
low
-up
Ris
k of
B
ias
Inco
nsis
tenc
yIn
dire
ctne
ssIm
prec
isio
nPu
blic
atio
n B
ias
Rel
ativ
e E
ffec
t (9
5% C
I)
Est
imat
ion
of A
bsol
ute
Eff
ects
Tim
e F
ram
e: 5
y
Qua
lity
of
Evi
denc
e E
vent
Rat
e W
ith A
spir
in
Ris
k D
iffer
ence
With
W
arfa
rin
1 A
spir
in
(95%
CI)
Tota
l mor
talit
y (c
ritic
al o
utco
me)
3,04
8 (3
RC
Ts),
35
-60
mo
No
seri
ous
ri
sk o
f bia
sSe
riou
s
inco
nsis
tenc
y a ( I
2 5 6
3%)
No
seri
ous
in
dire
ctne
ssIm
prec
ise
CI
in
clud
es b
enefi
t an
d ha
rm
Und
etec
ted
RR
1.1
1 (0
.79-
1.55
)12
0 pe
r 1,
000 b
13 m
ore
per
1,00
0
(fro
m 2
5 fe
wer
to
66 m
ore)
Low
due
to
im
prec
isio
n an
d in
cons
iste
ncy
Non
fata
l MI
(cri
tical
out
com
e)
3,04
8 (3
RC
Ts),
35
-60
mo
No
seri
ous
ri
sk o
f bia
sN
o se
riou
s
inco
nsis
tenc
yN
o se
riou
s
indi
rect
ness
Impr
ecis
e C
I
incl
udes
ben
efi t
and
harm
Und
etec
ted
RR
0.9
5 (0
.64-
0.1.
41)
80 p
er 1
,000
c 4
few
er p
er 1
,000
(fro
m 2
8 fe
wer
to
32 m
ore)
Mod
erat
e du
e to
impr
ecis
ion
Non
fata
l str
oke
(cri
tical
out
com
e): i
sche
mic
and
hem
orrh
agic
d
3,04
8 (3
RC
Ts),
35
-60
mo
No
seri
ous
ri
sk o
f bia
sN
o se
riou
s
inco
nsis
tenc
yN
o se
riou
s
indi
rect
ness
Impr
ecis
e C
I
incl
udes
ben
efi t
and
harm
Und
etec
ted
RR
0.9
2 (0
.64-
1.33
)11
0 pe
r 1,
000 c
8 fe
wer
per
1,0
00
(f
rom
39
few
er to
36
mor
e)
Mod
erat
e du
e to
impr
ecis
ion
Maj
or n
onfa
tal e
xtra
cran
ial b
leed
(cri
tical
out
com
e)
2,99
4 (2
RC
Ts),
35
-60
mo
No
seri
ous
ri
sk o
f bia
sN
o se
riou
s
inco
nsis
tenc
yN
o se
riou
s
indi
rect
ness
No
seri
ous
im
prec
isio
nU
ndet
ecte
dR
R 2
.39
(1.5
0-3.
82)
40 p
er 1
,000
e 55
mor
e pe
r 1,
000
(f
rom
20
mor
e to
11
2 m
ore)
Hig
h
Bur
den
of tr
eatm
ent (
impo
rtan
t out
com
e)
N/A
f W
arfa
rin
. a
spir
inW
arfa
rin:
dai
ly m
edic
atio
n,
di
etar
y an
d ac
tivity
re
stri
ctio
ns, f
requ
ent
bloo
d te
stin
g/m
onito
ring
, in
crea
sed
hosp
ital/c
linic
vi
sits
. d Asp
irin
: dai
ly
med
icat
ion
only
.
Hig
h
Bib
liogr
aphy
: Jo
hnso
n W
C,
Will
iford
WO
; D
epar
tmen
t of
Vet
eran
s A
ffai
rs C
oope
rativ
e St
udy
#362
. B
enefi
ts,
mor
bidi
ty,
and
mor
talit
y as
soci
ated
with
lon
g-te
rm a
dmin
istr
atio
n of
ora
l an
ticoa
gula
nt
ther
apy
to p
atie
nts
with
per
iphe
ral a
rter
ial b
ypas
s pr
oced
ures
: a p
rosp
ectiv
e ra
ndom
ized
stu
dy. J
Vas
c Su
rg . 2
002;
35(3
):41-
421.
Sar
ac T
P, H
uber
TS,
Bac
k M
R, e
t al
. War
fari
n im
prov
es t
he o
utco
me
of
infr
aing
uina
l vei
n by
pass
gra
ftin
g at
hig
h ri
sk fo
r fa
ilure
. J V
asc
Surg
. 199
8;28
(3):4
46-4
57. A
nand
S, Y
usuf
S, X
ie C
, et a
l; W
arfa
rin
Ant
ipla
tele
t Vas
cula
r E
valu
atio
n Tr
ial I
nves
tigat
ors.
Ora
l ant
icoa
gula
nt
and
antip
late
let t
hera
py a
nd p
erip
hera
l art
eria
l dis
ease
. N E
ngl J
Med
. 200
7;35
7(3)
:217
-227
. IN
R 5
inte
rnat
iona
l nor
mal
ized
rat
io; N
/A 5
not
app
licab
le. S
ee T
able
S1,
S2,
and
S3
lege
nds
for
expa
nsio
n of
ot
her
abbr
evia
tions
. a E
xces
s ca
ncer
dea
ths
in o
ne s
tudy
with
war
fari
n an
d as
piri
n.
b Con
trol
gro
up ri
sk e
stim
ates
for t
otal
mor
talit
y co
mes
from
the
aspi
rin
arm
of t
he C
HA
RIS
MA
tria
l. c C
ontr
ol g
roup
ris
k es
timat
es fo
r no
nfat
al M
I an
d no
nfat
al s
trok
es (i
sche
mic
, hem
orrh
agic
, and
unk
now
n ca
use)
com
e fr
om o
bser
ved
even
ts in
the
aspi
rin
arm
of a
met
a-an
alys
is o
f 16
RC
Ts in
sec
onda
ry
prev
entio
n (B
aige
nt e
t al,
see
Tabl
e S3
lege
nd).
d Of t
otal
str
okes
, tw
o of
48
(4%
) with
asp
irin
and
17
of 5
0 (3
4%) w
ith w
arfa
rin
plus
asp
irin
wer
e he
mor
rhag
ic.
e Con
trol
gro
up r
isk
estim
ates
for
maj
or b
leed
s co
me
from
obs
erve
d ra
tes
in th
e as
piri
n-al
one
arm
of t
he C
APR
IE tr
ial.
f As
far
as w
e ar
e aw
are,
no
stud
ies
have
eva
luat
ed d
iffer
ence
s in
bur
den
of tr
eatm
ent b
etw
een
patie
nts
with
PA
D ta
king
war
fari
n vs
asp
irin
. The
re a
re s
tudi
es e
valu
atin
g qu
ality
of l
ife in
pat
ient
s du
ring
w
arfa
rin
trea
tmen
t (w
ith d
ispa
rate
fi nd
ings
), bu
t the
se a
re li
mite
d by
sm
all s
ampl
e si
ze, l
ack
of c
ompa
rato
r, an
d ot
her
desi
gn is
sues
.
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
10© 2012 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/site/misc/reprints.xhtml). DOI: 10.1378/chest.11-2307
Tabl
e S7
—[S
ecti
on 4
.1-4
.4]
Evi
denc
e P
rofi l
e: C
ilos
tazo
l vs
Pla
ceb
o in
Pat
ient
s W
ith
Sym
ptom
atic
PA
D a
nd C
lau
dica
tion
Qua
lity
Ass
essm
ent
Sum
mar
y of
Fin
ding
s
Part
icip
ants
(S
tudi
es),
Fol
low
-up
Ris
k of
Bia
sIn
cons
iste
ncy
Indi
rect
ness
Impr
ecis
ion
Publ
icat
ion
Bia
sR
elat
ive
Eff
ect
(95%
CI)
Est
imat
ion
of A
bsol
ute
Eff
ects
Qua
lity
of
Evi
denc
e
Eve
nt r
ate
With
N
o C
ilost
azol
a
Ris
k D
iffer
ence
W
ith C
ilost
azol
(9
5% C
I)
Tota
l mor
talit
y (c
ritic
al o
utco
me)
1,43
9 (1
RC
T b )
, 34
mo
Seri
ous
risk
of
bi
as. U
ncle
ar
conc
ealm
ent
of a
lloca
tion
Sing
le s
tudy
only
No
seri
ous
in
dire
ctne
ssSe
riou
s im
prec
isio
n
CIs
are
wid
e an
d on
ly 1
01 e
vent
s
Und
etec
ted
RR
0.9
4 (0
.64-
1.39
)68
per
1,0
00 a
4 le
ss p
er 1
,000
(27
few
er to
26
mor
e)
Low
due
to b
ias
an
d im
prec
isio
n
Qua
lity
of li
fe a
s in
ferr
ed fr
om m
axim
um w
alki
ng d
ista
nce
(impo
rtan
t out
com
e)
1,89
0 (7
RC
Ts),
3-6
mo
Seri
ous
risk
of
bi
as. U
ncle
ar
conc
ealm
ent
of a
lloca
tion
in 4
/7 s
tudi
es
Seri
ous
in
cons
iste
ncy
( I 2 5
69%
)
Seri
ous
in
dire
ctne
ss
Use
of s
urro
gate
en
d po
int
No
seri
ous
im
prec
isio
nU
ndet
ecte
d1.
09 (1
.06-
1.12
)80
0 pe
r 1,
000 c
79 m
ore
per
1,00
0
(55
mor
e to
10
0 m
ore)
Low
due
to b
ias,
inco
nsis
tenc
y,
and
indi
rect
ness
Maj
or e
xtra
cran
ial b
leed
ing
(cri
tical
out
com
e)
2,27
3 (2
RC
Ts),
1-6
mo
No
seri
ous
ri
sk o
f bia
sN
o se
riou
s
inco
nsis
tenc
ySe
riou
s
indi
rect
ness
d Se
riou
s im
prec
isio
n
CIs
are
wid
e an
d bo
rder
on
no e
ffec
t
Und
etec
ted
RR
0.8
9 (0
.46-
1.73
) d 46
per
1,0
00 a
5 fe
wer
per
1,0
00
(f
rom
25
few
er to
33
mor
e)
Low
due
to
in
dire
ctne
ssan
d im
prec
isio
n
Non
fata
l MI
(cri
tical
out
com
e )
……
……
……
……
……
Non
fata
l str
oke
(cri
tical
out
com
e)
……
……
……
……
……
Bib
liogr
aphy
: Rob
less
P, M
ikha
ilidi
s D
P, S
tans
by G
P. C
ilost
azol
for
peri
pher
al a
rter
ial d
isea
se. C
ochr
ane
Dat
abas
e Sy
st R
ev . 2
008;
(1):C
D00
3748
. CA
STL
E 5
Cilo
staz
ol: A
Stu
dy in
Lon
g-Te
rm E
ffec
ts. S
ee
Tabl
e S1
and
S2
lege
nds
for
expa
nsio
n of
oth
er a
bbre
viat
ions
. a C
ontr
ol g
roup
ris
k es
timat
es c
ome
from
obs
erve
d ev
ents
rep
orte
d in
pla
cebo
arm
s of
incl
uded
stu
dies
. b H
iatt
WR
, Mon
ey S
R, B
rass
EP.
Lon
g-te
rm s
afet
y of
cilo
staz
ol in
pat
ient
s w
ith p
erip
hera
l art
ery
dise
ase:
the
CA
STL
E s
tudy
. J V
asc
Surg
. 200
8;47
(2):3
30-3
36.
c Cal
cula
ted
from
poo
led
stan
dard
ized
mea
n di
ffer
ence
s, c
onve
rted
into
ris
k di
ffer
ence
(ass
umed
con
trol
res
pons
e ra
te o
f 80%
). d S
tudi
es w
ere
cond
ucte
d in
pat
ient
s w
ith C
AD
und
ergo
ing
sten
t pla
cem
ent a
nd r
ecei
ving
asp
irin
and
clo
pido
grel
in a
dditi
on to
cilo
staz
ol a
nd p
lace
bo.
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
11© 2012 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/site/misc/reprints.xhtml). DOI: 10.1378/chest.11-2307
Tabl
e S8
—[S
ecti
on 4
.1-4
.4]
Evi
denc
e P
rofi l
e: H
epar
ins
vs P
lace
bo
in P
atie
nts
Wit
h Sy
mpt
omat
ic P
AD
and
Cla
udi
cati
on
Qua
lity
Ass
essm
ent
Sum
mar
y of
Fin
ding
s
Part
icip
ants
(S
tudi
es),
Fol
low
-up
Ris
k of
Bia
sIn
cons
iste
ncy
Indi
rect
ness
Impr
ecis
ion
Publ
icat
ion
Bia
sR
elat
ive
Eff
ect
(95%
CI)
Est
imat
ion
of A
bsol
ute
Eff
ects
Qua
lity
of
Evi
denc
e E
vent
Rat
e W
ith C
ontr
ol a
Ris
k D
iffer
ence
W
ith H
epar
ins
(95%
CI)
Tota
l mor
talit
y (c
ritic
al o
utco
me)
221
(2 R
CTs
), b,c 6
-18
mo
Seri
ous
risk
of b
ias
No
seri
ous
in
cons
iste
ncy
No
seri
ous
in
dire
ctne
ssSe
riou
s
impr
ecis
ion
Und
etec
ted
N/A
. No
even
ts in
ei
ther
arm
N/A
N/A
Low
due
to
bi
as a
nd s
erio
us
impr
ecis
ion
Dro
pout
and
with
draw
al
rate
29%
Car
diov
ascu
lar
even
ts (T
IA, s
trok
e, u
nsta
ble
angi
na, M
I [c
ritic
al o
utco
me]
)
221
(2 R
CTs
), b,c 6
-18
mo
Seri
ous
risk
of b
ias
No
seri
ous
in
cons
iste
ncy
No
seri
ous
in
dire
ctne
ssSe
riou
s
impr
ecis
ion
CIs
in
clud
e be
nefi t
an
d ha
rm
Und
etec
ted
RR
3.4
7 (0
.74-
16.2
8)18
per
1,0
0044
mor
e pe
r 1,
000
(f
rom
4 fe
wer
to
275
mor
e)
Low
due
to
bi
as a
nd s
erio
us
impr
ecis
ion
Dro
pout
and
with
draw
al r
ate
29%
Maj
or b
leed
ing
even
ts (c
ritic
al o
utco
me)
356
(5 R
CTs
), b-f 6
mo
Seri
ous
risk
of b
ias
No
seri
ous
in
cons
iste
ncy
No
seri
ous
in
dire
ctne
ssSe
riou
s
impr
ecis
ion
Und
etec
ted
N/A
. No
even
ts in
ei
ther
arm
N/A
N/A
Low
due
to
bi
as a
nd s
erio
us
impr
ecis
ion
Allo
catio
n co
ncea
lmen
t
uncl
ear
in 4
/5 s
tudi
es
Qua
lity
of li
fe a
s in
ferr
ed fr
om m
axim
um w
alki
ng d
ista
nce
(impo
rtan
t out
com
e)
201
(1 R
CTs
), b,g 1
8 m
oSe
riou
s ri
sk o
f bia
sSi
ngle
stu
dy
on
lySe
riou
s
indi
rect
ness
Seri
ous
im
prec
isio
n C
Is
incl
ude
bene
fi t
and
harm
Und
etec
ted
1.14
(1.0
7-1.
18 )
800
per
1,00
011
2 m
ore
per
1,00
0
(fro
m 5
8 fe
wer
to
149
mor
e) h
Low
due
to
st
udy
limita
tions
, in
dire
ctne
ss, a
nd
impr
ecis
ion
Dro
pout
and
with
draw
al r
ate
32%
Use
of s
urro
gate
endp
oint
Bib
liogr
aphy
: Cos
mi B
, Con
ti E
, Coc
cher
i S. A
ntic
oagu
lant
s (h
epar
in, l
ow m
olec
ular
wei
ght h
epar
in a
nd o
ral a
ntic
oagu
lant
s) fo
r in
term
itten
t cla
udic
atio
n. C
ochr
ane
Dat
abas
e Sy
st R
ev . 2
001;
(3):C
D00
1999
. Se
e Ta
ble
S1, S
2, a
nd S
6 le
gend
s fo
r ex
pans
ion
of a
bbre
viat
ions
. a C
ontr
ol g
roup
ris
k es
timat
es fo
r m
orta
lity,
car
diov
ascu
lar
even
ts, b
leed
ing
even
ts, a
nd w
alki
ng d
ista
nce
com
e fr
om o
bser
ved
even
ts in
con
trol
arm
s of
RC
Ts.
b Ant
onic
elli
R, S
ardi
na M
, Sco
tti A
, Bon
izzo
ni E
, Pac
iaro
ni E
; Ita
lian
CA
P St
udy
Gro
up. R
ando
miz
ed tr
ial o
f the
eff
ects
of l
ow-d
ose
calc
ium
hep
arin
in p
atie
nts
with
per
iphe
ral a
rter
ial d
isea
se a
nd c
laud
i-ca
tion.
Am
J M
ed . 1
999;
107(
3):2
34-2
39.
c Tes
i M, B
ronc
hi G
F, C
arin
i A, M
orfi n
i M, C
inot
ti S,
Fili
bert
i E. E
ffi ca
cy a
nd s
afet
y of
a n
ew lo
w m
olec
ular
wei
ght h
epar
in in
the
med
ium
term
trea
tmen
t of a
ther
oscl
erot
ic a
rter
iopa
thy
of th
e lo
wer
lim
bs.
J D
rug
Dev
. 198
9;2(
2):7
3-82
. d C
alab
rò A
, Pia
rulli
F, M
ilan
D, R
ossi
A, C
osce
tti G
, Cre
pald
i G. C
linic
al a
sses
smen
t of l
ow m
olec
ular
wei
ght h
epar
in e
ffec
ts in
per
iphe
ral v
ascu
lar
dise
ase.
Ang
iolo
gy . 1
993;
44(3
):188
-195
. e M
anna
rino
E,
Pasq
ualin
i L
, In
noce
nte
S, O
rlan
di U
, Sc
ricc
iolo
V,
Lom
bard
ini
R,
Ciu
ffet
ti G
. E
ffi ca
cy o
f lo
w-m
olec
ular
wei
ght
hepa
rin
in t
he m
anag
emen
t of
int
erm
itten
t cl
audi
catio
n. A
ngio
logy
. 19
91;4
2(1)
:1-7
. f P
alm
ieri
G, A
mbr
osi G
, Agr
ati A
M, F
erra
ro G
, Mar
cozz
i S. A
new
low
mol
ecul
ar w
eigh
t hep
arin
in th
e tr
eatm
ent o
f per
iphe
ral a
rter
ial d
isea
se. I
nt A
ngio
l . 19
88;7
(sup
pl 3
):41-
47.
g In
four
of fi
ve
stud
ies,
dat
a on
wal
king
dis
tanc
e w
as p
rese
nted
in b
ar g
raph
form
onl
y. U
nabl
e to
ass
ess
mea
n di
ffer
ence
bet
wee
n tr
eatm
ent a
rms
in c
hang
e in
wal
king
dis
tanc
e in
thes
e st
udie
s.
h Cal
cula
ted
from
poo
led
stan
dard
ized
mea
n di
ffer
ence
s, c
onve
rted
into
ris
k di
ffer
ence
(ass
umed
con
trol
res
pons
e ra
te o
f 80%
).
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
12© 2012 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/site/misc/reprints.xhtml). DOI: 10.1378/chest.11-2307
Tabl
e S9
—[S
ecti
on 4
.1-4
.4]
Evi
denc
e P
rofi l
e: P
rost
agla
ndin
s vs
Pla
ceb
o in
Pat
ient
s W
ith
Inte
rmit
tent
Cla
udi
cati
on
Qua
lity
Ass
essm
ent
Sum
mar
y of
Fin
ding
s
Part
icip
ants
(S
tudi
es),
Fol
low
-up
Ris
k of
Bia
sIn
cons
iste
ncy
Indi
rect
ness
Impr
ecis
ion
Publ
icat
ion
Bia
sR
elat
ive
Eff
ect
(95%
CI)
Est
imat
ion
of A
bsol
ute
Eff
ects
Qua
lity
of
Evi
denc
e
Eve
nt R
ate
With
No
Pros
tagl
andi
ns a
Ris
k D
iffer
ence
W
ith P
rost
agla
ndin
s (9
5% C
I)
Mor
talit
y (c
ritic
al o
utco
me )
∗
1,35
4 (3
RC
Ts),
6-
12 m
oSe
riou
s ri
sk o
f bia
sN
o se
riou
s
inco
nsis
tenc
yN
o se
riou
s
indi
rect
ness
Seri
ous
im
prec
isio
nC
Is in
clud
e be
nefi t
and
har
m;
only
5 e
vent
s
Und
etec
ted
RR
0.3
4 (0
.08-
2.39
)10
per
1,0
006
few
er p
er 1
,000
(fro
m 9
few
er to
14
mor
e)
Low
due
to b
ias
an
d im
prec
isio
n U
ncle
ar c
once
alm
ent
of
allo
catio
n in
al
l of t
he s
tudi
es
Qua
lity
of li
fe a
s in
ferr
ed fr
om m
axim
um w
alki
ng d
ista
nce
(impo
rtan
t out
com
e)
1,63
6 (5
RC
Ts),
3-
12 m
oSe
riou
s ri
sk o
f bia
sSe
riou
s
inco
nsis
tenc
y ( I
2 5 4
6%)
Seri
ous
in
dire
ctne
ssN
o se
riou
s
impr
ecis
ion
Und
etec
ted
1.09
(1.0
7-1.
12)
800
per
1,00
0 b 79
mor
e pe
r 1,
000
(5
8 m
ore
to
98 m
ore)
c
Low
due
to b
ias,
inco
nsis
tenc
y,
and
indi
rect
ness
U
ncle
ar c
once
alm
ent
of
allo
catio
n in
al
l of t
he s
tudi
es
Use
of s
urro
gate
end
poin
t
Maj
or e
xtra
cran
ial b
leed
ing
(cri
tical
out
com
e)
……
……
……
……
……
Non
fata
l MI
(cri
tical
out
com
e)
762
(1 R
CT
)
12 m
oSe
riou
s ri
sk o
f bia
sSi
ngle
stu
dy o
nly
No
seri
ous
in
dire
ctne
ssVe
ry s
erio
us
im
prec
isio
nU
ndet
ecte
dR
R 0
.09
(0.0
0-1.
60)
13 p
er 1
,000
11 fe
wer
per
1,0
00
(f
rom
13
few
er to
7
mor
e)
Low
due
to b
ias
an
d im
prec
isio
n U
ncle
ar c
once
alm
ent
of
allo
catio
n in
al
l of t
he s
tudi
es
Non
fata
l str
oke
(cri
tical
out
com
e)
762
(1 R
CT
)
12 m
oSe
riou
s ri
sk o
f bia
sSi
ngle
stu
dy o
nly
No
seri
ous
in
dire
ctne
ssVe
ry s
erio
us
im
prec
isio
nU
ndet
ecte
dR
R 1
.22
(0.3
3-4.
52)
10 p
er 1
,000
2 fe
wer
per
1,0
00
(f
rom
7 fe
wer
to
37
mor
e)
Low
due
to b
ias
an
d im
prec
isio
n U
ncle
ar c
once
alm
ent
of
allo
catio
n in
al
l of t
he s
tudi
es
Bib
liogr
aphy
: Mom
sen
AH
, Jen
sen
MB
, Nor
ager
CB
, Mad
sen
MR
, Ves
ters
gaar
d-A
nder
sen
T, L
indh
olt
JS. D
rug
ther
apy
for
impr
ovin
g w
alki
ng d
ista
nce
in in
term
itten
t cl
audi
catio
n: a
sys
tem
atic
rev
iew
an
d m
eta-
anal
ysis
of r
obus
t ran
dom
ised
con
trol
led
stud
ies.
Eur
J V
asc
End
ovas
c Su
rg . 2
009;
38(4
):463
-474
. See
Tab
le S
1 an
d S2
lege
nds
for
expa
nsio
n of
abb
revi
atio
ns.
a Con
trol
gro
up r
isk
estim
ates
com
e fr
om m
edia
n co
ntro
l rat
e or
rep
rese
ntat
ive
cont
rol g
roup
ris
k of
the
incl
uded
stu
dies
. b A
ssum
ed c
ontr
ol r
espo
nse
rate
of 8
0%.
c Cal
cula
ted
from
poo
led
stan
dard
ized
mea
n di
ffer
ence
s, c
onve
rted
into
ris
k di
ffer
ence
(ass
umed
con
trol
res
pons
e ra
te o
f 80%
)
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
13© 2012 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/site/misc/reprints.xhtml). DOI: 10.1378/chest.11-2307
Tabl
e S1
0 —[S
ecti
on 5
.1]
Evi
denc
e P
rofi l
e: P
rost
anoi
ds v
s P
lace
bo
in P
atie
nts
Wit
h C
riti
cal
Lim
b I
sche
mia
Ine
ligi
ble
for
Rev
ascu
lari
zati
on P
roce
dure
s
Qua
lity
Ass
essm
ent
Sum
mar
y of
Fin
ding
s
Part
icip
ants
(s
tudi
es),
Fol
low
- up
Ris
k of
Bia
sIn
cons
iste
ncy
Indi
rect
ness
Impr
ecis
ion
Publ
icat
ion
Bia
sR
elat
ive
Eff
ect
(95%
CI)
Est
imat
ion
of A
bsol
ute
Eff
ects
Qua
lity
of
Evi
denc
e
Eve
nt
Rat
e W
ith
Plac
ebo
Ris
k di
ffer
ence
W
ith P
rost
anoi
ds
(95%
CI)
Res
t pai
n re
lief (
any
impr
ovem
ent o
n a
valid
ated
sca
le) (
impo
rtan
t out
com
e)
1,11
6 (9
RC
Ts),
21
.4 w
kSe
riou
s ri
sk o
f
bias
. Allo
catio
n an
d bl
indi
ng
conc
erns
No
seri
ous
in
cons
iste
ncy
No
seri
ous
in
dire
ctne
ssN
o im
prec
isio
nU
ndet
ecte
dR
R 1
.32
(1.1
-1.5
7)24
3 pe
r 1,
000 a
77 m
ore
per
1,00
0
(fro
m 2
4 m
ore
to
138
mor
e)
Mod
erat
e du
e to
risk
of b
ias
Ulc
er h
ealin
g (a
ny d
ecre
ase
in s
ize
of u
lcer
or
pres
ence
of g
ranu
latio
n tis
sue)
(im
port
ant o
utco
me)
1,13
2 (8
RC
Ts),
17
.5 w
kSe
riou
s ri
sk o
f
bias
. Allo
catio
n an
d bl
indi
ng
conc
erns
Seri
ous
in
cons
iste
ncy
( I 2 5
44%
)
No
seri
ous
in
dire
ctne
ssN
o im
prec
isio
nU
ndet
ecte
dR
R 1
.54
(1.2
2-1.
96)
253
per
1,00
0 a 13
6 m
ore
per
1,00
0
(fro
m 5
5 m
ore
to
242
mor
e)
Low
due
to
ri
sk o
f bia
s an
d in
cons
iste
ncy
Am
puta
tions
(maj
or o
r m
inor
am
puta
tions
) (cr
itica
l out
com
e)
1,79
0 (9
RC
Ts),
23
.1 w
kSe
riou
s ri
sk o
f
bias
. Allo
catio
n an
d bl
indi
ng
conc
erns
No
seri
ous
in
cons
iste
ncy
No
seri
ous
in
dire
ctne
ssSe
riou
s im
prec
isio
nU
ndet
ecte
dR
R 0
.89
(0.7
6-1.
04)
313
per
1,00
0 a 34
few
er p
er 1
,000
(fro
m 7
5 fe
wer
to
12 m
ore)
Low
due
to
ri
sk o
f bia
s,
inco
nsis
tenc
y,
and
impr
ecis
ion
CI
incl
udes
bot
h
bene
fi ts
and
harm
s
Mor
talit
y (c
ritic
al o
utco
me)
1,39
1 (5
RC
Ts),
32
wk
Seri
ous
risk
of
bi
as. A
lloca
tion
and
blin
ding
co
ncer
ns
Seri
ous
in
cons
iste
ncy
( I 2 5
40%
)
No
seri
ous
in
dire
ctne
ssSe
riou
s im
prec
isio
nU
ndet
ecte
dR
R 1
.07
(0.6
5-1.
75)
121
per
1,00
0 a 8
mor
e pe
r 1,
000
(f
rom
42
few
er
to 9
0 m
ore)
Low
due
to
ri
sk o
f bia
s,
inco
nsis
tenc
y,
and
impr
ecis
ion
CI
incl
udes
bot
h
bene
fi ts
and
harm
s;
smal
l num
ber
of
even
ts (1
45)
Adv
erse
eve
nts
(impo
rtan
t out
com
e)
716
(8 R
CTs
),
14.4
mo
Seri
ous
risk
of
bi
as. A
lloca
tion
and
blin
ding
co
ncer
ns
No
seri
ous
in
cons
iste
ncy
No
seri
ous
in
dire
ctne
ssN
o im
prec
isio
nU
ndet
ecte
dR
R 2
.35
(1.9
9-2.
78)
77 p
er 1
,000
a 10
3 m
ore
per
1,00
0
(fro
m 7
6 m
ore
to
137
mor
e)
Mod
erat
e du
e to
risk
of b
ias
394
per
1,00
0 a 53
1 m
ore
per
1,00
0
(fro
m 3
90 m
ore
to
701
mor
e)
Bib
liogr
aphy
: Ruf
folo
AJ,
Rom
ano
M, C
iapp
oni A
. Pro
stan
oids
for
criti
cal l
imb
isch
emia
. Coc
hran
e D
atab
ase
of S
yst R
ev . 2
010;
(1):C
D00
6544
. See
Tab
le S
2 le
gend
for
expa
nsio
n of
abb
revi
atio
ns.
a Con
trol
gro
up r
isk
estim
ates
com
e fr
om m
edia
n co
ntro
l rat
e or
rep
rese
ntat
ive
cont
rol g
roup
ris
k of
the
incl
uded
stu
dies
. For
res
t pa
in r
elie
f or
ulc
er h
ealin
g co
ntro
l rat
es r
epre
sent
num
ber
of s
ubje
cts
with
impr
ovem
ent i
n co
ntro
l arm
.
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
14© 2012 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/site/misc/reprints.xhtml). DOI: 10.1378/chest.11-2307
Tabl
e S1
1 —[S
ecti
on 6
.1-6
.3]
Evi
denc
e P
rofi l
e: T
hrom
bol
ysis
vs
Surg
ery
for
the
Tre
atm
ent
of A
cute
Lim
b I
sche
mia
Qua
lity
Ass
essm
ent
Sum
mar
y of
Fin
ding
s
Part
icip
ants
(S
tudi
es),
Fol
low
-up
Ris
k of
Bia
sIn
cons
iste
ncy
Indi
rect
ness
Impr
ecis
ion
Publ
icat
ion
Bia
sR
elat
ive
Eff
ect
(95%
CI)
Est
imat
ion
of A
bsol
ute
Eff
ects
Qua
lity
of
Evi
denc
e W
ith S
urge
ryR
isk
Diff
eren
ce W
ith
Thr
ombo
lysi
s (9
5% C
I)
Lim
b sa
lvag
e at
1 y
(cri
tical
out
com
e)
654
(2 R
CTs
), a
12 m
oN
o se
riou
s
risk
of b
ias
Seri
ous
in
cons
iste
ncy
( I 2 5
49%
)
No
seri
ous
in
dire
ctne
ssSe
riou
s im
prec
isio
n
CI
incl
udes
har
ms
and
bene
fi ts
Und
etec
ted
RR
1.0
0 (0
.86-
1.17
)75
4 pe
r 1,
000 b
0 fe
wer
per
1,0
00
(f
rom
106
few
er to
12
8 m
ore)
Low
due
to
in
cons
iste
ncy
and
impr
ecis
ion
Am
puta
tion
at 1
y (c
ritic
al o
utco
me)
768
(3 R
CTs
), a
12 m
oN
o se
riou
s
risk
of b
ias
No
seri
ous
in
cons
iste
ncy
No
seri
ous
in
dire
ctne
ssSe
riou
s im
prec
isio
n
CI
incl
udes
har
ms
and
bene
fi ts
Low
num
ber
of e
vent
s
Und
etec
ted
RR
1.1
0 (0
.88-
1.38
)19
0 pe
r 1,
000 b
19 m
ore
per
1,00
0
(fro
m 2
2 fe
wer
to
72 m
ore)
Mod
erat
e du
e to
impr
ecis
ion
Dea
th a
t 1 y
(cri
tical
out
com
e) c
768
(3 R
CTs
), a
12 m
oN
o se
riou
s
risk
of b
ias
Seri
ous
in
cons
iste
ncy
( I 2 5
80%
)
No
seri
ous
in
dire
ctne
ssSe
riou
s im
prec
isio
n
CI
incl
udes
har
ms
and
bene
fi ts
Und
etec
ted
RR
0.7
4 (0
.35-
1.58
)16
9 pe
r 1,
000 b
43 fe
wer
per
1,0
00
(f
rom
109
few
er to
98
mor
e)
Low
due
to
in
cons
iste
ncy
and
impr
ecis
ion
Stro
ke a
t 30
d (c
ritic
al o
utco
me)
d
1,18
0 (5
RC
Ts), a,
e
1-12
mo
No
seri
ous
ri
sk o
f bia
sN
o se
riou
s
inco
nsis
tenc
yN
o se
riou
s
indi
rect
ness
Seri
ous
in
cons
iste
ncy
CI
incl
udes
har
ms
and
bene
fi ts
Low
num
ber
of e
vent
s (8
)
Und
etec
ted
0.01
(0.0
0-0.
02) f
0 pe
r 1,
000 b
10 m
ore
per
1,00
0
(fro
m 0
few
er to
20
mor
e)
Mod
erat
e du
e to
impr
ecis
ion
Ext
racr
ania
l maj
or h
emor
rhag
e at
30
d
1,07
0 (4
RC
Ts), a
1-
12 m
oN
o se
riou
s
risk
of b
ias g
No
seri
ous
in
cons
iste
ncy
No
seri
ous
in
dire
ctne
ss d
Seri
ous
impr
ecis
ion
C
I in
clud
es h
arm
s an
d be
nefi t
s L
ow n
umbe
r of
eve
nts
(60)
Und
etec
ted
RR
2.3
4 (1
.32-
4.14
)12
per
1,0
00 b
16 m
ore
per
1,00
0
(fro
m 3
mor
e to
37
mor
e)
Mod
erat
e du
e to
impr
ecis
ion
Bib
liogr
aphy
: Ber
ridg
e D
C, K
esse
l D
, Rob
erts
on I
. Sur
gery
ver
sus
thro
mbo
lysi
s fo
r ac
ute
limb
isch
aem
ia: i
nitia
l m
anag
emen
t. C
ochr
ane
Dat
abas
e Sy
st R
ev . 2
002;
(3):C
D00
2784
. Our
iel
K, V
eith
FJ,
Sa
saha
ra A
A;
Thr
ombo
lysi
s or
Per
iphe
ral
Art
eria
l Su
rger
y (T
OPA
S) I
nves
tigat
ors.
The
ST
ILE
inv
estig
ator
s. R
esul
ts o
f a
pros
pect
ive
rand
omiz
ed t
rial
eva
luat
ing
surg
ery
vers
us t
hrom
boly
sis
for
isch
aem
ia o
f the
low
er e
xtre
mity
. Ann
Sur
g . 1
994;
220(
3):2
51-2
68. A
com
pari
son
of r
ecom
bina
nt u
roki
nase
with
vas
cula
r su
rger
y as
initi
al tr
eatm
ent f
or a
cute
art
eria
l occ
lusi
on o
f the
legs
. N E
ngl J
Med
. 19
98;3
38(1
6):1
105-
1111
. See
Tab
le S
2 le
gend
for
expa
nsio
n of
abb
revi
atio
ns.
a For
one
stu
dy u
sing
thre
e di
ffer
ent d
oses
of t
he th
rom
boly
tic a
gent
, onl
y th
e op
timal
dos
e is
use
d fo
r co
mpa
riso
n w
ith s
urge
ry.
b Con
trol
gro
up r
isk
estim
ates
from
med
ian
or r
epre
sent
ativ
e co
ntro
l gro
up r
isk
of in
clud
ed s
tudi
es.
c Our
iel e
t al (
1998
) rep
orte
d th
at o
ne in
54
deat
hs in
the
thro
mbo
lysi
s gr
oup
wer
e fr
om in
trac
rani
al h
emor
rhag
e, w
here
as n
one
of 4
6 in
the
surg
ery
grou
p w
ere
from
intr
acra
nial
hem
orrh
age.
d O
f rep
orte
d no
nfat
al s
trok
es, a
ll ha
ppen
ed in
the
thro
mbo
lysi
s gr
oup
and
all w
ere
intr
acra
nial
hem
orrh
ages
(8/8
[100
%])
. e S
TIL
E in
vest
igat
ors
et a
l (19
94 ) i
nclu
ded
patie
nts
with
bot
h ac
ute
and
chro
nic
limb
isch
emia
. f P
oole
d ri
sk d
iffer
ence
pre
sent
ed in
stea
d of
rel
ativ
e ri
sk.
g Con
ceal
men
t of a
lloca
tion
uncl
ear
in o
ne s
tudy
.
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
15© 2012 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/site/misc/reprints.xhtml). DOI: 10.1378/chest.11-2307
Tabl
e S1
2 —[S
ecti
on 6
.1-6
.3]
Evi
denc
e P
rofi l
e: I
ntra
arte
rial
Uro
kina
se v
s In
traa
rter
ial
rt-P
A f
or A
cute
Lim
b I
sche
mia
Qua
lity
Ass
essm
ent
Sum
mar
y of
Fin
ding
s
Part
icip
ants
(S
tudi
es),
Fol
low
-up
Ris
k of
Bia
sIn
cons
iste
ncy
Indi
rect
ness
Impr
ecis
ion
Publ
icat
ion
Bia
sR
R (9
5% C
I)
Est
imat
ion
of A
bsol
ute
Eff
ects
Qua
lity
of
Evi
denc
e
Eve
nt R
ate
With
In
traa
rter
ial r
t-PA
Ris
k D
iffer
ence
W
ith U
roki
nase
(9
5% C
I)
All-
caus
e m
orta
lity
(cri
tical
out
com
e)
368
(3 R
CTs
), 1-
6 m
oSe
riou
s ri
sk o
f
bias
. Unc
lear
co
ncea
lmen
t of
allo
catio
n
No
seri
ous
in
cons
iste
ncy
No
seri
ous
in
dire
ctne
ssSe
riou
s im
prec
isio
n
CIs
are
wid
e an
d in
clud
e be
nefi t
an
d ha
rm
Und
etec
ted
RR
0.7
9 (0
.26-
2.46
)19
per
1,0
00 a
4 fe
wer
per
1,0
00
(f
rom
14
few
er to
27
mor
e)
Low
due
to
ri
sk o
f bia
s an
d im
prec
isio
n
Am
puta
tion
(cri
tical
out
com
e)
368
(3 R
CTs
), 1-
6 m
oSe
riou
s ri
sk o
f
bias
. Unc
lear
co
ncea
lmen
t of
allo
catio
n
No
seri
ous
in
cons
iste
ncy
No
seri
ous
in
dire
ctne
ssSe
riou
s im
prec
isio
n
CIs
are
wid
e an
d in
clud
e be
nefi t
an
d ha
rm
Und
etec
ted
RR
0.7
8 (0
.23,
2.7
1)89
per
1,0
00 a
20 fe
wer
per
1,0
00
(f
rom
68
few
er to
15
2 m
ore)
Low
due
to
ri
sk o
f bia
s an
d im
prec
isio
n
Maj
or n
onfa
tal e
xtra
cran
ial b
leed
(im
port
ant o
utco
me)
298
(3 R
CTs
), 1-
6 m
oSe
riou
s ri
sk o
f
bias
. Unc
lear
co
ncea
lmen
t of
allo
catio
n
No
seri
ous
in
cons
iste
ncy
No
seri
ous
in
dire
ctne
ssSe
riou
s im
prec
isio
nU
ndet
ecte
dR
R 0
.69
(0.2
3-2.
06)
8 pe
r 1,
000 a
2 fe
wer
per
1,0
00
(f
rom
6 fe
wer
to
8 m
ore)
Low
due
to
ri
sk o
f bia
s an
d im
prec
isio
n C
I in
clud
es h
arm
and
bene
fi t
Bib
liogr
aphy
: Rob
erts
on I
, Kes
sel D
O, B
erri
dge
DC
. Fib
rino
lytic
age
nts
for
peri
pher
al a
rter
ial o
cclu
sion
. Coc
hran
e D
atab
ase
Syst
Rev
. 201
0;(3
):CD
0010
99. S
ee T
able
S1
and
S2 le
gend
s fo
r ex
pans
ion
of a
bbre
viat
ions
. a C
ontr
ol g
roup
ris
k es
timat
e co
mes
from
med
ian
even
t rat
e in
the
rt-P
A a
rm.
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
16© 2012 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/site/misc/reprints.xhtml). DOI: 10.1378/chest.11-2307
Tabl
e S1
3 —[S
ecti
on 8
.1-8
.3]
Evi
denc
e P
rofi l
e: A
spir
in p
lus
Dip
yrid
amol
e vs
Pla
ceb
o fo
r P
reve
ntio
n of
Thr
omb
osis
Aft
er P
erip
hera
l B
ypas
s Su
rger
y
Qua
lity
Ass
essm
ent
Sum
mar
y of
Fin
ding
s
Part
icip
ants
(S
tudi
es),
Fol
low
-up
Ris
k of
Bia
sIn
cons
iste
ncy
Indi
rect
ness
Impr
ecis
ion
Publ
icat
ion
Bia
sR
elat
ive
Eff
ect
(95%
CI)
Est
imat
ion
of A
bsol
ute
Eff
ects
Ti
me
Peri
od: 1
y
Qua
lity
of
Evi
denc
e E
vent
Rat
e W
ith C
ontr
ol a
Diff
eren
ce W
ith
Asp
irin
1 D
ipyr
idam
ole
(95%
CI)
Am
puta
tion
infe
rred
from
loss
of p
rim
ary
graf
t pat
ency
(cri
tical
out
com
e)
966
(6 R
CTs
), 12
mo
Seri
ous
ri
sk o
f bia
s b N
o se
riou
s
inco
nsis
tenc
ySe
riou
s in
dire
ctne
ss
L
oss
of g
raft
pa
tenc
y is
a
surr
ogat
e
No
seri
ous
im
prec
isio
nU
ndet
ecte
dR
R 0
.68
(0.5
5-0.
83)
71 p
er 1
,000
22 fe
wer
per
1,0
00
(f
rom
32
few
er to
12
few
er)
Low
due
to
ri
sk o
f bia
s an
d
indi
rect
ness
Am
puta
tion
(cri
tical
out
com
e)
148
(1 R
CT
), 12
mo
Seri
ous
ri
sk o
f bia
s b N
o se
riou
s
inco
nsis
tenc
yN
o se
riou
s
indi
rect
ness
Seri
ous
im
prec
isio
n c U
ndet
ecte
dR
R 0
.52
(0.2
7-1.
01)
71 p
er 1
,000
34 fe
wer
per
1,0
00
(f
rom
51
few
er to
1
mor
e)
Low
due
to
ri
sk o
f bia
s an
d im
prec
isio
n
Dea
th (c
ritic
al o
utco
me)
750
(3 R
CTs
), 12
mo
No
risk
of b
ias
No
seri
ous
in
cons
iste
ncy
No
seri
ous
in
dire
ctne
ssSe
riou
s
impr
ecis
ion c
Und
etec
ted
RR
0.8
6 (0
.6-1
.22)
105
per
1,00
014
few
er p
er 1
,000
(fro
m 4
2 fe
wer
to
23 m
ore)
Mod
erat
e du
e to
impr
ecis
ion
MI
(cri
tical
out
com
e)
667
(3 R
CTs
), 12
mo
No
risk
of b
ias
No
seri
ous
in
cons
iste
ncy
No
seri
ous
in
dire
ctne
ssSe
riou
s
impr
ecis
ion c
Und
etec
ted
RR
0.6
5 (0
.4-1
.06)
28 p
er 1
,000
9 fe
wer
per
1,0
00
(f
rom
16
few
er to
1
mor
e)
Mod
erat
e du
e to
impr
ecis
ion
Stro
ke d (
criti
cal o
utco
me)
667
(3 R
CTs
), 12
mo
No
risk
of b
ias
No
seri
ous
in
cons
iste
ncy
No
seri
ous
in
dire
ctne
ssSe
riou
s
impr
ecis
ion c
Und
etec
ted
RR
0.7
9 (0
.42-
1.49
)27
per
1,0
005
few
er p
er 1
,000
(fro
m 1
5 fe
wer
to
13 m
ore)
Mod
erat
e du
e to
impr
ecis
ion
Maj
or e
xtra
cran
ial b
leed
ing e (
criti
cal o
utco
me)
598
(2 R
CTs
), 12
mo
No
risk
of b
ias
No
seri
ous
in
cons
iste
ncy
No
seri
ous
in
dire
ctne
ssSe
riou
s
impr
ecis
ion c
Und
etec
ted
RR
1.8
6 (0
.85-
4.04
)10
per
1,0
008
mor
e pe
r 1,
000
(f
rom
1 fe
wer
to
30 m
ore)
Mod
erat
e du
e to
impr
ecis
ion
Bib
liogr
aphy
: B
row
n J,
Let
haby
A,
Max
wel
l H
, W
awrz
ynia
k A
J, P
rins
MH
. A
ntip
late
let
agen
ts f
or p
reve
ntin
g th
rom
bosi
s af
ter
peri
pher
al a
rter
ial
bypa
ss s
urge
ry.
Coc
hran
e D
atab
ase
Syst
Rev
. 20
08;(4
):CD
0005
35. S
tudy
Gro
up o
n Ph
arm
acol
ogic
al T
reat
men
t A
fter
TPA
. Pla
tele
t in
hibi
tion
with
ASA
/dip
yrid
amol
e af
ter
perc
utan
eous
bal
loon
ang
iopl
asty
in p
atie
nts
with
sym
ptom
atic
low
er li
mb
arte
rial
dis
ease
. A p
rosp
ectiv
e do
uble
-blin
d tr
ial.
Eur
J V
asc
Surg
. 199
4;8(
1):8
3-88
. BO
A 5
Dut
ch B
ypas
s O
ral A
ntic
oagu
lant
s or
Asp
irin
. See
Tab
le S
1 an
d S2
lege
nds
for
expa
nsio
n of
oth
er a
bbre
viat
ions
. a C
ontr
ol g
roup
ris
k es
timat
e de
rive
d fr
om a
pplic
atio
n of
rel
ativ
e ri
sk o
f pla
cebo
vs
aspi
rin/
dipy
rida
mol
e to
asp
irin
eve
nt r
ate
in a
larg
e R
CT
(BO
A) c
ompa
ring
war
fari
n to
asp
irin
follo
win
g pe
riph
eral
art
ery
bypa
ss s
urge
ry (S
tudy
Gro
up o
n Ph
arm
acol
ogic
al T
reat
men
t Aft
er T
PA, 1
994)
. b P
robl
ems
with
allo
catio
n co
ncea
lmen
t and
blin
ding
. c L
ow n
umbe
r of
eve
nts,
CI
incl
udes
impo
rtan
t ben
efi ts
and
har
ms.
d N
one
of th
e st
roke
s w
as d
ue to
intr
acra
nial
ble
edin
g.
e Of t
hese
ble
edin
gs, fi
ve
of 1
9 (2
6%) w
ere
GI.
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
17© 2012 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/site/misc/reprints.xhtml). DOI: 10.1378/chest.11-2307
Tabl
e S1
4 —[S
ecti
on 8
.1-8
.3]
Evi
denc
e P
rofi l
e: A
spir
in a
nd C
lopi
dogr
el v
s A
spir
in A
lone
for
Pat
ient
s W
ith
PAD
Pos
tsu
rgic
al B
elow
Kne
e R
evas
cula
riza
tion
(V
enou
s or
Pro
sthe
tic
Gra
fts)
Qua
lity
Ass
essm
ent
Sum
mar
y of
Fin
ding
s
Part
icip
ants
(S
tudi
es),
Fol
low
- up
Ris
k of
Bia
sIn
cons
iste
ncy
Indi
rect
ness
Impr
ecis
ion
Publ
icat
ion
Bia
sR
elat
ive
Eff
ect
(95%
CI)
Est
imat
ion
of A
bsol
ute
Eff
ects
Ti
me
Peri
od: 1
y
Qua
lity
of
Evi
denc
e R
isk
With
A
spir
in a
Ris
k D
iffer
ence
With
A
spir
in 1
Clo
pido
grel
(9
5% C
I)
All
caus
e m
orta
lity
(cri
tical
out
com
e)
851
(1 R
CT
),
mea
n �
11
mo a
No
seri
ous
ri
sk o
f bia
s b N
o se
riou
s
inco
nsis
tenc
yN
o se
riou
s
indi
rect
ness
Seri
ous
impr
ecis
ion
C
Is in
clud
e si
gnifi
cant
ha
rm a
nd b
enefi
t (n
o. e
vent
s 5 4
1)
Und
etec
ted
RR
1.4
2 (0
.77-
2.60
)90
per
1,0
0037
mor
e pe
r 1,
000
(f
rom
20
few
er to
14
4 m
ore)
Mod
erat
e du
e to
impr
ecis
ion
MI
(cri
tical
out
com
e): n
ot r
epor
ted
……
……
……
……
……
Stro
ke (c
ritic
al o
utco
me)
: not
rep
orte
d
……
……
……
……
……
Ext
racr
ania
l maj
or b
leed
ing
(cri
tical
out
com
e); s
ever
e G
UST
O c
rite
ria c
851
(1 R
CT
),
mea
n �
11
mo a
No
seri
ous
ri
sk o
f bia
s b N
o se
riou
s
inco
nsis
tenc
yN
o se
riou
s
indi
rect
ness
Seri
ous
impr
ecis
ion
(n
o. e
vent
s 5 1
4U
ndet
ecte
dR
R 1
.73
(0.5
1-5.
88)
19 p
er 1
,000
13 m
ore
per
1,00
0
(fro
m 9
few
er to
92
mor
e)
Mod
erat
e du
e to
impr
ecis
ion
Am
puta
tions
(cri
tical
out
com
e)
851
(1 R
CT
),
mea
n �
11
mo a
No
seri
ous
ri
sk o
f bia
s b N
o se
riou
s
inco
nsis
tenc
yN
o se
riou
s
indi
rect
ness
Seri
ous
impr
ecis
ion
C
Is in
clud
e si
gnifi
cant
ha
rm a
nd b
enefi
t (n
o. e
vent
s 5 7
6)
Und
etec
ted
HR
0.6
9 (0
.45-
1.07
)48
per
1,0
0014
few
er p
er 1
,000
(fro
m 2
6 fe
wer
to
3 m
ore)
Mod
erat
e du
e to
impr
ecis
ion
Bib
liogr
aphy
: Bel
ch J
J, D
orm
andy
J, B
iasi
GM
, et
al. R
esul
ts o
f th
e ra
ndom
ized
, pla
cebo
-con
trol
led
clop
idog
rel a
nd a
cety
lsal
icyl
ic a
cid
in b
ypas
s su
rger
y fo
r pe
riph
eral
art
eria
l dis
ease
(C
ASP
AR
) tr
ial.
J V
asc
Surg
. 201
0;52
(4):8
25-8
33. S
ee T
able
S1,
S2,
S5,
and
S14
lege
nds
for
expa
nsio
n of
abb
revi
atio
ns.
a Con
trol
gro
up r
ates
obt
aine
d fr
om e
vent
rat
es in
asp
irin
arm
of B
OA
stu
dy n
orm
aliz
ed to
1 y
. b E
ight
pat
ient
s lo
st to
follo
w-u
p in
the
inte
rven
tion
grou
p (a
spir
in 1
clop
idog
rel)
and
11 p
atie
nts
in th
e co
mpa
riso
n gr
oup
(asp
irin
gro
up).
c Fat
al b
leed
ing
even
ts w
ere
two
of 4
26 in
the
inte
rven
tion
grou
p (a
spir
in 1
clop
idog
rel g
roup
) and
one
of 4
22 in
the
com
pari
son
grou
p (a
spir
in g
roup
).
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
18© 2012 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/site/misc/reprints.xhtml). DOI: 10.1378/chest.11-2307
Tabl
e S1
5 —[S
ecti
on 8
.1-8
.3]
Evi
denc
e P
rofi l
e: A
spir
in a
nd C
lopi
dogr
el v
s A
spir
in A
lone
for
Pat
ient
s W
ith
PAD
Pos
tsu
rgic
al B
elow
Kne
e R
evas
cula
riza
tion
Wit
h P
rost
heti
c G
raft
s
Qua
lity
Ass
essm
ent
Sum
mar
y of
Fin
ding
s
Part
icip
ants
(s
tudi
es),
Fol
low
-up
Ris
k of
Bia
sIn
cons
iste
ncy
Indi
rect
ness
Impr
ecis
ion
Publ
icat
ion
Bia
sR
elat
ive
Eff
ect
(95%
CI)
Est
imat
ion
of A
bsol
ute
Eff
ects
Ti
me
Peri
od: 1
y
Qua
lity
of
Evi
denc
e R
isk
With
A
spir
in a
Ris
k D
iffer
ence
With
A
spir
in 1
Clo
pido
grel
(9
5% C
I)
All-
caus
e m
orta
lity
(cri
tical
out
com
e)
253
(1 R
CT
),
mea
n �
11
mo a
No
seri
ous
ri
sk o
f bia
sN
o se
riou
s
inco
nsis
tenc
yN
o se
riou
s
indi
rect
ness
Very
ser
ious
impr
ecis
ion
CIs
incl
ude
sign
ifi ca
nt h
arm
an
d be
nefi t
(n
o. e
vent
s 5 1
0)
Und
etec
ted
RR
1.4
6 (0
.42-
5.07
)90
per
1,0
0041
mor
e pe
r 1,
000
(f
rom
52
few
er to
36
6 m
ore)
Low
due
to
im
prec
isio
n
MI
(cri
tical
out
com
e): n
ot r
epor
ted
Stro
ke (c
ritic
al o
utco
me)
: not
rep
orte
d
Ext
racr
ania
l maj
or b
leed
ing
(cri
tical
out
com
e); s
ever
e G
UST
O c
rite
ria b
253
(1 R
CT
),
mea
n �
11
mo a
No
seri
ous
ri
sk o
f bia
sN
o se
riou
s
inco
nsis
tenc
yN
o se
riou
s
indi
rect
ness
Very
ser
ious
impr
ecis
ion
(no.
eve
nts 5
3)
Und
etec
ted
RR
0.5
0 (0
.05-
5.44
)19
per
1,0
009
few
er p
er 1
,000
(fro
m 1
8 fe
wer
to
84 m
ore)
Low
due
to
im
prec
isio
n
Am
puta
tions
(cri
tical
out
com
e)
253
(1 R
CT
),
mea
n �
11
mo a
No
seri
ous
ri
sk o
f bia
sN
o se
riou
s
inco
nsis
tenc
yN
o se
riou
s
indi
rect
ness
Very
ser
ious
impr
ecis
ion
C
Is in
clud
e si
gnifi
cant
ha
rm a
nd b
enefi
t (n
o. e
vent
s 5 3
6)
Und
etec
ted
HR
0.4
9 (0
.26-
0.93
)48
per
1,0
0024
few
er p
er 1
,000
(fro
m 3
5 fe
wer
to
3 fe
wer
)
Low
due
to
im
prec
isio
n
Bib
liogr
aphy
: Bel
ch J
J, D
orm
andy
J, B
iasi
GM
, et
al. R
esul
ts o
f th
e ra
ndom
ized
, pla
cebo
-con
trol
led
clop
idog
rel a
nd a
cety
lsal
icyl
ic a
cid
in b
ypas
s su
rger
y fo
r pe
riph
eral
art
eria
l dis
ease
(C
ASP
AR
) tr
ial.
J V
asc
Surg
. 201
0;52
(4):8
25-8
33. H
R 5
haz
ard
ratio
. See
Tab
le S
1, S
2, S
5, a
nd S
14 le
gend
s fo
r ex
pans
ion
of o
ther
abb
revi
atio
ns.
a Con
trol
gro
up r
isk
estim
ates
obt
aine
d fr
om e
vent
rat
es in
asp
irin
arm
of B
OA
stu
dy, n
orm
aliz
ed to
1 y
. b U
ncle
ar w
heth
er a
ny o
f sev
ere
blee
ds w
ere
fata
l.
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
19© 2012 American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/site/misc/reprints.xhtml). DOI: 10.1378/chest.11-2307
Tabl
e S1
6 —[S
ecti
on 8
.1-8
.3]
Evi
denc
e P
rofi l
e: W
arfa
rin
vs A
spir
in f
or P
atie
nts
Wit
h PA
D P
osts
urg
ical
Rev
ascu
lari
zati
on
Qua
lity
Ass
essm
ent
Sum
mar
y of
Fin
ding
s
Part
icip
ants
(S
tudi
es),
Fol
low
-up
Ris
k of
Bia
sIn
cons
iste
ncy
Indi
rect
ness
Impr
ecis
ion
Publ
icat
ion
Bia
sR
elat
ive
Eff
ect
(95%
CI)
Est
imat
ion
of A
bsol
ute
Eff
ects
Ti
me
Peri
od: 1
y
Qua
lity
of
Evi
denc
e R
isk
With
A
spir
in a
Ris
k D
iffer
ence
W
ith O
AC
(95%
CI)
All-
caus
e m
orta
lity
(cri
tical
out
com
e)
2 65
0 (1
RC
T) 2
1 m
oN
o se
riou
s
risk
of b
ias b
No
seri
ous
in
cons
iste
ncy
No
seri
ous
in
dire
ctne
ssSe
riou
s im
prec
isio
n
CIs
incl
ude
sign
ifi ca
nt
harm
and
ben
efi t
(no.
eve
nts
, 4
00)
Und
etec
ted
RR
1.0
3 (0
.86-
1.23
)90
per
1,0
002
mor
e pe
r 1,
000
(f
rom
22
few
er to
20
mor
e)
Mod
erat
e du
e to
impr
ecis
ion
MI
(cri
tical
out
com
e), i
nclu
ding
fata
l str
okes
2 65
0 (1
RC
T) 2
1 m
oN
o se
riou
s
risk
of b
ias b
No
seri
ous
in
cons
iste
ncy
No
seri
ous
in
dire
ctne
ssSe
riou
s im
prec
isio
n
CIs
incl
ude
sign
ifi ca
nt
harm
and
ben
efi t
(no.
eve
nts
, 4
00)
Und
etec
ted
RR
0.6
9 (0
.43-
1.1)
18 p
er 1
,000
5 fe
wer
per
1,0
00
(f
rom
10
few
er to
1
mor
e)
Mod
erat
e du
e to
impr
ecis
ion
Stro
ke (c
ritic
al o
utco
me)
, c inc
ludi
ng is
chem
ic, h
emor
rhag
ic, a
nd o
ther
str
oke
type
s; in
clud
es fa
tal s
trok
es
2 65
0 (1
RC
T) 2
1 m
oN
o se
riou
s
risk
of b
ias b
No
seri
ous
in
cons
iste
ncy
No
seri
ous
in
dire
ctne
ssSe
riou
s im
prec
isio
n
CIs
incl
ude
sign
ifi ca
nt
harm
and
ben
efi t
(no.
eve
nts
, 4
00)
Und
etec
ted
RR
0.7
4 (0
.48-
1.14
)21
per
1,0
005
few
er p
er 1
,000
(fro
m 1
1 fe
wer
to
2 m
ore)
Mod
erat
e du
e to
impr
ecis
ion
Ext
racr
ania
l maj
or b
leed
ing
(cri
tical
out
com
e) d ;
nonf
atal
ble
edin
g re
quir
ing
hosp
italiz
atio
n, e
xclu
ding
all
repo
rts
of in
trac
rani
al h
emor
rhag
e or
pos
tsur
gica
l ble
edin
g
2 65
0 (1
RC
T) 2
1 m
oN
o se
riou
s
risk
of b
ias b
No
seri
ous
in
cons
iste
ncy
No
seri
ous
in
dire
ctne
ssSe
riou
s im
prec
isio
n
(no.
eve
nts
, 4
00)
Und
etec
ted
RR
1.9
0 (1
.33-
2.73
)19
per
1,0
0017
mor
e pe
r 1,
000
(f
rom
6 m
ore
to
32 m
ore)
Mod
erat
e du
e to
impr
ecis
ion
Lim
b lo
ss (c
ritic
al o
utco
me)
; all
ampu
tatio
n (ip
sila
tera
l and
con
tral
ater
al)
2 65
0 (1
RC
T) 2
1 m
oN
o se
riou
s
risk
of b
ias b
No
seri
ous
in
cons
iste
ncy
No
seri
ous
in
dire
ctne
ssSe
riou
s im
prec
isio
n
CIs
incl
ude
sign
ifi ca
nt
harm
and
ben
efi t
(no.
eve
nts
, 4
00)
Und
etec
ted
RR
0.9
1 (0
.7-1
.18)
48 p
er 1
,000
4 fe
wer
per
1,0
00
(f
rom
14
few
er to
8
mor
e)
Mod
erat
e du
e to
impr
ecis
ion
Bib
liogr
aphy
: D
utch
Byp
ass
Ora
l A
ntic
oagu
lant
s or
Asp
irin
(B
OA
) St
udy
Gro
up.
Effi
cacy
of
oral
ant
icoa
gula
nts
com
pare
d w
ith a
spir
in a
fter
inf
rain
guin
al b
ypas
s su
rger
y (T
he D
utch
Byp
ass
Ora
l A
ntic
oagu
lant
s or
Asp
irin
Stu
dy):
a ra
ndom
ised
tria
l. L
ance
t . 20
00;3
55(9
201)
:346
-351
. See
Tab
le S
1 an
d S2
lege
nds
for
expa
nsio
n of
abb
revi
atio
ns.
a Con
trol
gro
up r
isk
estim
ates
obt
aine
d fr
om e
vent
rat
es in
asp
irin
arm
of s
tudy
, nor
mal
ized
to 1
y.
b Thi
rtee
n an
d 27
pat
ient
s w
ithdr
ew fr
om th
e w
arfa
rin
and
aspi
rin
arm
s, r
espe
ctiv
ely.
Not
incl
uded
in a
naly
sis.
Six
teen
and
13
patie
nts
wer
e lo
st to
follo
w-u
p, r
espe
ctiv
ely;
incl
uded
in th
e an
alys
is.
c Hem
orrh
agic
str
okes
: 14
of 1
,326
in th
e in
terv
entio
n (O
AC
) gro
up a
nd fo
ur o
f 1,3
24 in
the
com
pari
son
(ant
ipla
tele
t age
nt) g
roup
. d F
atal
ble
edin
g ev
ents
: 16
of 1
,326
in th
e in
terv
entio
n gr
oup
(OA
C g
roup
) and
12
of 1
,324
in th
e co
mpa
riso
n gr
oup
(ant
ipla
tele
t age
nt g
roup
).
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from
DOI 10.1378/chest.11-2307 2012;141; e669S-e690SChest
Maarten G. Lansberg, Gordon H. Guyatt and Frederick A. SpencerRandolph Guzman, Michael H. Criqui, Elie A. Akl, Per Olav Vandvik,
Pablo Alonso-Coello, Sergi Bellmunt, Catherine McGorrian, Sonia S. Anand,Chest Physicians Evidence-Based Clinical Practice Guidelines
Therapy and Prevention of Thrombosis, 9th ed: American College of Antithrombotic Therapy in Peripheral Artery Disease : Antithrombotic
February 26, 2012This information is current as of
http://chestjournal.chestpubs.org/content/suppl/2012/02/03/141.2_suppl.e669S.DC1.html View e-supplements related to this article at:
Supplementary Material
http://chestjournal.chestpubs.org/content/141/2_suppl/e669S.full.htmlUpdated Information and services can be found at:
Updated Information & Services
http://chestjournal.chestpubs.org/content/141/2_suppl/e669S.full.html#ref-list-1This article cites 72 articles, 22 of which can be accessed free at:
References
http://chestjournal.chestpubs.org/content/141/2_suppl/e669S.full.html#related-urlsThis article has been cited by 2 HighWire-hosted articles:
Cited Bys
http://www.chestpubs.org/site/misc/reprints.xhtmlfound online at: Information about reproducing this article in parts (figures, tables) or in its entirety can bePermissions & Licensing
http://www.chestpubs.org/site/misc/reprints.xhtmlInformation about ordering reprints can be found online:
Reprints
"Services" link to the right of the online article.Receive free e-mail alerts when new articles cite this article. To sign up, select the
Citation Alerts
PowerPoint slide format. See any online figure for directions. articles can be downloaded for teaching purposes inCHESTFigures that appear in Images in PowerPoint format
© 2012 American College of Chest Physicians at sanofi-aventis R & D on February 27, 2012chestjournal.chestpubs.orgDownloaded from